Motif 1057 (n=172)
Position-wise Probabilities
Download
| uniprot | genes | site | source | protein | function |
|---|---|---|---|---|---|
| L7N2F9 | None | T79 | ochoa | V-SNARE coiled-coil homology domain-containing protein | None |
| O00567 | NOP56 | T529 | ochoa | Nucleolar protein 56 (Nucleolar protein 5A) | Involved in the early to middle stages of 60S ribosomal subunit biogenesis. Required for the biogenesis of box C/D snoRNAs such U3, U8 and U14 snoRNAs (PubMed:12777385, PubMed:15574333). Part of the small subunit (SSU) processome, first precursor of the small eukaryotic ribosomal subunit. During the assembly of the SSU processome in the nucleolus, many ribosome biogenesis factors, an RNA chaperone and ribosomal proteins associate with the nascent pre-rRNA and work in concert to generate RNA folding, modifications, rearrangements and cleavage as well as targeted degradation of pre-ribosomal RNA by the RNA exosome (PubMed:34516797). Core component of box C/D small nucleolar ribonucleoprotein (snoRNP) complexes that function in methylation of multiple sites on ribosomal RNAs (rRNAs) and messenger RNAs (mRNAs) (PubMed:12777385, PubMed:39570315). {ECO:0000269|PubMed:12777385, ECO:0000269|PubMed:15574333, ECO:0000269|PubMed:34516797, ECO:0000269|PubMed:39570315}. |
| O43175 | PHGDH | T57 | psp | D-3-phosphoglycerate dehydrogenase (3-PGDH) (EC 1.1.1.95) (2-oxoglutarate reductase) (EC 1.1.1.399) (Malate dehydrogenase) (EC 1.1.1.37) | Catalyzes the reversible oxidation of 3-phospho-D-glycerate to 3-phosphonooxypyruvate, the first step of the phosphorylated L-serine biosynthesis pathway. Also catalyzes the reversible oxidation of 2-hydroxyglutarate to 2-oxoglutarate and the reversible oxidation of (S)-malate to oxaloacetate. {ECO:0000269|PubMed:11751922, ECO:0000269|PubMed:25406093}. |
| O43918 | AIRE | T68 | psp | Autoimmune regulator (Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy protein) (APECED protein) | Transcription factor playing an essential role to promote self-tolerance in the thymus by regulating the expression of a wide array of self-antigens that have the commonality of being tissue-restricted in their expression pattern in the periphery, called tissue restricted antigens (TRA) (PubMed:26084028). Binds to G-doublets in an A/T-rich environment; the preferred motif is a tandem repeat of 5'-ATTGGTTA-3' combined with a 5'-TTATTA-3' box. Binds to nucleosomes (By similarity). Binds to chromatin and interacts selectively with histone H3 that is not methylated at 'Lys-4', not phosphorylated at 'Thr-3' and not methylated at 'Arg-2'. Functions as a sensor of histone H3 modifications that are important for the epigenetic regulation of gene expression. Mainly expressed by medullary thymic epithelial cells (mTECs), induces the expression of thousands of tissue-restricted proteins, which are presented on major histocompatibility complex class I (MHC-I) and MHC-II molecules to developing T-cells percolating through the thymic medulla (PubMed:26084028). Also induces self-tolerance through other mechanisms such as the regulation of the mTEC differentiation program. Controls the medullary accumulation of thymic dendritic cells and the development of regulatory T-cell through the regulation of XCL1 expression. Regulates the production of CCR4 and CCR7 ligands in medullary thymic epithelial cells and alters the coordinated maturation and migration of thymocytes. In thimic B-cells, allows the presentation of licensing-dependent endogenous self-anitgen for negative selection. In secondary lymphoid organs, induces functional inactivation of CD4(+) T-cells. Expressed by a distinct bone marrow-derived population, induces self-tolerance through a mechanism that does not require regulatory T-cells and is resitant to innate inflammatory stimuli (By similarity). {ECO:0000250|UniProtKB:Q9Z0E3, ECO:0000269|PubMed:11274163, ECO:0000269|PubMed:18292755, ECO:0000269|PubMed:26084028, ECO:0000305|PubMed:19302042, ECO:0000305|PubMed:26972725}. |
| O60216 | RAD21 | T186 | ochoa|psp | Double-strand-break repair protein rad21 homolog (hHR21) (Nuclear matrix protein 1) (NXP-1) (SCC1 homolog) [Cleaved into: 64-kDa C-terminal product (64-kDa carboxy-terminal product) (65-kDa carboxy-terminal product)] | [Double-strand-break repair protein rad21 homolog]: As a member of the cohesin complex, involved in sister chromatid cohesion from the time of DNA replication in S phase to their segregation in mitosis, a function that is essential for proper chromosome segregation, post-replicative DNA repair, and the prevention of inappropriate recombination between repetitive regions (PubMed:11509732). The cohesin complex may also play a role in spindle pole assembly during mitosis (PubMed:11590136). In interphase, cohesins may function in the control of gene expression by binding to numerous sites within the genome (By similarity). May control RUNX1 gene expression (Probable). Binds to and represses APOB gene promoter (PubMed:25575569). May play a role in embryonic gut development, possibly through the regulation of enteric neuron development (By similarity). {ECO:0000250|UniProtKB:Q61550, ECO:0000250|UniProtKB:Q6TEL1, ECO:0000269|PubMed:11509732, ECO:0000269|PubMed:11590136, ECO:0000269|PubMed:25575569, ECO:0000305|PubMed:25575569}.; FUNCTION: [64-kDa C-terminal product]: May promote apoptosis. {ECO:0000269|PubMed:11875078, ECO:0000269|PubMed:12417729}. |
| O75116 | ROCK2 | T814 | ochoa | Rho-associated protein kinase 2 (EC 2.7.11.1) (Rho kinase 2) (Rho-associated, coiled-coil-containing protein kinase 2) (Rho-associated, coiled-coil-containing protein kinase II) (ROCK-II) (p164 ROCK-2) | Protein kinase which is a key regulator of actin cytoskeleton and cell polarity. Involved in regulation of smooth muscle contraction, actin cytoskeleton organization, stress fiber and focal adhesion formation, neurite retraction, cell adhesion and motility via phosphorylation of ADD1, BRCA2, CNN1, EZR, DPYSL2, EP300, MSN, MYL9/MLC2, NPM1, RDX, PPP1R12A and VIM. Phosphorylates SORL1 and IRF4. Acts as a negative regulator of VEGF-induced angiogenic endothelial cell activation. Positively regulates the activation of p42/MAPK1-p44/MAPK3 and of p90RSK/RPS6KA1 during myogenic differentiation. Plays an important role in the timely initiation of centrosome duplication. Inhibits keratinocyte terminal differentiation. May regulate closure of the eyelids and ventral body wall through organization of actomyosin bundles. Plays a critical role in the regulation of spine and synaptic properties in the hippocampus. Plays an important role in generating the circadian rhythm of the aortic myofilament Ca(2+) sensitivity and vascular contractility by modulating the myosin light chain phosphorylation. {ECO:0000269|PubMed:10579722, ECO:0000269|PubMed:15699075, ECO:0000269|PubMed:16574662, ECO:0000269|PubMed:17015463, ECO:0000269|PubMed:19131646, ECO:0000269|PubMed:19997641, ECO:0000269|PubMed:21084279, ECO:0000269|PubMed:21147781}. |
| O75116 | ROCK2 | T977 | ochoa | Rho-associated protein kinase 2 (EC 2.7.11.1) (Rho kinase 2) (Rho-associated, coiled-coil-containing protein kinase 2) (Rho-associated, coiled-coil-containing protein kinase II) (ROCK-II) (p164 ROCK-2) | Protein kinase which is a key regulator of actin cytoskeleton and cell polarity. Involved in regulation of smooth muscle contraction, actin cytoskeleton organization, stress fiber and focal adhesion formation, neurite retraction, cell adhesion and motility via phosphorylation of ADD1, BRCA2, CNN1, EZR, DPYSL2, EP300, MSN, MYL9/MLC2, NPM1, RDX, PPP1R12A and VIM. Phosphorylates SORL1 and IRF4. Acts as a negative regulator of VEGF-induced angiogenic endothelial cell activation. Positively regulates the activation of p42/MAPK1-p44/MAPK3 and of p90RSK/RPS6KA1 during myogenic differentiation. Plays an important role in the timely initiation of centrosome duplication. Inhibits keratinocyte terminal differentiation. May regulate closure of the eyelids and ventral body wall through organization of actomyosin bundles. Plays a critical role in the regulation of spine and synaptic properties in the hippocampus. Plays an important role in generating the circadian rhythm of the aortic myofilament Ca(2+) sensitivity and vascular contractility by modulating the myosin light chain phosphorylation. {ECO:0000269|PubMed:10579722, ECO:0000269|PubMed:15699075, ECO:0000269|PubMed:16574662, ECO:0000269|PubMed:17015463, ECO:0000269|PubMed:19131646, ECO:0000269|PubMed:19997641, ECO:0000269|PubMed:21084279, ECO:0000269|PubMed:21147781}. |
| O94992 | HEXIM1 | T341 | ochoa | Protein HEXIM1 (Cardiac lineage protein 1) (Estrogen down-regulated gene 1 protein) (Hexamethylene bis-acetamide-inducible protein 1) (Menage a quatre protein 1) | Transcriptional regulator which functions as a general RNA polymerase II transcription inhibitor (PubMed:14580347, PubMed:15201869, PubMed:15713661). Core component of the 7SK RNP complex: in cooperation with 7SK snRNA sequesters P-TEFb in a large inactive 7SK snRNP complex preventing RNA polymerase II phosphorylation and subsequent transcriptional elongation (PubMed:12832472, PubMed:14580347, PubMed:15201869, PubMed:15713661). May also regulate NF-kappa-B, ESR1, NR3C1 and CIITA-dependent transcriptional activity (PubMed:15940264, PubMed:15941832, PubMed:17088550). Plays a role in the regulation of DNA virus-mediated innate immune response by assembling into the HDP-RNP complex, a complex that serves as a platform for IRF3 phosphorylation and subsequent innate immune response activation through the cGAS-STING pathway (PubMed:28712728). {ECO:0000269|PubMed:12581153, ECO:0000269|PubMed:12832472, ECO:0000269|PubMed:14580347, ECO:0000269|PubMed:15201869, ECO:0000269|PubMed:15713661, ECO:0000269|PubMed:15940264, ECO:0000269|PubMed:15941832, ECO:0000269|PubMed:17088550, ECO:0000269|PubMed:28712728}. |
| P06732 | CKM | T35 | ochoa | Creatine kinase M-type (EC 2.7.3.2) (Creatine kinase M chain) (Creatine phosphokinase M-type) (CPK-M) (M-CK) | Reversibly catalyzes the transfer of phosphate between ATP and various phosphogens (e.g. creatine phosphate). Creatine kinase isoenzymes play a central role in energy transduction in tissues with large, fluctuating energy demands, such as skeletal muscle, heart, brain and spermatozoa. {ECO:0000250|UniProtKB:P00563}. |
| P06732 | CKM | T327 | ochoa | Creatine kinase M-type (EC 2.7.3.2) (Creatine kinase M chain) (Creatine phosphokinase M-type) (CPK-M) (M-CK) | Reversibly catalyzes the transfer of phosphate between ATP and various phosphogens (e.g. creatine phosphate). Creatine kinase isoenzymes play a central role in energy transduction in tissues with large, fluctuating energy demands, such as skeletal muscle, heart, brain and spermatozoa. {ECO:0000250|UniProtKB:P00563}. |
| P07195 | LDHB | T302 | ochoa | L-lactate dehydrogenase B chain (LDH-B) (EC 1.1.1.27) (LDH heart subunit) (LDH-H) (Renal carcinoma antigen NY-REN-46) | Interconverts simultaneously and stereospecifically pyruvate and lactate with concomitant interconversion of NADH and NAD(+). {ECO:0000269|PubMed:27618187}. |
| P07900 | HSP90AA1 | T540 | ochoa | Heat shock protein HSP 90-alpha (EC 3.6.4.10) (Heat shock 86 kDa) (HSP 86) (HSP86) (Heat shock protein family C member 1) (Lipopolysaccharide-associated protein 2) (LAP-2) (LPS-associated protein 2) (Renal carcinoma antigen NY-REN-38) | Molecular chaperone that promotes the maturation, structural maintenance and proper regulation of specific target proteins involved for instance in cell cycle control and signal transduction. Undergoes a functional cycle that is linked to its ATPase activity which is essential for its chaperone activity. This cycle probably induces conformational changes in the client proteins, thereby causing their activation. Interacts dynamically with various co-chaperones that modulate its substrate recognition, ATPase cycle and chaperone function (PubMed:11274138, PubMed:12526792, PubMed:15577939, PubMed:15937123, PubMed:27353360, PubMed:29127155). Engages with a range of client protein classes via its interaction with various co-chaperone proteins or complexes, that act as adapters, simultaneously able to interact with the specific client and the central chaperone itself (PubMed:29127155). Recruitment of ATP and co-chaperone followed by client protein forms a functional chaperone. After the completion of the chaperoning process, properly folded client protein and co-chaperone leave HSP90 in an ADP-bound partially open conformation and finally, ADP is released from HSP90 which acquires an open conformation for the next cycle (PubMed:26991466, PubMed:27295069). Plays a critical role in mitochondrial import, delivers preproteins to the mitochondrial import receptor TOMM70 (PubMed:12526792). Apart from its chaperone activity, it also plays a role in the regulation of the transcription machinery. HSP90 and its co-chaperones modulate transcription at least at three different levels (PubMed:25973397). In the first place, they alter the steady-state levels of certain transcription factors in response to various physiological cues (PubMed:25973397). Second, they modulate the activity of certain epigenetic modifiers, such as histone deacetylases or DNA methyl transferases, and thereby respond to the change in the environment (PubMed:25973397). Third, they participate in the eviction of histones from the promoter region of certain genes and thereby turn on gene expression (PubMed:25973397). Binds bacterial lipopolysaccharide (LPS) and mediates LPS-induced inflammatory response, including TNF secretion by monocytes (PubMed:11276205). Antagonizes STUB1-mediated inhibition of TGF-beta signaling via inhibition of STUB1-mediated SMAD3 ubiquitination and degradation (PubMed:24613385). Mediates the association of TOMM70 with IRF3 or TBK1 in mitochondrial outer membrane which promotes host antiviral response (PubMed:20628368, PubMed:25609812). {ECO:0000269|PubMed:11274138, ECO:0000269|PubMed:11276205, ECO:0000269|PubMed:12526792, ECO:0000269|PubMed:15577939, ECO:0000269|PubMed:15937123, ECO:0000269|PubMed:20628368, ECO:0000269|PubMed:24613385, ECO:0000269|PubMed:25609812, ECO:0000269|PubMed:27353360, ECO:0000269|PubMed:29127155, ECO:0000303|PubMed:25973397, ECO:0000303|PubMed:26991466, ECO:0000303|PubMed:27295069}.; FUNCTION: (Microbial infection) Seems to interfere with N.meningitidis NadA-mediated invasion of human cells. Decreasing HSP90 levels increases adhesion and entry of E.coli expressing NadA into human Chang cells; increasing its levels leads to decreased adhesion and invasion. {ECO:0000305|PubMed:22066472}. |
| P08684 | CYP3A4 | T284 | psp | Cytochrome P450 3A4 (EC 1.14.14.1) (1,4-cineole 2-exo-monooxygenase) (1,8-cineole 2-exo-monooxygenase) (EC 1.14.14.56) (Albendazole monooxygenase (sulfoxide-forming)) (EC 1.14.14.73) (Albendazole sulfoxidase) (CYPIIIA3) (CYPIIIA4) (Cholesterol 25-hydroxylase) (Cytochrome P450 3A3) (Cytochrome P450 HLp) (Cytochrome P450 NF-25) (Cytochrome P450-PCN1) (Nifedipine oxidase) (Quinine 3-monooxygenase) (EC 1.14.14.55) | A cytochrome P450 monooxygenase involved in the metabolism of sterols, steroid hormones, retinoids and fatty acids (PubMed:10681376, PubMed:11093772, PubMed:11555828, PubMed:12865317, PubMed:14559847, PubMed:15373842, PubMed:15764715, PubMed:19965576, PubMed:20702771, PubMed:21490593, PubMed:21576599). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the hydroxylation of carbon-hydrogen bonds (PubMed:12865317, PubMed:14559847, PubMed:15373842, PubMed:15764715, PubMed:21490593, PubMed:21576599, PubMed:2732228). Exhibits high catalytic activity for the formation of hydroxyestrogens from estrone (E1) and 17beta-estradiol (E2), namely 2-hydroxy E1 and E2, as well as D-ring hydroxylated E1 and E2 at the C-16 position (PubMed:11555828, PubMed:12865317, PubMed:14559847). Plays a role in the metabolism of androgens, particularly in oxidative deactivation of testosterone (PubMed:15373842, PubMed:15764715, PubMed:22773874, PubMed:2732228). Metabolizes testosterone to less biologically active 2beta- and 6beta-hydroxytestosterones (PubMed:15373842, PubMed:15764715, PubMed:2732228). Contributes to the formation of hydroxycholesterols (oxysterols), particularly A-ring hydroxylated cholesterol at the C-4beta position, and side chain hydroxylated cholesterol at the C-25 position, likely contributing to cholesterol degradation and bile acid biosynthesis (PubMed:21576599). Catalyzes bisallylic hydroxylation of polyunsaturated fatty acids (PUFA) (PubMed:9435160). Catalyzes the epoxidation of double bonds of PUFA with a preference for the last double bond (PubMed:19965576). Metabolizes endocannabinoid arachidonoylethanolamide (anandamide) to 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs), potentially modulating endocannabinoid system signaling (PubMed:20702771). Plays a role in the metabolism of retinoids. Displays high catalytic activity for oxidation of all-trans-retinol to all-trans-retinal, a rate-limiting step for the biosynthesis of all-trans-retinoic acid (atRA) (PubMed:10681376). Further metabolizes atRA toward 4-hydroxyretinoate and may play a role in hepatic atRA clearance (PubMed:11093772). Responsible for oxidative metabolism of xenobiotics. Acts as a 2-exo-monooxygenase for plant lipid 1,8-cineole (eucalyptol) (PubMed:11159812). Metabolizes the majority of the administered drugs. Catalyzes sulfoxidation of the anthelmintics albendazole and fenbendazole (PubMed:10759686). Hydroxylates antimalarial drug quinine (PubMed:8968357). Acts as a 1,4-cineole 2-exo-monooxygenase (PubMed:11695850). Also involved in vitamin D catabolism and calcium homeostasis. Catalyzes the inactivation of the active hormone calcitriol (1-alpha,25-dihydroxyvitamin D(3)) (PubMed:29461981). {ECO:0000269|PubMed:10681376, ECO:0000269|PubMed:10759686, ECO:0000269|PubMed:11093772, ECO:0000269|PubMed:11159812, ECO:0000269|PubMed:11555828, ECO:0000269|PubMed:11695850, ECO:0000269|PubMed:12865317, ECO:0000269|PubMed:14559847, ECO:0000269|PubMed:15373842, ECO:0000269|PubMed:15764715, ECO:0000269|PubMed:19965576, ECO:0000269|PubMed:20702771, ECO:0000269|PubMed:21490593, ECO:0000269|PubMed:21576599, ECO:0000269|PubMed:22773874, ECO:0000269|PubMed:2732228, ECO:0000269|PubMed:29461981, ECO:0000269|PubMed:8968357, ECO:0000269|PubMed:9435160}. |
| P10745 | RBP3 | T821 | ochoa | Retinol-binding protein 3 (Interphotoreceptor retinoid-binding protein) (IRBP) (Interstitial retinol-binding protein) | IRBP shuttles 11-cis and all trans retinoids between the retinol isomerase in the pigment epithelium and the visual pigments in the photoreceptor cells of the retina. |
| P11055 | MYH3 | S949 | ochoa | Myosin-3 (Muscle embryonic myosin heavy chain) (Myosin heavy chain 3) (Myosin heavy chain, fast skeletal muscle, embryonic) (SMHCE) | Muscle contraction. |
| P11055 | MYH3 | T1480 | ochoa | Myosin-3 (Muscle embryonic myosin heavy chain) (Myosin heavy chain 3) (Myosin heavy chain, fast skeletal muscle, embryonic) (SMHCE) | Muscle contraction. |
| P12270 | TPR | T831 | ochoa | Nucleoprotein TPR (Megator) (NPC-associated intranuclear protein) (Translocated promoter region protein) | Component of the nuclear pore complex (NPC), a complex required for the trafficking across the nuclear envelope. Functions as a scaffolding element in the nuclear phase of the NPC essential for normal nucleocytoplasmic transport of proteins and mRNAs, plays a role in the establishment of nuclear-peripheral chromatin compartmentalization in interphase, and in the mitotic spindle checkpoint signaling during mitosis. Involved in the quality control and retention of unspliced mRNAs in the nucleus; in association with NUP153, regulates the nuclear export of unspliced mRNA species bearing constitutive transport element (CTE) in a NXF1- and KHDRBS1-independent manner. Negatively regulates both the association of CTE-containing mRNA with large polyribosomes and translation initiation. Does not play any role in Rev response element (RRE)-mediated export of unspliced mRNAs. Implicated in nuclear export of mRNAs transcribed from heat shock gene promoters; associates both with chromatin in the HSP70 promoter and with mRNAs transcribed from this promoter under stress-induced conditions. Modulates the nucleocytoplasmic transport of activated MAPK1/ERK2 and huntingtin/HTT and may serve as a docking site for the XPO1/CRM1-mediated nuclear export complex. According to some authors, plays a limited role in the regulation of nuclear protein export (PubMed:11952838, PubMed:22253824). Also plays a role as a structural and functional element of the perinuclear chromatin distribution; involved in the formation and/or maintenance of NPC-associated perinuclear heterochromatin exclusion zones (HEZs). Finally, acts as a spatial regulator of the spindle-assembly checkpoint (SAC) response ensuring a timely and effective recruitment of spindle checkpoint proteins like MAD1L1 and MAD2L1 to unattached kinetochore during the metaphase-anaphase transition before chromosome congression. Its N-terminus is involved in activation of oncogenic kinases. {ECO:0000269|PubMed:11952838, ECO:0000269|PubMed:15654337, ECO:0000269|PubMed:17897941, ECO:0000269|PubMed:18794356, ECO:0000269|PubMed:18981471, ECO:0000269|PubMed:19273613, ECO:0000269|PubMed:20133940, ECO:0000269|PubMed:20407419, ECO:0000269|PubMed:21613532, ECO:0000269|PubMed:22253824, ECO:0000269|PubMed:9864356}. |
| P12882 | MYH1 | S952 | ochoa | Myosin-1 (Myosin heavy chain 1) (Myosin heavy chain 2x) (MyHC-2x) (Myosin heavy chain IIx/d) (MyHC-IIx/d) (Myosin heavy chain, skeletal muscle, adult 1) | Required for normal hearing. It plays a role in cochlear amplification of auditory stimuli, likely through the positive regulation of prestin (SLC26A5) activity and outer hair cell (OHC) electromotility. {ECO:0000250|UniProtKB:Q5SX40}. |
| P12882 | MYH1 | T1023 | ochoa | Myosin-1 (Myosin heavy chain 1) (Myosin heavy chain 2x) (MyHC-2x) (Myosin heavy chain IIx/d) (MyHC-IIx/d) (Myosin heavy chain, skeletal muscle, adult 1) | Required for normal hearing. It plays a role in cochlear amplification of auditory stimuli, likely through the positive regulation of prestin (SLC26A5) activity and outer hair cell (OHC) electromotility. {ECO:0000250|UniProtKB:Q5SX40}. |
| P12882 | MYH1 | T1286 | ochoa | Myosin-1 (Myosin heavy chain 1) (Myosin heavy chain 2x) (MyHC-2x) (Myosin heavy chain IIx/d) (MyHC-IIx/d) (Myosin heavy chain, skeletal muscle, adult 1) | Required for normal hearing. It plays a role in cochlear amplification of auditory stimuli, likely through the positive regulation of prestin (SLC26A5) activity and outer hair cell (OHC) electromotility. {ECO:0000250|UniProtKB:Q5SX40}. |
| P12882 | MYH1 | T1483 | ochoa | Myosin-1 (Myosin heavy chain 1) (Myosin heavy chain 2x) (MyHC-2x) (Myosin heavy chain IIx/d) (MyHC-IIx/d) (Myosin heavy chain, skeletal muscle, adult 1) | Required for normal hearing. It plays a role in cochlear amplification of auditory stimuli, likely through the positive regulation of prestin (SLC26A5) activity and outer hair cell (OHC) electromotility. {ECO:0000250|UniProtKB:Q5SX40}. |
| P12882 | MYH1 | T1501 | ochoa | Myosin-1 (Myosin heavy chain 1) (Myosin heavy chain 2x) (MyHC-2x) (Myosin heavy chain IIx/d) (MyHC-IIx/d) (Myosin heavy chain, skeletal muscle, adult 1) | Required for normal hearing. It plays a role in cochlear amplification of auditory stimuli, likely through the positive regulation of prestin (SLC26A5) activity and outer hair cell (OHC) electromotility. {ECO:0000250|UniProtKB:Q5SX40}. |
| P12882 | MYH1 | T1722 | ochoa | Myosin-1 (Myosin heavy chain 1) (Myosin heavy chain 2x) (MyHC-2x) (Myosin heavy chain IIx/d) (MyHC-IIx/d) (Myosin heavy chain, skeletal muscle, adult 1) | Required for normal hearing. It plays a role in cochlear amplification of auditory stimuli, likely through the positive regulation of prestin (SLC26A5) activity and outer hair cell (OHC) electromotility. {ECO:0000250|UniProtKB:Q5SX40}. |
| P12883 | MYH7 | S948 | ochoa | Myosin-7 (Myosin heavy chain 7) (Myosin heavy chain slow isoform) (MyHC-slow) (Myosin heavy chain, cardiac muscle beta isoform) (MyHC-beta) | Myosins are actin-based motor molecules with ATPase activity essential for muscle contraction. Forms regular bipolar thick filaments that, together with actin thin filaments, constitute the fundamental contractile unit of skeletal and cardiac muscle. {ECO:0000305|PubMed:26150528, ECO:0000305|PubMed:26246073}. |
| P12883 | MYH7 | T1019 | ochoa | Myosin-7 (Myosin heavy chain 7) (Myosin heavy chain slow isoform) (MyHC-slow) (Myosin heavy chain, cardiac muscle beta isoform) (MyHC-beta) | Myosins are actin-based motor molecules with ATPase activity essential for muscle contraction. Forms regular bipolar thick filaments that, together with actin thin filaments, constitute the fundamental contractile unit of skeletal and cardiac muscle. {ECO:0000305|PubMed:26150528, ECO:0000305|PubMed:26246073}. |
| P12883 | MYH7 | T1127 | ochoa | Myosin-7 (Myosin heavy chain 7) (Myosin heavy chain slow isoform) (MyHC-slow) (Myosin heavy chain, cardiac muscle beta isoform) (MyHC-beta) | Myosins are actin-based motor molecules with ATPase activity essential for muscle contraction. Forms regular bipolar thick filaments that, together with actin thin filaments, constitute the fundamental contractile unit of skeletal and cardiac muscle. {ECO:0000305|PubMed:26150528, ECO:0000305|PubMed:26246073}. |
| P12883 | MYH7 | T1282 | ochoa | Myosin-7 (Myosin heavy chain 7) (Myosin heavy chain slow isoform) (MyHC-slow) (Myosin heavy chain, cardiac muscle beta isoform) (MyHC-beta) | Myosins are actin-based motor molecules with ATPase activity essential for muscle contraction. Forms regular bipolar thick filaments that, together with actin thin filaments, constitute the fundamental contractile unit of skeletal and cardiac muscle. {ECO:0000305|PubMed:26150528, ECO:0000305|PubMed:26246073}. |
| P12883 | MYH7 | T1479 | ochoa | Myosin-7 (Myosin heavy chain 7) (Myosin heavy chain slow isoform) (MyHC-slow) (Myosin heavy chain, cardiac muscle beta isoform) (MyHC-beta) | Myosins are actin-based motor molecules with ATPase activity essential for muscle contraction. Forms regular bipolar thick filaments that, together with actin thin filaments, constitute the fundamental contractile unit of skeletal and cardiac muscle. {ECO:0000305|PubMed:26150528, ECO:0000305|PubMed:26246073}. |
| P12883 | MYH7 | T1497 | ochoa | Myosin-7 (Myosin heavy chain 7) (Myosin heavy chain slow isoform) (MyHC-slow) (Myosin heavy chain, cardiac muscle beta isoform) (MyHC-beta) | Myosins are actin-based motor molecules with ATPase activity essential for muscle contraction. Forms regular bipolar thick filaments that, together with actin thin filaments, constitute the fundamental contractile unit of skeletal and cardiac muscle. {ECO:0000305|PubMed:26150528, ECO:0000305|PubMed:26246073}. |
| P12883 | MYH7 | T1599 | ochoa | Myosin-7 (Myosin heavy chain 7) (Myosin heavy chain slow isoform) (MyHC-slow) (Myosin heavy chain, cardiac muscle beta isoform) (MyHC-beta) | Myosins are actin-based motor molecules with ATPase activity essential for muscle contraction. Forms regular bipolar thick filaments that, together with actin thin filaments, constitute the fundamental contractile unit of skeletal and cardiac muscle. {ECO:0000305|PubMed:26150528, ECO:0000305|PubMed:26246073}. |
| P13533 | MYH6 | S950 | ochoa | Myosin-6 (Myosin heavy chain 6) (Myosin heavy chain, cardiac muscle alpha isoform) (MyHC-alpha) | Muscle contraction. |
| P13533 | MYH6 | T1129 | ochoa | Myosin-6 (Myosin heavy chain 6) (Myosin heavy chain, cardiac muscle alpha isoform) (MyHC-alpha) | Muscle contraction. |
| P13533 | MYH6 | T1481 | ochoa | Myosin-6 (Myosin heavy chain 6) (Myosin heavy chain, cardiac muscle alpha isoform) (MyHC-alpha) | Muscle contraction. |
| P13533 | MYH6 | T1499 | ochoa | Myosin-6 (Myosin heavy chain 6) (Myosin heavy chain, cardiac muscle alpha isoform) (MyHC-alpha) | Muscle contraction. |
| P13533 | MYH6 | T1601 | ochoa | Myosin-6 (Myosin heavy chain 6) (Myosin heavy chain, cardiac muscle alpha isoform) (MyHC-alpha) | Muscle contraction. |
| P13535 | MYH8 | S951 | ochoa | Myosin-8 (Myosin heavy chain 8) (Myosin heavy chain, skeletal muscle, perinatal) (MyHC-perinatal) | Muscle contraction. |
| P13535 | MYH8 | T1482 | ochoa | Myosin-8 (Myosin heavy chain 8) (Myosin heavy chain, skeletal muscle, perinatal) (MyHC-perinatal) | Muscle contraction. |
| P13535 | MYH8 | T1721 | ochoa | Myosin-8 (Myosin heavy chain 8) (Myosin heavy chain, skeletal muscle, perinatal) (MyHC-perinatal) | Muscle contraction. |
| P15374 | UCHL3 | T150 | ochoa | Ubiquitin carboxyl-terminal hydrolase isozyme L3 (UCH-L3) (EC 3.4.19.12) (Ubiquitin thioesterase L3) | Deubiquitinating enzyme (DUB) that controls levels of cellular ubiquitin through processing of ubiquitin precursors and ubiquitinated proteins. Thiol protease that recognizes and hydrolyzes a peptide bond at the C-terminal glycine of either ubiquitin or NEDD8. Has a 10-fold preference for Arg and Lys at position P3'', and exhibits a preference towards 'Lys-48'-linked ubiquitin chains. Deubiquitinates ENAC in apical compartments, thereby regulating apical membrane recycling. Indirectly increases the phosphorylation of IGFIR, AKT and FOXO1 and promotes insulin-signaling and insulin-induced adipogenesis. Required for stress-response retinal, skeletal muscle and germ cell maintenance. May be involved in working memory. Can hydrolyze UBB(+1), a mutated form of ubiquitin which is not effectively degraded by the proteasome and is associated with neurogenerative disorders. {ECO:0000269|PubMed:19154770, ECO:0000269|PubMed:21762696, ECO:0000269|PubMed:22689415, ECO:0000269|PubMed:2530630, ECO:0000269|PubMed:9790970}. |
| P17535 | JUND | T115 | ochoa | Transcription factor JunD (Transcription factor AP-1 subunit JunD) | Transcription factor binding AP-1 sites (PubMed:9989505). Heterodimerizes with proteins of the FOS family to form an AP-1 transcription factor complex, thereby enhancing their DNA binding activity to an AP-1 consensus sequence 3'-TGA[GC]TCA-5' and enhancing their transcriptional activity (PubMed:28981703, PubMed:9989505). {ECO:0000269|PubMed:28981703, ECO:0000269|PubMed:9989505}. |
| P19012 | KRT15 | T145 | ochoa | Keratin, type I cytoskeletal 15 (Cytokeratin-15) (CK-15) (Keratin-15) (K15) | None |
| P20700 | LMNB1 | T55 | ochoa | Lamin-B1 | Lamins are intermediate filament proteins that assemble into a filamentous meshwork, and which constitute the major components of the nuclear lamina, a fibrous layer on the nucleoplasmic side of the inner nuclear membrane (PubMed:28716252, PubMed:32910914). Lamins provide a framework for the nuclear envelope, bridging the nuclear envelope and chromatin, thereby playing an important role in nuclear assembly, chromatin organization, nuclear membrane and telomere dynamics (PubMed:28716252, PubMed:32910914). The structural integrity of the lamina is strictly controlled by the cell cycle, as seen by the disintegration and formation of the nuclear envelope in prophase and telophase, respectively (PubMed:28716252, PubMed:32910914). {ECO:0000269|PubMed:28716252, ECO:0000269|PubMed:32910914}. |
| P20936 | RASA1 | T462 | ochoa | Ras GTPase-activating protein 1 (GAP) (GTPase-activating protein) (RasGAP) (Ras p21 protein activator) (p120GAP) | Inhibitory regulator of the Ras-cyclic AMP pathway. Stimulates the GTPase of normal but not oncogenic Ras p21; this stimulation may be further increased in the presence of NCK1. {ECO:0000269|PubMed:11389730, ECO:0000269|PubMed:8360177}. |
| P27348 | YWHAQ | T215 | ochoa | 14-3-3 protein theta (14-3-3 protein T-cell) (14-3-3 protein tau) (Protein HS1) | Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways. Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif. Binding generally results in the modulation of the activity of the binding partner. Negatively regulates the kinase activity of PDPK1. {ECO:0000269|PubMed:12177059}. |
| P29353 | SHC1 | T514 | ochoa | SHC-transforming protein 1 (SHC-transforming protein 3) (SHC-transforming protein A) (Src homology 2 domain-containing-transforming protein C1) (SH2 domain protein C1) | Signaling adapter that couples activated growth factor receptors to signaling pathways. Participates in a signaling cascade initiated by activated KIT and KITLG/SCF. Isoform p46Shc and isoform p52Shc, once phosphorylated, couple activated receptor tyrosine kinases to Ras via the recruitment of the GRB2/SOS complex and are implicated in the cytoplasmic propagation of mitogenic signals. Isoform p46Shc and isoform p52Shc may thus function as initiators of the Ras signaling cascade in various non-neuronal systems. Isoform p66Shc does not mediate Ras activation, but is involved in signal transduction pathways that regulate the cellular response to oxidative stress and life span. Isoform p66Shc acts as a downstream target of the tumor suppressor p53 and is indispensable for the ability of stress-activated p53 to induce elevation of intracellular oxidants, cytochrome c release and apoptosis. The expression of isoform p66Shc has been correlated with life span (By similarity). Participates in signaling downstream of the angiopoietin receptor TEK/TIE2, and plays a role in the regulation of endothelial cell migration and sprouting angiogenesis. {ECO:0000250, ECO:0000269|PubMed:14665640}. |
| P30305 | CDC25B | T404 | psp | M-phase inducer phosphatase 2 (EC 3.1.3.48) (Dual specificity phosphatase Cdc25B) | Tyrosine protein phosphatase which functions as a dosage-dependent inducer of mitotic progression (PubMed:1836978, PubMed:20360007). Directly dephosphorylates CDK1 and stimulates its kinase activity (PubMed:20360007). Required for G2/M phases of the cell cycle progression and abscission during cytokinesis in a ECT2-dependent manner (PubMed:17332740). The three isoforms seem to have a different level of activity (PubMed:1836978). {ECO:0000269|PubMed:17332740, ECO:0000269|PubMed:1836978, ECO:0000269|PubMed:20360007}. |
| P31946 | YWHAB | T217 | ochoa | 14-3-3 protein beta/alpha (Protein 1054) (Protein kinase C inhibitor protein 1) (KCIP-1) [Cleaved into: 14-3-3 protein beta/alpha, N-terminally processed] | Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways. Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif. Binding generally results in the modulation of the activity of the binding partner. Negative regulator of osteogenesis. Blocks the nuclear translocation of the phosphorylated form (by AKT1) of SRPK2 and antagonizes its stimulatory effect on cyclin D1 expression resulting in blockage of neuronal apoptosis elicited by SRPK2. Negative regulator of signaling cascades that mediate activation of MAP kinases via AKAP13. {ECO:0000269|PubMed:17717073, ECO:0000269|PubMed:19592491, ECO:0000269|PubMed:21224381}. |
| P31947 | SFN | T217 | ochoa | 14-3-3 protein sigma (Epithelial cell marker protein 1) (Stratifin) | Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways (PubMed:15731107, PubMed:22634725, PubMed:28202711, PubMed:37797010). Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif (PubMed:15731107, PubMed:22634725, PubMed:28202711, PubMed:37797010). Binding generally results in the modulation of the activity of the binding partner (PubMed:15731107, PubMed:22634725, PubMed:28202711, PubMed:37797010). Promotes cytosolic retention of GBP1 GTPase by binding to phosphorylated GBP1, thereby inhibiting the innate immune response (PubMed:37797010). Also acts as a TP53/p53-regulated inhibitor of G2/M progression (PubMed:9659898). When bound to KRT17, regulates protein synthesis and epithelial cell growth by stimulating Akt/mTOR pathway (By similarity). Acts to maintain desmosome cell junction adhesion in epithelial cells via interacting with and sequestering PKP3 to the cytoplasm, thereby restricting its translocation to existing desmosome structures and therefore maintaining desmosome protein homeostasis (PubMed:24124604). Also acts to facilitate PKP3 exchange at desmosome plaques, thereby maintaining keratinocyte intercellular adhesion (PubMed:29678907). May also regulate MDM2 autoubiquitination and degradation and thereby activate p53/TP53 (PubMed:18382127). {ECO:0000250|UniProtKB:O70456, ECO:0000269|PubMed:15731107, ECO:0000269|PubMed:18382127, ECO:0000269|PubMed:22634725, ECO:0000269|PubMed:24124604, ECO:0000269|PubMed:28202711, ECO:0000269|PubMed:29678907, ECO:0000269|PubMed:37797010, ECO:0000269|PubMed:9659898}. |
| P35580 | MYH10 | T1203 | ochoa | Myosin-10 (Cellular myosin heavy chain, type B) (Myosin heavy chain 10) (Myosin heavy chain, non-muscle IIb) (Non-muscle myosin heavy chain B) (NMMHC-B) (Non-muscle myosin heavy chain IIb) (NMMHC II-b) (NMMHC-IIB) | Cellular myosin that appears to play a role in cytokinesis, cell shape, and specialized functions such as secretion and capping. Involved with LARP6 in the stabilization of type I collagen mRNAs for CO1A1 and CO1A2. During cell spreading, plays an important role in cytoskeleton reorganization, focal contacts formation (in the central part but not the margins of spreading cells), and lamellipodial extension; this function is mechanically antagonized by MYH9. {ECO:0000269|PubMed:20052411, ECO:0000269|PubMed:20603131}.; FUNCTION: (Microbial infection) Acts as a receptor for herpes simplex virus 1/HHV-1 envelope glycoprotein B. {ECO:0000305|PubMed:25428876, ECO:0000305|PubMed:39048823}. |
| P35606 | COPB2 | T869 | ochoa | Coatomer subunit beta' (Beta'-coat protein) (Beta'-COP) (p102) | The coatomer is a cytosolic protein complex that binds to dilysine motifs and reversibly associates with Golgi non-clathrin-coated vesicles, which further mediate biosynthetic protein transport from the ER, via the Golgi up to the trans Golgi network. Coatomer complex is required for budding from Golgi membranes, and is essential for the retrograde Golgi-to-ER transport of dilysine-tagged proteins. In mammals, the coatomer can only be recruited by membranes associated to ADP-ribosylation factors (ARFs), which are small GTP-binding proteins; the complex also influences the Golgi structural integrity, as well as the processing, activity, and endocytic recycling of LDL receptors. {ECO:0000269|PubMed:34450031}.; FUNCTION: This coatomer complex protein, essential for Golgi budding and vesicular trafficking, is a selective binding protein (RACK) for protein kinase C, epsilon type. It binds to Golgi membranes in a GTP-dependent manner (By similarity). {ECO:0000250}. |
| P40926 | MDH2 | T235 | ochoa | Malate dehydrogenase, mitochondrial (EC 1.1.1.37) | None |
| P46013 | MKI67 | T1111 | ochoa | Proliferation marker protein Ki-67 (Antigen identified by monoclonal antibody Ki-67) (Antigen KI-67) (Antigen Ki67) | Protein that associates with the surface of mitotic chromosomes and acts both as a chromosome repellent during early mitosis and chromosome attractant during late mitosis (PubMed:27362226, PubMed:32879492, PubMed:35513709, PubMed:39153474). Required to maintain individual mitotic chromosomes dispersed in the cytoplasm following nuclear envelope disassembly (PubMed:27362226). During early mitosis, relocalizes from nucleoli to the chromosome surface where it forms extended brush structures that cover a substantial fraction of the chromosome surface (PubMed:27362226). The MKI67 brush structure prevents chromosomes from collapsing into a single chromatin mass by forming a steric and electrostatic charge barrier: the protein has a high net electrical charge and acts as a surfactant, dispersing chromosomes and enabling independent chromosome motility (PubMed:27362226). During mitotic anaphase, the MKI67 brush structure collapses and MKI67 switches from a chromosome repellent to a chromosome attractant to promote chromosome clustering and facilitate the exclusion of large cytoplasmic particles from the future nuclear space (PubMed:32879492, PubMed:39153474). Mechanistically, dephosphorylation during mitotic exit and simultaneous exposure of a conserved basic patch induce the RNA-dependent formation of a liquid-like condensed phase on the chromosome surface, promoting coalescence of neighboring chromosome surfaces and clustering of chromosomes (PubMed:39153474). Binds premature ribosomal RNAs during anaphase; promoting liquid-liquid phase separation (PubMed:28935370, PubMed:39153474). Binds DNA, with a preference for supercoiled DNA and AT-rich DNA (PubMed:10878551). Does not contribute to the internal structure of mitotic chromosomes (By similarity). May play a role in chromatin organization; it is however unclear whether it plays a direct role in chromatin organization or whether it is an indirect consequence of its function in mitotic chromosome (PubMed:24867636). {ECO:0000250|UniProtKB:E9PVX6, ECO:0000269|PubMed:10878551, ECO:0000269|PubMed:24867636, ECO:0000269|PubMed:27362226, ECO:0000269|PubMed:28935370, ECO:0000269|PubMed:32879492, ECO:0000269|PubMed:35513709, ECO:0000269|PubMed:39153474}. |
| P46013 | MKI67 | T1233 | ochoa | Proliferation marker protein Ki-67 (Antigen identified by monoclonal antibody Ki-67) (Antigen KI-67) (Antigen Ki67) | Protein that associates with the surface of mitotic chromosomes and acts both as a chromosome repellent during early mitosis and chromosome attractant during late mitosis (PubMed:27362226, PubMed:32879492, PubMed:35513709, PubMed:39153474). Required to maintain individual mitotic chromosomes dispersed in the cytoplasm following nuclear envelope disassembly (PubMed:27362226). During early mitosis, relocalizes from nucleoli to the chromosome surface where it forms extended brush structures that cover a substantial fraction of the chromosome surface (PubMed:27362226). The MKI67 brush structure prevents chromosomes from collapsing into a single chromatin mass by forming a steric and electrostatic charge barrier: the protein has a high net electrical charge and acts as a surfactant, dispersing chromosomes and enabling independent chromosome motility (PubMed:27362226). During mitotic anaphase, the MKI67 brush structure collapses and MKI67 switches from a chromosome repellent to a chromosome attractant to promote chromosome clustering and facilitate the exclusion of large cytoplasmic particles from the future nuclear space (PubMed:32879492, PubMed:39153474). Mechanistically, dephosphorylation during mitotic exit and simultaneous exposure of a conserved basic patch induce the RNA-dependent formation of a liquid-like condensed phase on the chromosome surface, promoting coalescence of neighboring chromosome surfaces and clustering of chromosomes (PubMed:39153474). Binds premature ribosomal RNAs during anaphase; promoting liquid-liquid phase separation (PubMed:28935370, PubMed:39153474). Binds DNA, with a preference for supercoiled DNA and AT-rich DNA (PubMed:10878551). Does not contribute to the internal structure of mitotic chromosomes (By similarity). May play a role in chromatin organization; it is however unclear whether it plays a direct role in chromatin organization or whether it is an indirect consequence of its function in mitotic chromosome (PubMed:24867636). {ECO:0000250|UniProtKB:E9PVX6, ECO:0000269|PubMed:10878551, ECO:0000269|PubMed:24867636, ECO:0000269|PubMed:27362226, ECO:0000269|PubMed:28935370, ECO:0000269|PubMed:32879492, ECO:0000269|PubMed:35513709, ECO:0000269|PubMed:39153474}. |
| P46013 | MKI67 | T1355 | ochoa | Proliferation marker protein Ki-67 (Antigen identified by monoclonal antibody Ki-67) (Antigen KI-67) (Antigen Ki67) | Protein that associates with the surface of mitotic chromosomes and acts both as a chromosome repellent during early mitosis and chromosome attractant during late mitosis (PubMed:27362226, PubMed:32879492, PubMed:35513709, PubMed:39153474). Required to maintain individual mitotic chromosomes dispersed in the cytoplasm following nuclear envelope disassembly (PubMed:27362226). During early mitosis, relocalizes from nucleoli to the chromosome surface where it forms extended brush structures that cover a substantial fraction of the chromosome surface (PubMed:27362226). The MKI67 brush structure prevents chromosomes from collapsing into a single chromatin mass by forming a steric and electrostatic charge barrier: the protein has a high net electrical charge and acts as a surfactant, dispersing chromosomes and enabling independent chromosome motility (PubMed:27362226). During mitotic anaphase, the MKI67 brush structure collapses and MKI67 switches from a chromosome repellent to a chromosome attractant to promote chromosome clustering and facilitate the exclusion of large cytoplasmic particles from the future nuclear space (PubMed:32879492, PubMed:39153474). Mechanistically, dephosphorylation during mitotic exit and simultaneous exposure of a conserved basic patch induce the RNA-dependent formation of a liquid-like condensed phase on the chromosome surface, promoting coalescence of neighboring chromosome surfaces and clustering of chromosomes (PubMed:39153474). Binds premature ribosomal RNAs during anaphase; promoting liquid-liquid phase separation (PubMed:28935370, PubMed:39153474). Binds DNA, with a preference for supercoiled DNA and AT-rich DNA (PubMed:10878551). Does not contribute to the internal structure of mitotic chromosomes (By similarity). May play a role in chromatin organization; it is however unclear whether it plays a direct role in chromatin organization or whether it is an indirect consequence of its function in mitotic chromosome (PubMed:24867636). {ECO:0000250|UniProtKB:E9PVX6, ECO:0000269|PubMed:10878551, ECO:0000269|PubMed:24867636, ECO:0000269|PubMed:27362226, ECO:0000269|PubMed:28935370, ECO:0000269|PubMed:32879492, ECO:0000269|PubMed:35513709, ECO:0000269|PubMed:39153474}. |
| P46013 | MKI67 | T1476 | ochoa | Proliferation marker protein Ki-67 (Antigen identified by monoclonal antibody Ki-67) (Antigen KI-67) (Antigen Ki67) | Protein that associates with the surface of mitotic chromosomes and acts both as a chromosome repellent during early mitosis and chromosome attractant during late mitosis (PubMed:27362226, PubMed:32879492, PubMed:35513709, PubMed:39153474). Required to maintain individual mitotic chromosomes dispersed in the cytoplasm following nuclear envelope disassembly (PubMed:27362226). During early mitosis, relocalizes from nucleoli to the chromosome surface where it forms extended brush structures that cover a substantial fraction of the chromosome surface (PubMed:27362226). The MKI67 brush structure prevents chromosomes from collapsing into a single chromatin mass by forming a steric and electrostatic charge barrier: the protein has a high net electrical charge and acts as a surfactant, dispersing chromosomes and enabling independent chromosome motility (PubMed:27362226). During mitotic anaphase, the MKI67 brush structure collapses and MKI67 switches from a chromosome repellent to a chromosome attractant to promote chromosome clustering and facilitate the exclusion of large cytoplasmic particles from the future nuclear space (PubMed:32879492, PubMed:39153474). Mechanistically, dephosphorylation during mitotic exit and simultaneous exposure of a conserved basic patch induce the RNA-dependent formation of a liquid-like condensed phase on the chromosome surface, promoting coalescence of neighboring chromosome surfaces and clustering of chromosomes (PubMed:39153474). Binds premature ribosomal RNAs during anaphase; promoting liquid-liquid phase separation (PubMed:28935370, PubMed:39153474). Binds DNA, with a preference for supercoiled DNA and AT-rich DNA (PubMed:10878551). Does not contribute to the internal structure of mitotic chromosomes (By similarity). May play a role in chromatin organization; it is however unclear whether it plays a direct role in chromatin organization or whether it is an indirect consequence of its function in mitotic chromosome (PubMed:24867636). {ECO:0000250|UniProtKB:E9PVX6, ECO:0000269|PubMed:10878551, ECO:0000269|PubMed:24867636, ECO:0000269|PubMed:27362226, ECO:0000269|PubMed:28935370, ECO:0000269|PubMed:32879492, ECO:0000269|PubMed:35513709, ECO:0000269|PubMed:39153474}. |
| P46013 | MKI67 | T1841 | ochoa | Proliferation marker protein Ki-67 (Antigen identified by monoclonal antibody Ki-67) (Antigen KI-67) (Antigen Ki67) | Protein that associates with the surface of mitotic chromosomes and acts both as a chromosome repellent during early mitosis and chromosome attractant during late mitosis (PubMed:27362226, PubMed:32879492, PubMed:35513709, PubMed:39153474). Required to maintain individual mitotic chromosomes dispersed in the cytoplasm following nuclear envelope disassembly (PubMed:27362226). During early mitosis, relocalizes from nucleoli to the chromosome surface where it forms extended brush structures that cover a substantial fraction of the chromosome surface (PubMed:27362226). The MKI67 brush structure prevents chromosomes from collapsing into a single chromatin mass by forming a steric and electrostatic charge barrier: the protein has a high net electrical charge and acts as a surfactant, dispersing chromosomes and enabling independent chromosome motility (PubMed:27362226). During mitotic anaphase, the MKI67 brush structure collapses and MKI67 switches from a chromosome repellent to a chromosome attractant to promote chromosome clustering and facilitate the exclusion of large cytoplasmic particles from the future nuclear space (PubMed:32879492, PubMed:39153474). Mechanistically, dephosphorylation during mitotic exit and simultaneous exposure of a conserved basic patch induce the RNA-dependent formation of a liquid-like condensed phase on the chromosome surface, promoting coalescence of neighboring chromosome surfaces and clustering of chromosomes (PubMed:39153474). Binds premature ribosomal RNAs during anaphase; promoting liquid-liquid phase separation (PubMed:28935370, PubMed:39153474). Binds DNA, with a preference for supercoiled DNA and AT-rich DNA (PubMed:10878551). Does not contribute to the internal structure of mitotic chromosomes (By similarity). May play a role in chromatin organization; it is however unclear whether it plays a direct role in chromatin organization or whether it is an indirect consequence of its function in mitotic chromosome (PubMed:24867636). {ECO:0000250|UniProtKB:E9PVX6, ECO:0000269|PubMed:10878551, ECO:0000269|PubMed:24867636, ECO:0000269|PubMed:27362226, ECO:0000269|PubMed:28935370, ECO:0000269|PubMed:32879492, ECO:0000269|PubMed:35513709, ECO:0000269|PubMed:39153474}. |
| P46013 | MKI67 | T1963 | ochoa | Proliferation marker protein Ki-67 (Antigen identified by monoclonal antibody Ki-67) (Antigen KI-67) (Antigen Ki67) | Protein that associates with the surface of mitotic chromosomes and acts both as a chromosome repellent during early mitosis and chromosome attractant during late mitosis (PubMed:27362226, PubMed:32879492, PubMed:35513709, PubMed:39153474). Required to maintain individual mitotic chromosomes dispersed in the cytoplasm following nuclear envelope disassembly (PubMed:27362226). During early mitosis, relocalizes from nucleoli to the chromosome surface where it forms extended brush structures that cover a substantial fraction of the chromosome surface (PubMed:27362226). The MKI67 brush structure prevents chromosomes from collapsing into a single chromatin mass by forming a steric and electrostatic charge barrier: the protein has a high net electrical charge and acts as a surfactant, dispersing chromosomes and enabling independent chromosome motility (PubMed:27362226). During mitotic anaphase, the MKI67 brush structure collapses and MKI67 switches from a chromosome repellent to a chromosome attractant to promote chromosome clustering and facilitate the exclusion of large cytoplasmic particles from the future nuclear space (PubMed:32879492, PubMed:39153474). Mechanistically, dephosphorylation during mitotic exit and simultaneous exposure of a conserved basic patch induce the RNA-dependent formation of a liquid-like condensed phase on the chromosome surface, promoting coalescence of neighboring chromosome surfaces and clustering of chromosomes (PubMed:39153474). Binds premature ribosomal RNAs during anaphase; promoting liquid-liquid phase separation (PubMed:28935370, PubMed:39153474). Binds DNA, with a preference for supercoiled DNA and AT-rich DNA (PubMed:10878551). Does not contribute to the internal structure of mitotic chromosomes (By similarity). May play a role in chromatin organization; it is however unclear whether it plays a direct role in chromatin organization or whether it is an indirect consequence of its function in mitotic chromosome (PubMed:24867636). {ECO:0000250|UniProtKB:E9PVX6, ECO:0000269|PubMed:10878551, ECO:0000269|PubMed:24867636, ECO:0000269|PubMed:27362226, ECO:0000269|PubMed:28935370, ECO:0000269|PubMed:32879492, ECO:0000269|PubMed:35513709, ECO:0000269|PubMed:39153474}. |
| P46013 | MKI67 | T2085 | ochoa | Proliferation marker protein Ki-67 (Antigen identified by monoclonal antibody Ki-67) (Antigen KI-67) (Antigen Ki67) | Protein that associates with the surface of mitotic chromosomes and acts both as a chromosome repellent during early mitosis and chromosome attractant during late mitosis (PubMed:27362226, PubMed:32879492, PubMed:35513709, PubMed:39153474). Required to maintain individual mitotic chromosomes dispersed in the cytoplasm following nuclear envelope disassembly (PubMed:27362226). During early mitosis, relocalizes from nucleoli to the chromosome surface where it forms extended brush structures that cover a substantial fraction of the chromosome surface (PubMed:27362226). The MKI67 brush structure prevents chromosomes from collapsing into a single chromatin mass by forming a steric and electrostatic charge barrier: the protein has a high net electrical charge and acts as a surfactant, dispersing chromosomes and enabling independent chromosome motility (PubMed:27362226). During mitotic anaphase, the MKI67 brush structure collapses and MKI67 switches from a chromosome repellent to a chromosome attractant to promote chromosome clustering and facilitate the exclusion of large cytoplasmic particles from the future nuclear space (PubMed:32879492, PubMed:39153474). Mechanistically, dephosphorylation during mitotic exit and simultaneous exposure of a conserved basic patch induce the RNA-dependent formation of a liquid-like condensed phase on the chromosome surface, promoting coalescence of neighboring chromosome surfaces and clustering of chromosomes (PubMed:39153474). Binds premature ribosomal RNAs during anaphase; promoting liquid-liquid phase separation (PubMed:28935370, PubMed:39153474). Binds DNA, with a preference for supercoiled DNA and AT-rich DNA (PubMed:10878551). Does not contribute to the internal structure of mitotic chromosomes (By similarity). May play a role in chromatin organization; it is however unclear whether it plays a direct role in chromatin organization or whether it is an indirect consequence of its function in mitotic chromosome (PubMed:24867636). {ECO:0000250|UniProtKB:E9PVX6, ECO:0000269|PubMed:10878551, ECO:0000269|PubMed:24867636, ECO:0000269|PubMed:27362226, ECO:0000269|PubMed:28935370, ECO:0000269|PubMed:32879492, ECO:0000269|PubMed:35513709, ECO:0000269|PubMed:39153474}. |
| P46013 | MKI67 | T2203 | ochoa | Proliferation marker protein Ki-67 (Antigen identified by monoclonal antibody Ki-67) (Antigen KI-67) (Antigen Ki67) | Protein that associates with the surface of mitotic chromosomes and acts both as a chromosome repellent during early mitosis and chromosome attractant during late mitosis (PubMed:27362226, PubMed:32879492, PubMed:35513709, PubMed:39153474). Required to maintain individual mitotic chromosomes dispersed in the cytoplasm following nuclear envelope disassembly (PubMed:27362226). During early mitosis, relocalizes from nucleoli to the chromosome surface where it forms extended brush structures that cover a substantial fraction of the chromosome surface (PubMed:27362226). The MKI67 brush structure prevents chromosomes from collapsing into a single chromatin mass by forming a steric and electrostatic charge barrier: the protein has a high net electrical charge and acts as a surfactant, dispersing chromosomes and enabling independent chromosome motility (PubMed:27362226). During mitotic anaphase, the MKI67 brush structure collapses and MKI67 switches from a chromosome repellent to a chromosome attractant to promote chromosome clustering and facilitate the exclusion of large cytoplasmic particles from the future nuclear space (PubMed:32879492, PubMed:39153474). Mechanistically, dephosphorylation during mitotic exit and simultaneous exposure of a conserved basic patch induce the RNA-dependent formation of a liquid-like condensed phase on the chromosome surface, promoting coalescence of neighboring chromosome surfaces and clustering of chromosomes (PubMed:39153474). Binds premature ribosomal RNAs during anaphase; promoting liquid-liquid phase separation (PubMed:28935370, PubMed:39153474). Binds DNA, with a preference for supercoiled DNA and AT-rich DNA (PubMed:10878551). Does not contribute to the internal structure of mitotic chromosomes (By similarity). May play a role in chromatin organization; it is however unclear whether it plays a direct role in chromatin organization or whether it is an indirect consequence of its function in mitotic chromosome (PubMed:24867636). {ECO:0000250|UniProtKB:E9PVX6, ECO:0000269|PubMed:10878551, ECO:0000269|PubMed:24867636, ECO:0000269|PubMed:27362226, ECO:0000269|PubMed:28935370, ECO:0000269|PubMed:32879492, ECO:0000269|PubMed:35513709, ECO:0000269|PubMed:39153474}. |
| P46013 | MKI67 | T2325 | ochoa | Proliferation marker protein Ki-67 (Antigen identified by monoclonal antibody Ki-67) (Antigen KI-67) (Antigen Ki67) | Protein that associates with the surface of mitotic chromosomes and acts both as a chromosome repellent during early mitosis and chromosome attractant during late mitosis (PubMed:27362226, PubMed:32879492, PubMed:35513709, PubMed:39153474). Required to maintain individual mitotic chromosomes dispersed in the cytoplasm following nuclear envelope disassembly (PubMed:27362226). During early mitosis, relocalizes from nucleoli to the chromosome surface where it forms extended brush structures that cover a substantial fraction of the chromosome surface (PubMed:27362226). The MKI67 brush structure prevents chromosomes from collapsing into a single chromatin mass by forming a steric and electrostatic charge barrier: the protein has a high net electrical charge and acts as a surfactant, dispersing chromosomes and enabling independent chromosome motility (PubMed:27362226). During mitotic anaphase, the MKI67 brush structure collapses and MKI67 switches from a chromosome repellent to a chromosome attractant to promote chromosome clustering and facilitate the exclusion of large cytoplasmic particles from the future nuclear space (PubMed:32879492, PubMed:39153474). Mechanistically, dephosphorylation during mitotic exit and simultaneous exposure of a conserved basic patch induce the RNA-dependent formation of a liquid-like condensed phase on the chromosome surface, promoting coalescence of neighboring chromosome surfaces and clustering of chromosomes (PubMed:39153474). Binds premature ribosomal RNAs during anaphase; promoting liquid-liquid phase separation (PubMed:28935370, PubMed:39153474). Binds DNA, with a preference for supercoiled DNA and AT-rich DNA (PubMed:10878551). Does not contribute to the internal structure of mitotic chromosomes (By similarity). May play a role in chromatin organization; it is however unclear whether it plays a direct role in chromatin organization or whether it is an indirect consequence of its function in mitotic chromosome (PubMed:24867636). {ECO:0000250|UniProtKB:E9PVX6, ECO:0000269|PubMed:10878551, ECO:0000269|PubMed:24867636, ECO:0000269|PubMed:27362226, ECO:0000269|PubMed:28935370, ECO:0000269|PubMed:32879492, ECO:0000269|PubMed:35513709, ECO:0000269|PubMed:39153474}. |
| P46013 | MKI67 | T2927 | ochoa | Proliferation marker protein Ki-67 (Antigen identified by monoclonal antibody Ki-67) (Antigen KI-67) (Antigen Ki67) | Protein that associates with the surface of mitotic chromosomes and acts both as a chromosome repellent during early mitosis and chromosome attractant during late mitosis (PubMed:27362226, PubMed:32879492, PubMed:35513709, PubMed:39153474). Required to maintain individual mitotic chromosomes dispersed in the cytoplasm following nuclear envelope disassembly (PubMed:27362226). During early mitosis, relocalizes from nucleoli to the chromosome surface where it forms extended brush structures that cover a substantial fraction of the chromosome surface (PubMed:27362226). The MKI67 brush structure prevents chromosomes from collapsing into a single chromatin mass by forming a steric and electrostatic charge barrier: the protein has a high net electrical charge and acts as a surfactant, dispersing chromosomes and enabling independent chromosome motility (PubMed:27362226). During mitotic anaphase, the MKI67 brush structure collapses and MKI67 switches from a chromosome repellent to a chromosome attractant to promote chromosome clustering and facilitate the exclusion of large cytoplasmic particles from the future nuclear space (PubMed:32879492, PubMed:39153474). Mechanistically, dephosphorylation during mitotic exit and simultaneous exposure of a conserved basic patch induce the RNA-dependent formation of a liquid-like condensed phase on the chromosome surface, promoting coalescence of neighboring chromosome surfaces and clustering of chromosomes (PubMed:39153474). Binds premature ribosomal RNAs during anaphase; promoting liquid-liquid phase separation (PubMed:28935370, PubMed:39153474). Binds DNA, with a preference for supercoiled DNA and AT-rich DNA (PubMed:10878551). Does not contribute to the internal structure of mitotic chromosomes (By similarity). May play a role in chromatin organization; it is however unclear whether it plays a direct role in chromatin organization or whether it is an indirect consequence of its function in mitotic chromosome (PubMed:24867636). {ECO:0000250|UniProtKB:E9PVX6, ECO:0000269|PubMed:10878551, ECO:0000269|PubMed:24867636, ECO:0000269|PubMed:27362226, ECO:0000269|PubMed:28935370, ECO:0000269|PubMed:32879492, ECO:0000269|PubMed:35513709, ECO:0000269|PubMed:39153474}. |
| P55010 | EIF5 | T227 | ochoa | Eukaryotic translation initiation factor 5 (eIF-5) | Component of the 43S pre-initiation complex (43S PIC), which binds to the mRNA cap-proximal region, scans mRNA 5'-untranslated region, and locates the initiation codon (PubMed:11166181, PubMed:22813744, PubMed:24319994). In this complex, acts as a GTPase-activating protein, by promoting GTP hydrolysis by eIF2G (EIF2S3) (PubMed:11166181). During scanning, interacts with both EIF1 (via its C-terminal domain (CTD)) and EIF1A (via its NTD) (PubMed:22813744). This interaction with EIF1A contributes to the maintenance of EIF1 within the open 43S PIC (PubMed:24319994). When start codon is recognized, EIF5, via its NTD, induces eIF2G (EIF2S3) to hydrolyze the GTP (PubMed:11166181). Start codon recognition also induces a conformational change of the PIC to a closed state (PubMed:22813744). This change increases the affinity of EIF5-CTD for EIF2-beta (EIF2S2), which allows the release, by an indirect mechanism, of EIF1 from the PIC (PubMed:22813744). Finally, EIF5 stabilizes the PIC in its closed conformation (PubMed:22813744). {ECO:0000269|PubMed:11166181, ECO:0000269|PubMed:22813744, ECO:0000269|PubMed:24319994}. |
| P61981 | YWHAG | T220 | ochoa | 14-3-3 protein gamma (Protein kinase C inhibitor protein 1) (KCIP-1) [Cleaved into: 14-3-3 protein gamma, N-terminally processed] | Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways (PubMed:15696159, PubMed:16511572, PubMed:36732624). Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif (PubMed:15696159, PubMed:16511572, PubMed:36732624). Binding generally results in the modulation of the activity of the binding partner (PubMed:16511572). Promotes inactivation of WDR24 component of the GATOR2 complex by binding to phosphorylated WDR24 (PubMed:36732624). Participates in the positive regulation of NMDA glutamate receptor activity by promoting the L-glutamate secretion through interaction with BEST1 (PubMed:29121962). Reduces keratinocyte intercellular adhesion, via interacting with PKP1 and sequestering it in the cytoplasm, thereby reducing its incorporation into desmosomes (PubMed:29678907). Plays a role in mitochondrial protein catabolic process (also named MALM) that promotes the degradation of damaged proteins inside mitochondria (PubMed:22532927). {ECO:0000269|PubMed:15696159, ECO:0000269|PubMed:16511572, ECO:0000269|PubMed:22532927, ECO:0000269|PubMed:29121962, ECO:0000269|PubMed:29678907, ECO:0000269|PubMed:36732624}. |
| P62258 | YWHAE | T218 | ochoa | 14-3-3 protein epsilon (14-3-3E) | Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways (PubMed:21189250). Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif (PubMed:35343654). Binding generally results in the modulation of the activity of the binding partner (By similarity). Positively regulates phosphorylated protein HSF1 nuclear export to the cytoplasm (PubMed:12917326). Plays a positive role in the antiviral signaling pathway upstream of TBK1 via interaction with RIGI (PubMed:37555661). Mechanistically, directs RIGI redistribution from the cytosol to mitochondrial associated membranes where it mediates MAVS-dependent innate immune signaling during viral infection (PubMed:22607805). Plays a role in proliferation inhibition and cell cycle arrest by exporting HNRNPC from the nucleus to the cytoplasm to be degraded by ubiquitination (PubMed:37599448). {ECO:0000250|UniProtKB:P62261, ECO:0000269|PubMed:12917326, ECO:0000269|PubMed:21189250, ECO:0000269|PubMed:22607805, ECO:0000269|PubMed:35343654, ECO:0000269|PubMed:37555661, ECO:0000269|PubMed:37599448}. |
| P62258 | YWHAE | T229 | ochoa | 14-3-3 protein epsilon (14-3-3E) | Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways (PubMed:21189250). Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif (PubMed:35343654). Binding generally results in the modulation of the activity of the binding partner (By similarity). Positively regulates phosphorylated protein HSF1 nuclear export to the cytoplasm (PubMed:12917326). Plays a positive role in the antiviral signaling pathway upstream of TBK1 via interaction with RIGI (PubMed:37555661). Mechanistically, directs RIGI redistribution from the cytosol to mitochondrial associated membranes where it mediates MAVS-dependent innate immune signaling during viral infection (PubMed:22607805). Plays a role in proliferation inhibition and cell cycle arrest by exporting HNRNPC from the nucleus to the cytoplasm to be degraded by ubiquitination (PubMed:37599448). {ECO:0000250|UniProtKB:P62261, ECO:0000269|PubMed:12917326, ECO:0000269|PubMed:21189250, ECO:0000269|PubMed:22607805, ECO:0000269|PubMed:35343654, ECO:0000269|PubMed:37555661, ECO:0000269|PubMed:37599448}. |
| P63027 | VAMP2 | T79 | ochoa | Vesicle-associated membrane protein 2 (VAMP-2) (Synaptobrevin-2) | Involved in the targeting and/or fusion of transport vesicles to their target membrane (By similarity). Major SNARE protein of synaptic vesicles which mediates fusion of synaptic vesicles to release neurotransmitters. Essential for fast vesicular exocytosis and activity-dependent neurotransmitter release as well as fast endocytosis that mediates rapid reuse of synaptic vesicles (By similarity) (PubMed:30929742). Modulates the gating characteristics of the delayed rectifier voltage-dependent potassium channel KCNB1. {ECO:0000250|UniProtKB:P63044, ECO:0000250|UniProtKB:P63045, ECO:0000269|PubMed:30929742}. |
| P63104 | YWHAZ | T215 | ochoa | 14-3-3 protein zeta/delta (Protein kinase C inhibitor protein 1) (KCIP-1) | Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways (PubMed:14578935, PubMed:15071501, PubMed:15644438, PubMed:16376338, PubMed:16959763, PubMed:31024343, PubMed:9360956). Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif (PubMed:35662396). Binding generally results in the modulation of the activity of the binding partner (PubMed:35662396). Promotes cytosolic retention and inactivation of TFEB transcription factor by binding to phosphorylated TFEB (PubMed:35662396). Induces ARHGEF7 activity on RAC1 as well as lamellipodia and membrane ruffle formation (PubMed:16959763). In neurons, regulates spine maturation through the modulation of ARHGEF7 activity (By similarity). {ECO:0000250|UniProtKB:O55043, ECO:0000269|PubMed:14578935, ECO:0000269|PubMed:15071501, ECO:0000269|PubMed:15644438, ECO:0000269|PubMed:16376338, ECO:0000269|PubMed:16959763, ECO:0000269|PubMed:31024343, ECO:0000269|PubMed:35662396, ECO:0000269|PubMed:9360956}. |
| P78559 | MAP1A | T1224 | ochoa | Microtubule-associated protein 1A (MAP-1A) (Proliferation-related protein p80) [Cleaved into: MAP1A heavy chain; MAP1 light chain LC2] | Structural protein involved in the filamentous cross-bridging between microtubules and other skeletal elements. |
| P82094 | TMF1 | T364 | ochoa | TATA element modulatory factor (TMF) (Androgen receptor coactivator 160 kDa protein) (Androgen receptor-associated protein of 160 kDa) | Potential coactivator of the androgen receptor. Mediates STAT3 degradation. May play critical roles in two RAB6-dependent retrograde transport processes: one from endosomes to the Golgi and the other from the Golgi to the ER. This protein binds the HIV-1 TATA element and inhibits transcriptional activation by the TATA-binding protein (TBP). {ECO:0000269|PubMed:10428808, ECO:0000269|PubMed:1409643, ECO:0000269|PubMed:15467733, ECO:0000269|PubMed:17698061}. |
| Q00653 | NFKB2 | T859 | ochoa | Nuclear factor NF-kappa-B p100 subunit (DNA-binding factor KBF2) (H2TF1) (Lymphocyte translocation chromosome 10 protein) (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2) (Oncogene Lyt-10) (Lyt10) [Cleaved into: Nuclear factor NF-kappa-B p52 subunit] | NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. In a non-canonical activation pathway, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. The NF-kappa-B heterodimeric RelB-p52 complex is a transcriptional activator. The NF-kappa-B p52-p52 homodimer is a transcriptional repressor. NFKB2 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p100 and generation of p52 by a cotranslational processing. The proteasome-mediated process ensures the production of both p52 and p100 and preserves their independent function. p52 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. p52 and p100 are respectively the minor and major form; the processing of p100 being relatively poor. Isoform p49 is a subunit of the NF-kappa-B protein complex, which stimulates the HIV enhancer in synergy with p65. In concert with RELB, regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-BMAL1 heterodimer. {ECO:0000269|PubMed:7925301}. |
| Q04917 | YWHAH | T220 | ochoa | 14-3-3 protein eta (Protein AS1) | Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways. Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif. Binding generally results in the modulation of the activity of the binding partner. Negatively regulates the kinase activity of PDPK1. {ECO:0000269|PubMed:12177059}. |
| Q08477 | CYP4F3 | T233 | ochoa | Cytochrome P450 4F3 (EC 1.14.14.1) (20-hydroxyeicosatetraenoic acid synthase) (20-HETE synthase) (CYPIVF3) (Cytochrome P450-LTB-omega) (Docosahexaenoic acid omega-hydroxylase CYP4F3) (EC 1.14.14.79) (Leukotriene-B(4) 20-monooxygenase 2) (Leukotriene-B(4) omega-hydroxylase 2) (EC 1.14.14.94) | A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids and their oxygenated derivatives (oxylipins) (PubMed:11461919, PubMed:15145985, PubMed:16547005, PubMed:16820285, PubMed:18065749, PubMed:18182499, PubMed:18577768, PubMed:8486631, PubMed:9675028). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase) (PubMed:9675028). May play a role in inactivation of pro-inflammatory and anti-inflammatory oxylipins during the resolution of inflammation (PubMed:11461919, PubMed:15145985, PubMed:15364545, PubMed:16547005, PubMed:16820285, PubMed:18065749, PubMed:18182499, PubMed:18577768, PubMed:8486631, PubMed:9675028). {ECO:0000269|PubMed:11461919, ECO:0000269|PubMed:15145985, ECO:0000269|PubMed:15364545, ECO:0000269|PubMed:16547005, ECO:0000269|PubMed:16820285, ECO:0000269|PubMed:18065749, ECO:0000269|PubMed:18182499, ECO:0000269|PubMed:18577768, ECO:0000269|PubMed:8486631, ECO:0000269|PubMed:9675028}.; FUNCTION: [Isoform CYP4F3A]: Catalyzes predominantly the oxidation of the terminal carbon (omega-oxidation) of oxylipins in myeloid cells, displaying higher affinity for arachidonate metabolite leukotriene B4 (LTB4) (PubMed:11461919, PubMed:15364545, PubMed:8486631, PubMed:9675028). Inactivates LTB4 via three successive oxidative transformations to 20-hydroxy-LTB4, then to 20-oxo-LTB4 and to 20-carboxy-LTB4 (PubMed:9675028). Has omega-hydroxylase activity toward long-chain fatty acid epoxides with preference for 8,9-epoxy-(5Z,11Z,14Z)-eicosatrienoate (EET) and 9,10-epoxyoctadecanoate (PubMed:15145985). Omega-hydroxylates monohydroxy polyunsaturated fatty acids (PUFAs), including hydroxyeicosatetraenoates (HETEs) and hydroxyeicosapentaenoates (HEPEs), to dihydroxy compounds (PubMed:15364545, PubMed:9675028). Contributes to the degradation of saturated very long-chain fatty acids (VLCFAs) such as docosanoic acid, by catalyzing successive omega-oxidations to the corresponding dicarboxylic acid, thereby initiating chain shortening (PubMed:18182499). Has low hydroxylase activity toward PUFAs (PubMed:11461919, PubMed:18577768). {ECO:0000269|PubMed:11461919, ECO:0000269|PubMed:15145985, ECO:0000269|PubMed:15364545, ECO:0000269|PubMed:18182499, ECO:0000269|PubMed:18577768, ECO:0000269|PubMed:8486631, ECO:0000269|PubMed:9675028}.; FUNCTION: [Isoform CYP4F3B]: Catalyzes predominantly the oxidation of the terminal carbon (omega-oxidation) of polyunsaturated fatty acids (PUFAs) (PubMed:11461919, PubMed:16820285, PubMed:18577768). Participates in the conversion of arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE), a signaling molecule acting both as vasoconstrictive and natriuretic with overall effect on arterial blood pressure (PubMed:11461919, PubMed:16820285, PubMed:18577768). Has high omega-hydroxylase activity toward other PUFAs, including eicosatrienoic acid (ETA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (PubMed:16820285, PubMed:18577768). Can also catalyze the oxidation of the penultimate carbon (omega-1 oxidation) of PUFAs with lower efficiency (PubMed:18577768). Contributes to the degradation of saturated very long-chain fatty acids (VLCFAs) such as docosanoic acid and hexacosanoic acid, by catalyzing successive omega-oxidations to the corresponding dicarboxylic acids, thereby initiating chain shortening (PubMed:16547005, PubMed:18182499). Omega-hydroxylates long-chain 3-hydroxy fatty acids, likely initiating the oxidative conversion to the corresponding 3-hydroxydicarboxylic fatty acids (PubMed:18065749). Has omega-hydroxylase activity toward long-chain fatty acid epoxides with preference for 8,9-epoxy-(5Z,11Z,14Z)-eicosatrienoate (EET) and 9,10-epoxyoctadecanoate (PubMed:15145985). {ECO:0000269|PubMed:11461919, ECO:0000269|PubMed:15145985, ECO:0000269|PubMed:16547005, ECO:0000269|PubMed:16820285, ECO:0000269|PubMed:18065749, ECO:0000269|PubMed:18182499, ECO:0000269|PubMed:18577768}. |
| Q12888 | TP53BP1 | T200 | ochoa | TP53-binding protein 1 (53BP1) (p53-binding protein 1) (p53BP1) | Double-strand break (DSB) repair protein involved in response to DNA damage, telomere dynamics and class-switch recombination (CSR) during antibody genesis (PubMed:12364621, PubMed:17190600, PubMed:21144835, PubMed:22553214, PubMed:23333306, PubMed:27153538, PubMed:28241136, PubMed:31135337, PubMed:37696958). Plays a key role in the repair of double-strand DNA breaks (DSBs) in response to DNA damage by promoting non-homologous end joining (NHEJ)-mediated repair of DSBs and specifically counteracting the function of the homologous recombination (HR) repair protein BRCA1 (PubMed:22553214, PubMed:23333306, PubMed:23727112, PubMed:27153538, PubMed:31135337). In response to DSBs, phosphorylation by ATM promotes interaction with RIF1 and dissociation from NUDT16L1/TIRR, leading to recruitment to DSBs sites (PubMed:28241136). Recruited to DSBs sites by recognizing and binding histone H2A monoubiquitinated at 'Lys-15' (H2AK15Ub) and histone H4 dimethylated at 'Lys-20' (H4K20me2), two histone marks that are present at DSBs sites (PubMed:17190600, PubMed:23760478, PubMed:27153538, PubMed:28241136). Required for immunoglobulin class-switch recombination (CSR) during antibody genesis, a process that involves the generation of DNA DSBs (PubMed:23345425). Participates in the repair and the orientation of the broken DNA ends during CSR (By similarity). In contrast, it is not required for classic NHEJ and V(D)J recombination (By similarity). Promotes NHEJ of dysfunctional telomeres via interaction with PAXIP1 (PubMed:23727112). {ECO:0000250|UniProtKB:P70399, ECO:0000269|PubMed:12364621, ECO:0000269|PubMed:17190600, ECO:0000269|PubMed:21144835, ECO:0000269|PubMed:22553214, ECO:0000269|PubMed:23333306, ECO:0000269|PubMed:23345425, ECO:0000269|PubMed:23727112, ECO:0000269|PubMed:23760478, ECO:0000269|PubMed:27153538, ECO:0000269|PubMed:28241136, ECO:0000269|PubMed:31135337, ECO:0000269|PubMed:37696958}. |
| Q13769 | THOC5 | T322 | ochoa | THO complex subunit 5 (Functional spliceosome-associated protein 79) (fSAP79) (NF2/meningioma region protein pK1.3) (Placental protein 39.2) (PP39.2) (hTREX90) | Component of the THO subcomplex of the TREX complex which is thought to couple mRNA transcription, processing and nuclear export, and which specifically associates with spliced mRNA and not with unspliced pre-mRNA (PubMed:15833825, PubMed:15998806, PubMed:17190602). Plays a key structural role in the oligomerization of the THO-DDX39B complex (PubMed:33191911). TREX is recruited to spliced mRNAs by a transcription-independent mechanism, binds to mRNA upstream of the exon-junction complex (EJC) and is recruited in a splicing- and cap-dependent manner to a region near the 5' end of the mRNA where it functions in mRNA export to the cytoplasm via the TAP/NXF1 pathway (PubMed:15833825, PubMed:15998806, PubMed:17190602). THOC5 in conjunction with ALYREF/THOC4 functions in NXF1-NXT1 mediated nuclear export of HSP70 mRNA; both proteins enhance the RNA binding activity of NXF1 and are required for NXF1 localization to the nuclear rim. Involved in transcription elongation and genome stability (PubMed:18974867). Involved in alternative polyadenylation site choice by recruiting CPSF6 to 5' region of target genes; probably mediates association of the TREX and CFIm complexes (PubMed:23685434). {ECO:0000269|PubMed:15833825, ECO:0000269|PubMed:15998806, ECO:0000269|PubMed:17190602, ECO:0000269|PubMed:18974867, ECO:0000269|PubMed:23685434, ECO:0000269|PubMed:33191911}.; FUNCTION: Regulates the expression of myeloid transcription factors CEBPA, CEBPB and GAB2 by enhancing the levels of phosphatidylinositol 3,4,5-trisphosphate. May be involved in the differentiation of granulocytes and adipocytes. Essential for hematopoietic primitive cell survival and plays an integral role in monocytic development. {ECO:0000250|UniProtKB:Q8BKT7}.; FUNCTION: (Microbial infection) The TREX complex is essential for the export of Kaposi's sarcoma-associated herpesvirus (KSHV) intronless mRNAs and infectious virus production. {ECO:0000269|PubMed:18974867}. |
| Q14164 | IKBKE | T501 | psp | Inhibitor of nuclear factor kappa-B kinase subunit epsilon (I-kappa-B kinase epsilon) (IKK-E) (IKK-epsilon) (IkBKE) (EC 2.7.11.10) (Inducible I kappa-B kinase) (IKK-i) | Serine/threonine kinase that plays an essential role in regulating inflammatory responses to viral infection, through the activation of the type I IFN, NF-kappa-B and STAT signaling. Also involved in TNFA and inflammatory cytokines, like Interleukin-1, signaling. Following activation of viral RNA sensors, such as RIG-I-like receptors, associates with DDX3X and phosphorylates interferon regulatory factors (IRFs), IRF3 and IRF7, as well as DDX3X. This activity allows subsequent homodimerization and nuclear translocation of the IRF3 leading to transcriptional activation of pro-inflammatory and antiviral genes including IFNB. In order to establish such an antiviral state, IKBKE forms several different complexes whose composition depends on the type of cell and cellular stimuli. Thus, several scaffolding molecules including IPS1/MAVS, TANK, AZI2/NAP1 or TBKBP1/SINTBAD can be recruited to the IKBKE-containing-complexes. Activated by polyubiquitination in response to TNFA and interleukin-1, regulates the NF-kappa-B signaling pathway through, at least, the phosphorylation of CYLD. Phosphorylates inhibitors of NF-kappa-B thus leading to the dissociation of the inhibitor/NF-kappa-B complex and ultimately the degradation of the inhibitor. In addition, is also required for the induction of a subset of ISGs which displays antiviral activity, may be through the phosphorylation of STAT1 at 'Ser-708'. Phosphorylation of STAT1 at 'Ser-708' also seems to promote the assembly and DNA binding of ISGF3 (STAT1:STAT2:IRF9) complexes compared to GAF (STAT1:STAT1) complexes, in this way regulating the balance between type I and type II IFN responses. Protects cells against DNA damage-induced cell death. Also plays an important role in energy balance regulation by sustaining a state of chronic, low-grade inflammation in obesity, wich leads to a negative impact on insulin sensitivity. Phosphorylates AKT1. {ECO:0000269|PubMed:17568778, ECO:0000269|PubMed:18583960, ECO:0000269|PubMed:19153231, ECO:0000269|PubMed:20188669, ECO:0000269|PubMed:21138416, ECO:0000269|PubMed:21464307, ECO:0000269|PubMed:22532683, ECO:0000269|PubMed:23453969, ECO:0000269|PubMed:23478265}. |
| Q14978 | NOLC1 | T607 | ochoa | Nucleolar and coiled-body phosphoprotein 1 (140 kDa nucleolar phosphoprotein) (Nopp140) (Hepatitis C virus NS5A-transactivated protein 13) (HCV NS5A-transactivated protein 13) (Nucleolar 130 kDa protein) (Nucleolar phosphoprotein p130) | Nucleolar protein that acts as a regulator of RNA polymerase I by connecting RNA polymerase I with enzymes responsible for ribosomal processing and modification (PubMed:10567578, PubMed:26399832). Required for neural crest specification: following monoubiquitination by the BCR(KBTBD8) complex, associates with TCOF1 and acts as a platform to connect RNA polymerase I with enzymes responsible for ribosomal processing and modification, leading to remodel the translational program of differentiating cells in favor of neural crest specification (PubMed:26399832). Involved in nucleologenesis, possibly by playing a role in the maintenance of the fundamental structure of the fibrillar center and dense fibrillar component in the nucleolus (PubMed:9016786). It has intrinsic GTPase and ATPase activities (PubMed:9016786). {ECO:0000269|PubMed:10567578, ECO:0000269|PubMed:26399832, ECO:0000269|PubMed:9016786}. |
| Q15836 | VAMP3 | T62 | ochoa | Vesicle-associated membrane protein 3 (VAMP-3) (Cellubrevin) (CEB) (Synaptobrevin-3) | SNARE involved in vesicular transport from the late endosomes to the trans-Golgi network. {ECO:0000269|PubMed:18195106}. |
| Q16625 | OCLN | T424 | psp | Occludin | May play a role in the formation and regulation of the tight junction (TJ) paracellular permeability barrier. It is able to induce adhesion when expressed in cells lacking tight junctions. {ECO:0000269|PubMed:19114660}.; FUNCTION: (Microbial infection) Acts as a coreceptor for hepatitis C virus (HCV) in hepatocytes. {ECO:0000269|PubMed:19182773, ECO:0000269|PubMed:20375010}. |
| Q58FG1 | HSP90AA4P | T248 | ochoa | Putative heat shock protein HSP 90-alpha A4 (Heat shock 90 kDa protein 1 alpha-like 2) (Heat shock protein 90-alpha D) (Heat shock protein 90Ad) | Putative molecular chaperone that may promote the maturation, structural maintenance and proper regulation of specific target proteins. {ECO:0000250}. |
| Q5M775 | SPECC1 | T424 | ochoa | Cytospin-B (Nuclear structure protein 5) (NSP5) (Sperm antigen HCMOGT-1) (Sperm antigen with calponin homology and coiled-coil domains 1) | None |
| Q5VZL5 | ZMYM4 | T1089 | ochoa | Zinc finger MYM-type protein 4 (Zinc finger protein 262) | Plays a role in the regulation of cell morphology and cytoskeletal organization. {ECO:0000269|PubMed:21834987}. |
| Q5ZPR3 | CD276 | T515 | ochoa | CD276 antigen (4Ig-B7-H3) (B7 homolog 3) (B7-H3) (Costimulatory molecule) (CD antigen CD276) | May participate in the regulation of T-cell-mediated immune response. May play a protective role in tumor cells by inhibiting natural-killer mediated cell lysis as well as a role of marker for detection of neuroblastoma cells. May be involved in the development of acute and chronic transplant rejection and in the regulation of lymphocytic activity at mucosal surfaces. Could also play a key role in providing the placenta and fetus with a suitable immunological environment throughout pregnancy. Both isoform 1 and isoform 2 appear to be redundant in their ability to modulate CD4 T-cell responses. Isoform 2 is shown to enhance the induction of cytotoxic T-cells and selectively stimulates interferon gamma production in the presence of T-cell receptor signaling. {ECO:0000269|PubMed:11224528, ECO:0000269|PubMed:12906861, ECO:0000269|PubMed:14764704, ECO:0000269|PubMed:15314238, ECO:0000269|PubMed:15682454, ECO:0000269|PubMed:15961727}. |
| Q641Q2 | WASHC2A | T531 | ochoa | WASH complex subunit 2A | Acts at least in part as component of the WASH core complex whose assembly at the surface of endosomes inhibits WASH nucleation-promoting factor (NPF) activity in recruiting and activating the Arp2/3 complex to induce actin polymerization and is involved in the fission of tubules that serve as transport intermediates during endosome sorting. Mediates the recruitment of the WASH core complex to endosome membranes via binding to phospholipids and VPS35 of the retromer CSC. Mediates the recruitment of the F-actin-capping protein dimer to the WASH core complex probably promoting localized F-actin polymerization needed for vesicle scission. Via its C-terminus binds various phospholipids, most strongly phosphatidylinositol 4-phosphate (PtdIns-(4)P), phosphatidylinositol 5-phosphate (PtdIns-(5)P) and phosphatidylinositol 3,5-bisphosphate (PtdIns-(3,5)P2). Involved in the endosome-to-plasma membrane trafficking and recycling of SNX27-retromer-dependent cargo proteins, such as GLUT1. Required for the association of DNAJC13, ENTR1, ANKRD50 with retromer CSC subunit VPS35. Required for the endosomal recruitment of CCC complex subunits COMMD1 and CCDC93 as well as the retriever complex subunit VPS35L. {ECO:0000269|PubMed:25355947, ECO:0000269|PubMed:28892079}. |
| Q6NXT6 | TAPT1 | T529 | ochoa | Transmembrane anterior posterior transformation protein 1 homolog (Cytomegalovirus partial fusion receptor) | Plays a role in primary cilia formation (PubMed:26365339). May act as a downstream effector of HOXC8 possibly by transducing or transmitting extracellular information required for axial skeletal patterning during development (By similarity). May be involved in cartilage and bone development (By similarity). May play a role in the differentiation of cranial neural crest cells (By similarity). {ECO:0000250|UniProtKB:A2BIE7, ECO:0000250|UniProtKB:Q4VBD2, ECO:0000269|PubMed:26365339}.; FUNCTION: (Microbial infection) In case of infection, may act as a fusion receptor for cytomegalovirus (HCMV) strain AD169. {ECO:0000269|PubMed:10640539}. |
| Q6P3W7 | SCYL2 | T708 | ochoa | SCY1-like protein 2 (Coated vesicle-associated kinase of 104 kDa) | Component of the AP2-containing clathrin coat that may regulate clathrin-dependent trafficking at plasma membrane, TGN and endosomal system (Probable). A possible serine/threonine-protein kinase toward the beta2-subunit of the plasma membrane adapter complex AP2 and other proteins in presence of poly-L-lysine has not been confirmed (PubMed:15809293, PubMed:16914521). By regulating the expression of excitatory receptors at synapses, plays an essential role in neuronal function and signaling and in brain development (By similarity). {ECO:0000250|UniProtKB:Q8CFE4, ECO:0000269|PubMed:15809293, ECO:0000269|PubMed:16914521, ECO:0000305|PubMed:15809293, ECO:0000305|PubMed:16914521}. |
| Q6PKG0 | LARP1 | T647 | ochoa | La-related protein 1 (La ribonucleoprotein domain family member 1) | RNA-binding protein that regulates the translation of specific target mRNA species downstream of the mTORC1 complex, in function of growth signals and nutrient availability (PubMed:20430826, PubMed:23711370, PubMed:24532714, PubMed:25940091, PubMed:28650797, PubMed:28673543, PubMed:29244122). Interacts on the one hand with the 3' poly-A tails that are present in all mRNA molecules, and on the other hand with the 7-methylguanosine cap structure of mRNAs containing a 5' terminal oligopyrimidine (5'TOP) motif, which is present in mRNAs encoding ribosomal proteins and several components of the translation machinery (PubMed:23711370, PubMed:25940091, PubMed:26206669, PubMed:28379136, PubMed:28650797, PubMed:29244122). The interaction with the 5' end of mRNAs containing a 5'TOP motif leads to translational repression by preventing the binding of EIF4G1 (PubMed:25940091, PubMed:28379136, PubMed:28650797, PubMed:29244122). When mTORC1 is activated, LARP1 is phosphorylated and dissociates from the 5' untranslated region (UTR) of mRNA (PubMed:25940091, PubMed:28650797). Does not prevent binding of EIF4G1 to mRNAs that lack a 5'TOP motif (PubMed:28379136). Interacts with the free 40S ribosome subunit and with ribosomes, both monosomes and polysomes (PubMed:20430826, PubMed:24532714, PubMed:25940091, PubMed:28673543). Under normal nutrient availability, interacts primarily with the 3' untranslated region (UTR) of mRNAs encoding ribosomal proteins and increases protein synthesis (PubMed:23711370, PubMed:28650797). Associates with actively translating ribosomes and stimulates translation of mRNAs containing a 5'TOP motif, thereby regulating protein synthesis, and as a consequence, cell growth and proliferation (PubMed:20430826, PubMed:24532714). Stabilizes mRNAs species with a 5'TOP motif, which is required to prevent apoptosis (PubMed:20430826, PubMed:23711370, PubMed:25940091, PubMed:28673543). {ECO:0000269|PubMed:20430826, ECO:0000269|PubMed:23711370, ECO:0000269|PubMed:24532714, ECO:0000269|PubMed:25940091, ECO:0000269|PubMed:26206669, ECO:0000269|PubMed:28379136, ECO:0000269|PubMed:28650797, ECO:0000269|PubMed:28673543, ECO:0000269|PubMed:29244122}.; FUNCTION: (Microbial infection) Positively regulates the replication of dengue virus (DENV). {ECO:0000269|PubMed:26735137}. |
| Q6ZNB7 | AGMO | T22 | ochoa | Alkylglycerol monooxygenase (EC 1.14.16.5) (Transmembrane protein 195) | Glyceryl-ether monooxygenase that cleaves the O-alkyl bond of ether lipids. Ether lipids are essential components of brain membranes. {ECO:0000269|PubMed:20643956}. |
| Q6ZRV2 | FAM83H | T1014 | ochoa | Protein FAM83H | May play a major role in the structural organization and calcification of developing enamel (PubMed:18252228). May play a role in keratin cytoskeleton disassembly by recruiting CSNK1A1 to keratin filaments. Thereby, it may regulate epithelial cell migration (PubMed:23902688). {ECO:0000269|PubMed:18252228, ECO:0000269|PubMed:23902688}. |
| Q7L4E1 | MIGA2 | T273 | ochoa | Mitoguardin 2 (Protein FAM73B) | Regulator of mitochondrial fusion: acts by forming homo- and heterodimers at the mitochondrial outer membrane and facilitating the formation of PLD6/MitoPLD dimers. May act by regulating phospholipid metabolism via PLD6/MitoPLD. {ECO:0000269|PubMed:26711011}. |
| Q7Z406 | MYH14 | T1462 | ochoa | Myosin-14 (Myosin heavy chain 14) (Myosin heavy chain, non-muscle IIc) (Non-muscle myosin heavy chain IIc) (NMHC II-C) | Cellular myosin that appears to play a role in cytokinesis, cell shape, and specialized functions such as secretion and capping. {ECO:0000250}. |
| Q86T23 | CROCCP2 | T28 | ochoa | Putative ciliary rootlet coiled-coil protein-like 1 protein (Ciliary rootlet coiled-coil protein pseudogene 2) | None |
| Q86Y82 | STX12 | T93 | ochoa | Syntaxin-12 | SNARE promoting fusion of transport vesicles with target membranes. Together with SNARE STX6, promotes movement of vesicles from endosomes to the cell membrane, and may therefore function in the endocytic recycling pathway. Through complex formation with GRIP1, GRIA2 and NSG1 controls the intracellular fate of AMPAR and the endosomal sorting of the GRIA2 subunit toward recycling and membrane targeting. {ECO:0000250|UniProtKB:G3V7P1}. |
| Q8IUG5 | MYO18B | T1548 | ochoa | Unconventional myosin-XVIIIb | May be involved in intracellular trafficking of the muscle cell when in the cytoplasm, whereas entering the nucleus, may be involved in the regulation of muscle specific genes. May play a role in the control of tumor development and progression; restored MYO18B expression in lung cancer cells suppresses anchorage-independent growth. |
| Q8N163 | CCAR2 | T897 | ochoa|psp | Cell cycle and apoptosis regulator protein 2 (Cell division cycle and apoptosis regulator protein 2) (DBIRD complex subunit KIAA1967) (Deleted in breast cancer gene 1 protein) (DBC-1) (DBC.1) (NET35) (p30 DBC) | Core component of the DBIRD complex, a multiprotein complex that acts at the interface between core mRNP particles and RNA polymerase II (RNAPII) and integrates transcript elongation with the regulation of alternative splicing: the DBIRD complex affects local transcript elongation rates and alternative splicing of a large set of exons embedded in (A + T)-rich DNA regions (PubMed:22446626). Inhibits SIRT1 deacetylase activity leading to increasing levels of p53/TP53 acetylation and p53-mediated apoptosis (PubMed:18235501, PubMed:18235502, PubMed:23352644). Inhibits SUV39H1 methyltransferase activity (PubMed:19218236). Mediates ligand-dependent transcriptional activation by nuclear hormone receptors (PubMed:19131338). Plays a critical role in maintaining genomic stability and cellular integrity following UV-induced genotoxic stress (PubMed:23398316). Regulates the circadian expression of the core clock components NR1D1 and BMAL1 (PubMed:23398316). Enhances the transcriptional repressor activity of NR1D1 through stabilization of NR1D1 protein levels by preventing its ubiquitination and subsequent degradation (PubMed:23398316). Represses the ligand-dependent transcriptional activation function of ESR2 (PubMed:20074560). Acts as a regulator of PCK1 expression and gluconeogenesis by a mechanism that involves, at least in part, both NR1D1 and SIRT1 (PubMed:24415752). Negatively regulates the deacetylase activity of HDAC3 and can alter its subcellular localization (PubMed:21030595). Positively regulates the beta-catenin pathway (canonical Wnt signaling pathway) and is required for MCC-mediated repression of the beta-catenin pathway (PubMed:24824780). Represses ligand-dependent transcriptional activation function of NR1H2 and NR1H3 and inhibits the interaction of SIRT1 with NR1H3 (PubMed:25661920). Plays an important role in tumor suppression through p53/TP53 regulation; stabilizes p53/TP53 by affecting its interaction with ubiquitin ligase MDM2 (PubMed:25732823). Represses the transcriptional activator activity of BRCA1 (PubMed:20160719). Inhibits SIRT1 in a CHEK2 and PSEM3-dependent manner and inhibits the activity of CHEK2 in vitro (PubMed:25361978). {ECO:0000269|PubMed:18235501, ECO:0000269|PubMed:18235502, ECO:0000269|PubMed:19131338, ECO:0000269|PubMed:19218236, ECO:0000269|PubMed:20074560, ECO:0000269|PubMed:20160719, ECO:0000269|PubMed:21030595, ECO:0000269|PubMed:22446626, ECO:0000269|PubMed:23352644, ECO:0000269|PubMed:23398316, ECO:0000269|PubMed:24415752, ECO:0000269|PubMed:24824780, ECO:0000269|PubMed:25361978, ECO:0000269|PubMed:25661920, ECO:0000269|PubMed:25732823}. |
| Q8N4C6 | NIN | T1303 | ochoa | Ninein (hNinein) (Glycogen synthase kinase 3 beta-interacting protein) (GSK3B-interacting protein) | Centrosomal protein required in the positioning and anchorage of the microtubule minus-end in epithelial cells (PubMed:15190203, PubMed:23386061). May also act as a centrosome maturation factor (PubMed:11956314). May play a role in microtubule nucleation, by recruiting the gamma-tubulin ring complex to the centrosome (PubMed:15190203). Overexpression does not perturb nucleation or elongation of microtubules but suppresses release of microtubules (PubMed:15190203). Required for centriole organization and microtubule anchoring at the mother centriole (PubMed:23386061). {ECO:0000269|PubMed:11956314, ECO:0000269|PubMed:15190203, ECO:0000269|PubMed:23386061}. |
| Q8N806 | UBR7 | T271 | ochoa | Putative E3 ubiquitin-protein ligase UBR7 (EC 2.3.2.27) (N-recognin-7) (RING-type E3 ubiquitin transferase UBR7) | E3 ubiquitin-protein ligase which is a component of the N-end rule pathway. Recognizes and binds to proteins bearing specific N-terminal residues that are destabilizing according to the N-end rule, leading to their ubiquitination and subsequent degradation. {ECO:0000250}. |
| Q8N8S7 | ENAH | T464 | ochoa | Protein enabled homolog | Ena/VASP proteins are actin-associated proteins involved in a range of processes dependent on cytoskeleton remodeling and cell polarity such as axon guidance and lamellipodial and filopodial dynamics in migrating cells. ENAH induces the formation of F-actin rich outgrowths in fibroblasts. Acts synergistically with BAIAP2-alpha and downstream of NTN1 to promote filipodia formation (By similarity). {ECO:0000250, ECO:0000269|PubMed:11696321, ECO:0000269|PubMed:18158903}. |
| Q8ND71 | GIMAP8 | T557 | ochoa | GTPase IMAP family member 8 (Immune-associated nucleotide-binding protein 9) (IAN-9) (Protein IanT) | Exerts an anti-apoptotic effect in the immune system and is involved in responses to infections. {ECO:0000250|UniProtKB:Q75N62}. |
| Q8NDX1 | PSD4 | T484 | ochoa | PH and SEC7 domain-containing protein 4 (Exchange factor for ADP-ribosylation factor guanine nucleotide factor 6 B) (Exchange factor for ARF6 B) (Pleckstrin homology and SEC7 domain-containing protein 4) (Telomeric of interleukin-1 cluster protein) | Guanine nucleotide exchange factor for ARF6 and ARL14/ARF7. Through ARL14 activation, controls the movement of MHC class II-containing vesicles along the actin cytoskeleton in dendritic cells. Involved in membrane recycling. Interacts with several phosphatidylinositol phosphate species, including phosphatidylinositol 3,4-bisphosphate, phosphatidylinositol 3,5-bisphosphate and phosphatidylinositol 4,5-bisphosphate. {ECO:0000269|PubMed:12082148, ECO:0000269|PubMed:21458045}. |
| Q8NFC6 | BOD1L1 | T2478 | ochoa | Biorientation of chromosomes in cell division protein 1-like 1 | Component of the fork protection machinery required to protect stalled/damaged replication forks from uncontrolled DNA2-dependent resection. Acts by stabilizing RAD51 at stalled replication forks and protecting RAD51 nucleofilaments from the antirecombinogenic activities of FBH1 and BLM (PubMed:26166705, PubMed:29937342). Does not regulate spindle orientation (PubMed:26166705). {ECO:0000269|PubMed:26166705, ECO:0000269|PubMed:29937342}. |
| Q8TED0 | UTP15 | T493 | ochoa | U3 small nucleolar RNA-associated protein 15 homolog | Ribosome biogenesis factor. Involved in nucleolar processing of pre-18S ribosomal RNA. Required for optimal pre-ribosomal RNA transcription by RNA polymerase I (PubMed:17699751). Part of the small subunit (SSU) processome, first precursor of the small eukaryotic ribosomal subunit. During the assembly of the SSU processome in the nucleolus, many ribosome biogenesis factors, an RNA chaperone and ribosomal proteins associate with the nascent pre-rRNA and work in concert to generate RNA folding, modifications, rearrangements and cleavage as well as targeted degradation of pre-ribosomal RNA by the RNA exosome (PubMed:34516797). {ECO:0000269|PubMed:17699751, ECO:0000269|PubMed:34516797}. |
| Q8TEQ6 | GEMIN5 | T1330 | ochoa | Gem-associated protein 5 (Gemin5) | The SMN complex catalyzes the assembly of small nuclear ribonucleoproteins (snRNPs), the building blocks of the spliceosome, and thereby plays an important role in the splicing of cellular pre-mRNAs (PubMed:16857593, PubMed:18984161, PubMed:20513430, PubMed:33963192). Most spliceosomal snRNPs contain a common set of Sm proteins SNRPB, SNRPD1, SNRPD2, SNRPD3, SNRPE, SNRPF and SNRPG that assemble in a heptameric protein ring on the Sm site of the small nuclear RNA to form the core snRNP (Sm core). In the cytosol, the Sm proteins SNRPD1, SNRPD2, SNRPE, SNRPF and SNRPG are trapped in an inactive 6S pICln-Sm complex by the chaperone CLNS1A that controls the assembly of the core snRNP (PubMed:18984161). To assemble core snRNPs, the SMN complex accepts the trapped 5Sm proteins from CLNS1A forming an intermediate (PubMed:18984161). Binding of snRNA inside 5Sm ultimately triggers eviction of the SMN complex, thereby allowing binding of SNRPD3 and SNRPB to complete assembly of the core snRNP. Within the SMN complex, GEMIN5 recognizes and delivers the small nuclear RNAs (snRNAs) to the SMN complex (PubMed:11714716, PubMed:16314521, PubMed:16857593, PubMed:19377484, PubMed:19750007, PubMed:20513430, PubMed:27834343, PubMed:27881600, PubMed:27881601). Binds to the 7-methylguanosine cap of RNA molecules (PubMed:19750007, PubMed:27834343, PubMed:27881600, PubMed:27881601, Ref.27). Binds to the 3'-UTR of SMN1 mRNA and regulates its translation; does not affect mRNA stability (PubMed:25911097). May play a role in the regulation of protein synthesis via its interaction with ribosomes (PubMed:27507887). {ECO:0000269|PubMed:11714716, ECO:0000269|PubMed:16314521, ECO:0000269|PubMed:16857593, ECO:0000269|PubMed:18984161, ECO:0000269|PubMed:19377484, ECO:0000269|PubMed:19750007, ECO:0000269|PubMed:20513430, ECO:0000269|PubMed:25911097, ECO:0000269|PubMed:27507887, ECO:0000269|PubMed:27834343, ECO:0000269|PubMed:27881600, ECO:0000269|PubMed:27881601, ECO:0000269|PubMed:33963192, ECO:0000269|Ref.27}. |
| Q8WX93 | PALLD | T55 | ochoa | Palladin (SIH002) (Sarcoma antigen NY-SAR-77) | Cytoskeletal protein required for organization of normal actin cytoskeleton. Roles in establishing cell morphology, motility, cell adhesion and cell-extracellular matrix interactions in a variety of cell types. May function as a scaffolding molecule with the potential to influence both actin polymerization and the assembly of existing actin filaments into higher-order arrays. Binds to proteins that bind to either monomeric or filamentous actin. Localizes at sites where active actin remodeling takes place, such as lamellipodia and membrane ruffles. Different isoforms may have functional differences. Involved in the control of morphological and cytoskeletal changes associated with dendritic cell maturation. Involved in targeting ACTN to specific subcellular foci. {ECO:0000269|PubMed:11598191, ECO:0000269|PubMed:15147863, ECO:0000269|PubMed:17537434}. |
| Q92576 | PHF3 | T1034 | ochoa | PHD finger protein 3 | None |
| Q96AC1 | FERMT2 | T362 | ochoa | Fermitin family homolog 2 (Kindlin-2) (Mitogen-inducible gene 2 protein) (MIG-2) (Pleckstrin homology domain-containing family C member 1) (PH domain-containing family C member 1) | Scaffolding protein that enhances integrin activation mediated by TLN1 and/or TLN2, but activates integrins only weakly by itself. Binds to membranes enriched in phosphoinositides. Enhances integrin-mediated cell adhesion onto the extracellular matrix and cell spreading; this requires both its ability to interact with integrins and with phospholipid membranes. Required for the assembly of focal adhesions. Participates in the connection between extracellular matrix adhesion sites and the actin cytoskeleton and also in the orchestration of actin assembly and cell shape modulation. Recruits FBLIM1 to focal adhesions. Plays a role in the TGFB1 and integrin signaling pathways. Stabilizes active CTNNB1 and plays a role in the regulation of transcription mediated by CTNNB1 and TCF7L2/TCF4 and in Wnt signaling. {ECO:0000269|PubMed:12679033, ECO:0000269|PubMed:18458155, ECO:0000269|PubMed:21325030, ECO:0000269|PubMed:22030399, ECO:0000269|PubMed:22078565, ECO:0000269|PubMed:22699938}. |
| Q96K21 | ZFYVE19 | T236 | ochoa | Abscission/NoCut checkpoint regulator (ANCHR) (MLL partner containing FYVE domain) (Zinc finger FYVE domain-containing protein 19) | Key regulator of abscission step in cytokinesis: part of the cytokinesis checkpoint, a process required to delay abscission to prevent both premature resolution of intercellular chromosome bridges and accumulation of DNA damage. Together with CHMP4C, required to retain abscission-competent VPS4 (VPS4A and/or VPS4B) at the midbody ring until abscission checkpoint signaling is terminated at late cytokinesis. Deactivation of AURKB results in dephosphorylation of CHMP4C followed by its dissociation from ZFYVE19/ANCHR and VPS4 and subsequent abscission. {ECO:0000269|PubMed:24814515}. |
| Q96RT1 | ERBIN | T433 | ochoa | Erbin (Densin-180-like protein) (Erbb2-interacting protein) (Protein LAP2) | Acts as an adapter for the receptor ERBB2, in epithelia. By binding the unphosphorylated 'Tyr-1248' of receptor ERBB2, it may contribute to stabilize this unphosphorylated state (PubMed:16203728). Inhibits NOD2-dependent NF-kappa-B signaling and pro-inflammatory cytokine secretion (PubMed:16203728). {ECO:0000269|PubMed:10878805, ECO:0000269|PubMed:16203728}. |
| Q96ST2 | IWS1 | T721 | ochoa|psp | Protein IWS1 homolog (IWS1-like protein) | Transcription factor which plays a key role in defining the composition of the RNA polymerase II (RNAPII) elongation complex and in modulating the production of mature mRNA transcripts. Acts as an assembly factor to recruit various factors to the RNAPII elongation complex and is recruited to the complex via binding to the transcription elongation factor SUPT6H bound to the C-terminal domain (CTD) of the RNAPII subunit RPB1 (POLR2A). The SUPT6H:IWS1:CTD complex recruits mRNA export factors (ALYREF/THOC4, EXOSC10) as well as histone modifying enzymes (such as SETD2) to ensure proper mRNA splicing, efficient mRNA export and elongation-coupled H3K36 methylation, a signature chromatin mark of active transcription. {ECO:0000269|PubMed:17184735, ECO:0000269|PubMed:17234882, ECO:0000269|PubMed:19141475}. |
| Q99549 | MPHOSPH8 | T502 | ochoa | M-phase phosphoprotein 8 (Two hybrid-associated protein 3 with RanBPM) (Twa3) | Heterochromatin component that specifically recognizes and binds methylated 'Lys-9' of histone H3 (H3K9me) and promotes recruitment of proteins that mediate epigenetic repression (PubMed:20871592, PubMed:26022416). Mediates recruitment of the HUSH complex to H3K9me3 sites: the HUSH complex is recruited to genomic loci rich in H3K9me3 and is required to maintain transcriptional silencing by promoting recruitment of SETDB1, a histone methyltransferase that mediates further deposition of H3K9me3, as well as MORC2 (PubMed:26022416, PubMed:28581500). Binds H3K9me and promotes DNA methylation by recruiting DNMT3A to target CpG sites; these can be situated within the coding region of the gene (PubMed:20871592). Mediates down-regulation of CDH1 expression (PubMed:20871592). Also represses L1 retrotransposons in collaboration with MORC2 and, probably, SETDB1, the silencing is dependent of repressive epigenetic modifications, such as H3K9me3 mark. Silencing events often occur within introns of transcriptionally active genes, and lead to the down-regulation of host gene expression (PubMed:29211708). The HUSH complex is also involved in the silencing of unintegrated retroviral DNA by being recruited by ZNF638: some part of the retroviral DNA formed immediately after infection remains unintegrated in the host genome and is transcriptionally repressed (PubMed:30487602). {ECO:0000269|PubMed:20871592, ECO:0000269|PubMed:26022416, ECO:0000269|PubMed:28581500, ECO:0000269|PubMed:29211708, ECO:0000269|PubMed:30487602}. |
| Q9H223 | EHD4 | T421 | ochoa | EH domain-containing protein 4 (Hepatocellular carcinoma-associated protein 10/11) (PAST homolog 4) | ATP- and membrane-binding protein that probably controls membrane reorganization/tubulation upon ATP hydrolysis. Plays a role in early endosomal transport (PubMed:17233914, PubMed:18331452). During sprouting angiogenesis, in complex with PACSIN2 and MICALL1, forms recycling endosome-like tubular structure at asymmetric adherens junctions to control CDH5 trafficking (By similarity). {ECO:0000250|UniProtKB:Q9EQP2, ECO:0000269|PubMed:17233914, ECO:0000269|PubMed:18331452}. |
| Q9H2K0 | MTIF3 | Y128 | ochoa | Translation initiation factor IF-3, mitochondrial (IF-3(Mt)) (IF-3Mt) (IF3(mt)) (IF3mt) | IF-3 binds to the 28S ribosomal subunit and shifts the equilibrium between 55S ribosomes and their 39S and 28S subunits in favor of the free subunits, thus enhancing the availability of 28S subunits on which protein synthesis initiation begins. {ECO:0000269|PubMed:12095986}. |
| Q9H6H4 | REEP4 | T117 | ochoa | Receptor expression-enhancing protein 4 | Microtubule-binding protein required to ensure proper cell division and nuclear envelope reassembly by sequestering the endoplasmic reticulum away from chromosomes during mitosis. Probably acts by clearing the endoplasmic reticulum membrane from metaphase chromosomes. {ECO:0000269|PubMed:23911198}. |
| Q9NPD8 | UBE2T | T178 | ochoa | Ubiquitin-conjugating enzyme E2 T (EC 2.3.2.23) (Cell proliferation-inducing gene 50 protein) (E2 ubiquitin-conjugating enzyme T) (Ubiquitin carrier protein T) (Ubiquitin-protein ligase T) | Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. Catalyzes monoubiquitination. Involved in mitomycin-C (MMC)-induced DNA repair. Acts as a specific E2 ubiquitin-conjugating enzyme for the Fanconi anemia complex by associating with E3 ubiquitin-protein ligase FANCL and catalyzing monoubiquitination of FANCD2, a key step in the DNA damage pathway (PubMed:16916645, PubMed:17938197, PubMed:19111657, PubMed:19589784, PubMed:28437106). Also mediates monoubiquitination of FANCL and FANCI (PubMed:16916645, PubMed:17938197, PubMed:19111657, PubMed:19589784). May contribute to ubiquitination and degradation of BRCA1 (PubMed:19887602). In vitro able to promote polyubiquitination using all 7 ubiquitin Lys residues, but may prefer 'Lys-11'-, 'Lys-27'-, 'Lys-48'- and 'Lys-63'-linked polyubiquitination (PubMed:20061386). {ECO:0000269|PubMed:16916645, ECO:0000269|PubMed:17938197, ECO:0000269|PubMed:19111657, ECO:0000269|PubMed:19589784, ECO:0000269|PubMed:19887602, ECO:0000269|PubMed:20061386, ECO:0000269|PubMed:28437106}. |
| Q9NX58 | LYAR | T280 | ochoa | Cell growth-regulating nucleolar protein | Plays a role in the maintenance of the appropriate processing of 47S/45S pre-rRNA to 32S/30S pre-rRNAs and their subsequent processing to produce 18S and 28S rRNAs (PubMed:24495227). Also acts at the level of transcription regulation. Along with PRMT5, binds the gamma-globin (HBG1/HBG2) promoter and represses its expression (PubMed:25092918). In neuroblastoma cells, may also repress the expression of oxidative stress genes, including CHAC1, HMOX1, SLC7A11, ULBP1 and SNORD41 that encodes a small nucleolar RNA (PubMed:28686580). Preferentially binds to a DNA motif containing 5'-GGTTAT-3' (PubMed:25092918). Negatively regulates the antiviral innate immune response by targeting IRF3 and impairing its DNA-binding activity (PubMed:31413131). In addition, inhibits NF-kappa-B-mediated expression of pro-inflammatory cytokines (PubMed:31413131). Stimulates phagocytosis of photoreceptor outer segments by retinal pigment epithelial cells (By similarity). Prevents nucleolin/NCL self-cleavage, maintaining a normal steady-state level of NCL protein in undifferentiated embryonic stem cells (ESCs), which in turn is essential for ESC self-renewal (By similarity). {ECO:0000250|UniProtKB:Q08288, ECO:0000269|PubMed:24495227, ECO:0000269|PubMed:25092918, ECO:0000269|PubMed:28686580, ECO:0000269|PubMed:31413131}. |
| Q9NYF8 | BCLAF1 | T473 | ochoa | Bcl-2-associated transcription factor 1 (Btf) (BCLAF1 and THRAP3 family member 1) | Death-promoting transcriptional repressor. May be involved in cyclin-D1/CCND1 mRNA stability through the SNARP complex which associates with both the 3'end of the CCND1 gene and its mRNA. {ECO:0000269|PubMed:18794151}. |
| Q9NYL9 | TMOD3 | T27 | ochoa | Tropomodulin-3 (Ubiquitous tropomodulin) (U-Tmod) | Blocks the elongation and depolymerization of the actin filaments at the pointed end. The Tmod/TM complex contributes to the formation of the short actin protofilament, which in turn defines the geometry of the membrane skeleton (By similarity). {ECO:0000250}. |
| Q9P0K7 | RAI14 | T360 | ochoa | Ankycorbin (Ankyrin repeat and coiled-coil structure-containing protein) (Novel retinal pigment epithelial cell protein) (Retinoic acid-induced protein 14) | Plays a role in actin regulation at the ectoplasmic specialization, a type of cell junction specific to testis. Important for establishment of sperm polarity and normal spermatid adhesion. May also promote integrity of Sertoli cell tight junctions at the blood-testis barrier. {ECO:0000250|UniProtKB:Q5U312}. |
| Q9P270 | SLAIN2 | T397 | ochoa | SLAIN motif-containing protein 2 | Binds to the plus end of microtubules and regulates microtubule dynamics and microtubule organization. Promotes cytoplasmic microtubule nucleation and elongation. Required for normal structure of the microtubule cytoskeleton during interphase. {ECO:0000269|PubMed:21646404}. |
| Q9UBU7 | DBF4 | T449 | psp | Protein DBF4 homolog A (Activator of S phase kinase) (Chiffon homolog A) (DBF4-type zinc finger-containing protein 1) | Regulatory subunit for CDC7 which activates its kinase activity thereby playing a central role in DNA replication and cell proliferation. Required for progression of S phase. The complex CDC7-DBF4A selectively phosphorylates MCM2 subunit at 'Ser-40' and 'Ser-53' and then is involved in regulating the initiation of DNA replication during cell cycle. {ECO:0000269|PubMed:10373557, ECO:0000269|PubMed:10523313, ECO:0000269|PubMed:17062569}. |
| Q9UKV3 | ACIN1 | T363 | ochoa | Apoptotic chromatin condensation inducer in the nucleus (Acinus) | Auxiliary component of the splicing-dependent multiprotein exon junction complex (EJC) deposited at splice junction on mRNAs. The EJC is a dynamic structure consisting of core proteins and several peripheral nuclear and cytoplasmic associated factors that join the complex only transiently either during EJC assembly or during subsequent mRNA metabolism. Component of the ASAP complexes which bind RNA in a sequence-independent manner and are proposed to be recruited to the EJC prior to or during the splicing process and to regulate specific excision of introns in specific transcription subsets; ACIN1 confers RNA-binding to the complex. The ASAP complex can inhibit RNA processing during in vitro splicing reactions. The ASAP complex promotes apoptosis and is disassembled after induction of apoptosis. Involved in the splicing modulation of BCL2L1/Bcl-X (and probably other apoptotic genes); specifically inhibits formation of proapoptotic isoforms such as Bcl-X(S); the activity is different from the established EJC assembly and function. Induces apoptotic chromatin condensation after activation by CASP3. Regulates cyclin A1, but not cyclin A2, expression in leukemia cells. {ECO:0000269|PubMed:10490026, ECO:0000269|PubMed:12665594, ECO:0000269|PubMed:18559500, ECO:0000269|PubMed:22203037, ECO:0000269|PubMed:22388736}. |
| Q9UKV3 | ACIN1 | T902 | ochoa | Apoptotic chromatin condensation inducer in the nucleus (Acinus) | Auxiliary component of the splicing-dependent multiprotein exon junction complex (EJC) deposited at splice junction on mRNAs. The EJC is a dynamic structure consisting of core proteins and several peripheral nuclear and cytoplasmic associated factors that join the complex only transiently either during EJC assembly or during subsequent mRNA metabolism. Component of the ASAP complexes which bind RNA in a sequence-independent manner and are proposed to be recruited to the EJC prior to or during the splicing process and to regulate specific excision of introns in specific transcription subsets; ACIN1 confers RNA-binding to the complex. The ASAP complex can inhibit RNA processing during in vitro splicing reactions. The ASAP complex promotes apoptosis and is disassembled after induction of apoptosis. Involved in the splicing modulation of BCL2L1/Bcl-X (and probably other apoptotic genes); specifically inhibits formation of proapoptotic isoforms such as Bcl-X(S); the activity is different from the established EJC assembly and function. Induces apoptotic chromatin condensation after activation by CASP3. Regulates cyclin A1, but not cyclin A2, expression in leukemia cells. {ECO:0000269|PubMed:10490026, ECO:0000269|PubMed:12665594, ECO:0000269|PubMed:18559500, ECO:0000269|PubMed:22203037, ECO:0000269|PubMed:22388736}. |
| Q9UKX2 | MYH2 | S954 | ochoa | Myosin-2 (Myosin heavy chain 2) (Myosin heavy chain 2a) (MyHC-2a) (Myosin heavy chain IIa) (MyHC-IIa) (Myosin heavy chain, skeletal muscle, adult 2) | Myosins are actin-based motor molecules with ATPase activity essential for muscle contraction. {ECO:0000250|UniProtKB:P12883}. |
| Q9UKX2 | MYH2 | T1025 | ochoa | Myosin-2 (Myosin heavy chain 2) (Myosin heavy chain 2a) (MyHC-2a) (Myosin heavy chain IIa) (MyHC-IIa) (Myosin heavy chain, skeletal muscle, adult 2) | Myosins are actin-based motor molecules with ATPase activity essential for muscle contraction. {ECO:0000250|UniProtKB:P12883}. |
| Q9UKX2 | MYH2 | T1288 | ochoa | Myosin-2 (Myosin heavy chain 2) (Myosin heavy chain 2a) (MyHC-2a) (Myosin heavy chain IIa) (MyHC-IIa) (Myosin heavy chain, skeletal muscle, adult 2) | Myosins are actin-based motor molecules with ATPase activity essential for muscle contraction. {ECO:0000250|UniProtKB:P12883}. |
| Q9UKX2 | MYH2 | T1485 | ochoa | Myosin-2 (Myosin heavy chain 2) (Myosin heavy chain 2a) (MyHC-2a) (Myosin heavy chain IIa) (MyHC-IIa) (Myosin heavy chain, skeletal muscle, adult 2) | Myosins are actin-based motor molecules with ATPase activity essential for muscle contraction. {ECO:0000250|UniProtKB:P12883}. |
| Q9UKX2 | MYH2 | T1503 | ochoa | Myosin-2 (Myosin heavy chain 2) (Myosin heavy chain 2a) (MyHC-2a) (Myosin heavy chain IIa) (MyHC-IIa) (Myosin heavy chain, skeletal muscle, adult 2) | Myosins are actin-based motor molecules with ATPase activity essential for muscle contraction. {ECO:0000250|UniProtKB:P12883}. |
| Q9UKX2 | MYH2 | T1724 | ochoa | Myosin-2 (Myosin heavy chain 2) (Myosin heavy chain 2a) (MyHC-2a) (Myosin heavy chain IIa) (MyHC-IIa) (Myosin heavy chain, skeletal muscle, adult 2) | Myosins are actin-based motor molecules with ATPase activity essential for muscle contraction. {ECO:0000250|UniProtKB:P12883}. |
| Q9UKX3 | MYH13 | T1483 | ochoa | Myosin-13 (Myosin heavy chain 13) (Myosin heavy chain, skeletal muscle, extraocular) (MyHC-EO) (Myosin heavy chain, skeletal muscle, laryngeal) (MyHC-IIL) (Superfast myosin) | Fast twitching myosin mediating the high-velocity and low-tension contractions of specific striated muscles. {ECO:0000269|PubMed:23908353}. |
| Q9ULD2 | MTUS1 | T1204 | ochoa | Microtubule-associated tumor suppressor 1 (AT2 receptor-binding protein) (Angiotensin-II type 2 receptor-interacting protein) (Mitochondrial tumor suppressor 1) | Cooperates with AGTR2 to inhibit ERK2 activation and cell proliferation. May be required for AGTR2 cell surface expression. Together with PTPN6, induces UBE2V2 expression upon angiotensin-II stimulation. Isoform 1 inhibits breast cancer cell proliferation, delays the progression of mitosis by prolonging metaphase and reduces tumor growth. {ECO:0000269|PubMed:12692079, ECO:0000269|PubMed:19794912}. |
| Q9ULI0 | ATAD2B | T1322 | ochoa | ATPase family AAA domain-containing protein 2B | None |
| Q9UQ35 | SRRM2 | T1265 | ochoa | Serine/arginine repetitive matrix protein 2 (300 kDa nuclear matrix antigen) (Serine/arginine-rich splicing factor-related nuclear matrix protein of 300 kDa) (SR-related nuclear matrix protein of 300 kDa) (Ser/Arg-related nuclear matrix protein of 300 kDa) (Splicing coactivator subunit SRm300) (Tax-responsive enhancer element-binding protein 803) (TaxREB803) | Required for pre-mRNA splicing as component of the spliceosome. As a component of the minor spliceosome, involved in the splicing of U12-type introns in pre-mRNAs (Probable). {ECO:0000269|PubMed:19854871, ECO:0000269|PubMed:28076346, ECO:0000269|PubMed:28502770, ECO:0000269|PubMed:29301961, ECO:0000269|PubMed:29360106, ECO:0000269|PubMed:29361316, ECO:0000269|PubMed:30705154, ECO:0000269|PubMed:9531537, ECO:0000305|PubMed:33509932}. |
| Q9UQ80 | PA2G4 | T366 | ochoa|psp | Proliferation-associated protein 2G4 (Cell cycle protein p38-2G4 homolog) (hG4-1) (ErbB3-binding protein 1) | May play a role in a ERBB3-regulated signal transduction pathway. Seems be involved in growth regulation. Acts a corepressor of the androgen receptor (AR) and is regulated by the ERBB3 ligand neuregulin-1/heregulin (HRG). Inhibits transcription of some E2F1-regulated promoters, probably by recruiting histone acetylase (HAT) activity. Binds RNA. Associates with 28S, 18S and 5.8S mature rRNAs, several rRNA precursors and probably U3 small nucleolar RNA. May be involved in regulation of intermediate and late steps of rRNA processing. May be involved in ribosome assembly. Mediates cap-independent translation of specific viral IRESs (internal ribosomal entry site) (By similarity). Regulates cell proliferation, differentiation, and survival. Isoform 1 suppresses apoptosis whereas isoform 2 promotes cell differentiation (By similarity). {ECO:0000250|UniProtKB:P50580, ECO:0000250|UniProtKB:Q6AYD3, ECO:0000269|PubMed:11268000, ECO:0000269|PubMed:12682367, ECO:0000269|PubMed:15064750, ECO:0000269|PubMed:15583694, ECO:0000269|PubMed:16832058}. |
| Q9Y490 | TLN1 | T1254 | ochoa | Talin-1 | High molecular weight cytoskeletal protein concentrated at regions of cell-matrix and cell-cell contacts. Involved in connections of major cytoskeletal structures to the plasma membrane. With KANK1 co-organize the assembly of cortical microtubule stabilizing complexes (CMSCs) positioned to control microtubule-actin crosstalk at focal adhesions (FAs) rims. {ECO:0000250|UniProtKB:P26039}. |
| Q9Y623 | MYH4 | S952 | ochoa | Myosin-4 (Myosin heavy chain 2b) (MyHC-2b) (Myosin heavy chain 4) (Myosin heavy chain IIb) (MyHC-IIb) (Myosin heavy chain, skeletal muscle, fetal) | Muscle contraction. |
| Q9Y623 | MYH4 | T1483 | ochoa | Myosin-4 (Myosin heavy chain 2b) (MyHC-2b) (Myosin heavy chain 4) (Myosin heavy chain IIb) (MyHC-IIb) (Myosin heavy chain, skeletal muscle, fetal) | Muscle contraction. |
| Q9Y623 | MYH4 | T1722 | ochoa | Myosin-4 (Myosin heavy chain 2b) (MyHC-2b) (Myosin heavy chain 4) (Myosin heavy chain IIb) (MyHC-IIb) (Myosin heavy chain, skeletal muscle, fetal) | Muscle contraction. |
| Q9Y6D9 | MAD1L1 | T323 | psp | Mitotic spindle assembly checkpoint protein MAD1 (Mitotic arrest deficient 1-like protein 1) (MAD1-like protein 1) (Mitotic checkpoint MAD1 protein homolog) (HsMAD1) (hMAD1) (Tax-binding protein 181) | Component of the spindle-assembly checkpoint that prevents the onset of anaphase until all chromosomes are properly aligned at the metaphase plate (PubMed:10049595, PubMed:20133940, PubMed:29162720). Forms a heterotetrameric complex with the closed conformation form of MAD2L1 (C-MAD2) at unattached kinetochores during prometaphase, recruits an open conformation of MAD2L1 (O-MAD2) and promotes the conversion of O-MAD2 to C-MAD2, which ensures mitotic checkpoint signaling (PubMed:29162720). {ECO:0000269|PubMed:10049595, ECO:0000269|PubMed:20133940, ECO:0000269|PubMed:29162720, ECO:0000269|PubMed:36322655}.; FUNCTION: [Isoform 3]: Sequesters MAD2L1 in the cytoplasm preventing its function as an activator of the mitotic spindle assembly checkpoint (SAC) resulting in SAC impairment and chromosomal instability in hepatocellular carcinomas. {ECO:0000269|PubMed:19010891}. |
| P30101 | PDIA3 | T485 | Sugiyama | Protein disulfide-isomerase A3 (EC 5.3.4.1) (58 kDa glucose-regulated protein) (58 kDa microsomal protein) (p58) (Disulfide isomerase ER-60) (Endoplasmic reticulum resident protein 57) (ER protein 57) (ERp57) (Endoplasmic reticulum resident protein 60) (ER protein 60) (ERp60) | Protein disulfide isomerase that catalyzes the formation, isomerization, and reduction or oxidation of disulfide bonds in client proteins and functions as a protein folding chaperone (PubMed:11825568, PubMed:16193070, PubMed:27897272, PubMed:36104323, PubMed:7487104). Core component of the major histocompatibility complex class I (MHC I) peptide loading complex where it functions as an essential folding chaperone for TAPBP. Through TAPBP, assists the dynamic assembly of the MHC I complex with high affinity antigens in the endoplasmic reticulum. Therefore, plays a crucial role in the presentation of antigens to cytotoxic T cells in adaptive immunity (PubMed:35948544, PubMed:36104323). {ECO:0000269|PubMed:11825568, ECO:0000269|PubMed:16193070, ECO:0000269|PubMed:27897272, ECO:0000269|PubMed:35948544, ECO:0000269|PubMed:36104323, ECO:0000269|PubMed:7487104}. |
| P31948 | STIP1 | T243 | Sugiyama | Stress-induced-phosphoprotein 1 (STI1) (Hsc70/Hsp90-organizing protein) (Hop) (Renal carcinoma antigen NY-REN-11) (Transformation-sensitive protein IEF SSP 3521) | Acts as a co-chaperone for HSP90AA1 (PubMed:27353360). Mediates the association of the molecular chaperones HSPA8/HSC70 and HSP90 (By similarity). {ECO:0000250|UniProtKB:O35814, ECO:0000303|PubMed:27353360}. |
| P33176 | KIF5B | T809 | Sugiyama | Kinesin-1 heavy chain (Conventional kinesin heavy chain) (Ubiquitous kinesin heavy chain) (UKHC) | Microtubule-dependent motor required for normal distribution of mitochondria and lysosomes. Can induce formation of neurite-like membrane protrusions in non-neuronal cells in a ZFYVE27-dependent manner (By similarity). Regulates centrosome and nuclear positioning during mitotic entry. During the G2 phase of the cell cycle in a BICD2-dependent manner, antagonizes dynein function and drives the separation of nuclei and centrosomes (PubMed:20386726). Required for anterograde axonal transportation of MAPK8IP3/JIP3 which is essential for MAPK8IP3/JIP3 function in axon elongation (By similarity). Through binding with PLEKHM2 and ARL8B, directs lysosome movement toward microtubule plus ends (Probable). Involved in NK cell-mediated cytotoxicity. Drives the polarization of cytolytic granules and microtubule-organizing centers (MTOCs) toward the immune synapse between effector NK lymphocytes and target cells (PubMed:24088571). {ECO:0000250|UniProtKB:Q2PQA9, ECO:0000250|UniProtKB:Q61768, ECO:0000269|PubMed:20386726, ECO:0000269|PubMed:24088571, ECO:0000305|PubMed:22172677, ECO:0000305|PubMed:24088571}. |
| Q00341 | HDLBP | T729 | Sugiyama | Vigilin (High density lipoprotein-binding protein) (HDL-binding protein) | Appears to play a role in cell sterol metabolism. It may function to protect cells from over-accumulation of cholesterol. |
| P39748 | FEN1 | T195 | EPSD|PSP | Flap endonuclease 1 (FEN-1) (EC 3.1.-.-) (DNase IV) (Flap structure-specific endonuclease 1) (Maturation factor 1) (MF1) (hFEN-1) | Structure-specific nuclease with 5'-flap endonuclease and 5'-3' exonuclease activities involved in DNA replication and repair. During DNA replication, cleaves the 5'-overhanging flap structure that is generated by displacement synthesis when DNA polymerase encounters the 5'-end of a downstream Okazaki fragment. It enters the flap from the 5'-end and then tracks to cleave the flap base, leaving a nick for ligation. Also involved in the long patch base excision repair (LP-BER) pathway, by cleaving within the apurinic/apyrimidinic (AP) site-terminated flap. Acts as a genome stabilization factor that prevents flaps from equilibrating into structures that lead to duplications and deletions. Also possesses 5'-3' exonuclease activity on nicked or gapped double-stranded DNA, and exhibits RNase H activity. Also involved in replication and repair of rDNA and in repairing mitochondrial DNA. {ECO:0000255|HAMAP-Rule:MF_03140, ECO:0000269|PubMed:10744741, ECO:0000269|PubMed:11986308, ECO:0000269|PubMed:18443037, ECO:0000269|PubMed:20729856, ECO:0000269|PubMed:26751069, ECO:0000269|PubMed:7961795, ECO:0000269|PubMed:8621570}. |
| Q99848 | EBNA1BP2 | T182 | EPSD|PSP | Probable rRNA-processing protein EBP2 (EBNA1-binding protein 2) (Nucleolar protein p40) | Required for the processing of the 27S pre-rRNA. {ECO:0000250}. |
| Q86VS8 | HOOK3 | T291 | Sugiyama | Protein Hook homolog 3 (h-hook3) (hHK3) | Acts as an adapter protein linking the dynein motor complex to various cargos and converts dynein from a non-processive to a highly processive motor in the presence of dynactin. Facilitates the interaction between dynein and dynactin and activates dynein processivity (the ability to move along a microtubule for a long distance without falling off the track). Predominantly recruits 2 dyneins, which increases both the force and speed of the microtubule motor (PubMed:25035494, PubMed:33734450). Component of the FTS/Hook/FHIP complex (FHF complex). The FHF complex may function to promote vesicle trafficking and/or fusion via the homotypic vesicular protein sorting complex (the HOPS complex). May regulate clearance of endocytosed receptors such as MSR1. Participates in defining the architecture and localization of the Golgi complex. FHF complex promotes the distribution of AP-4 complex to the perinuclear area of the cell (PubMed:32073997). {ECO:0000250|UniProtKB:Q8BUK6, ECO:0000269|PubMed:11238449, ECO:0000269|PubMed:17237231, ECO:0000269|PubMed:18799622, ECO:0000269|PubMed:25035494, ECO:0000269|PubMed:32073997, ECO:0000269|PubMed:33734450}.; FUNCTION: (Microbial infection) May serve as a target for the spiC protein from Salmonella typhimurium, which inactivates it, leading to a strong alteration in cellular trafficking. {ECO:0000305}. |
| O43423 | ANP32CP | T101 | Sugiyama | Putative uncharacterized protein ANP32CP (Acidic leucine-rich nuclear phosphoprotein 32 family member C) (Phosphoprotein 32-related protein 1) (Tumorigenic protein pp32r1) | None |
| O95626 | ANP32D | T105 | Sugiyama | Acidic leucine-rich nuclear phosphoprotein 32 family member D (Phosphoprotein 32-related protein 2) (Tumorigenic protein pp32r2) | None |
| P39687 | ANP32A | T105 | Sugiyama | Acidic leucine-rich nuclear phosphoprotein 32 family member A (Acidic nuclear phosphoprotein pp32) (pp32) (Leucine-rich acidic nuclear protein) (LANP) (Mapmodulin) (Potent heat-stable protein phosphatase 2A inhibitor I1PP2A) (Putative HLA-DR-associated protein I) (PHAPI) | Multifunctional protein that is involved in the regulation of many processes including tumor suppression, apoptosis, cell cycle progression or transcription (PubMed:10400610, PubMed:11360199, PubMed:16341127, PubMed:18439902). Promotes apoptosis by favouring the activation of caspase-9/CASP9 and allowing apoptosome formation (PubMed:18439902). In addition, plays a role in the modulation of histone acetylation and transcription as part of the INHAT (inhibitor of histone acetyltransferases) complex. Inhibits the histone-acetyltranferase activity of EP300/CREBBP (CREB-binding protein) and EP300/CREBBP-associated factor by histone masking (PubMed:11830591). Preferentially binds to unmodified histone H3 and sterically inhibiting its acetylation and phosphorylation leading to cell growth inhibition (PubMed:16341127). Participates in other biochemical processes such as regulation of mRNA nuclear-to-cytoplasmic translocation and stability by its association with ELAVL1 (Hu-antigen R) (PubMed:18180367). Plays a role in E4F1-mediated transcriptional repression as well as inhibition of protein phosphatase 2A (PubMed:15642345, PubMed:17557114). {ECO:0000269|PubMed:10400610, ECO:0000269|PubMed:11360199, ECO:0000269|PubMed:11830591, ECO:0000269|PubMed:15642345, ECO:0000269|PubMed:16341127, ECO:0000269|PubMed:17557114, ECO:0000269|PubMed:18180367, ECO:0000269|PubMed:18439902}.; FUNCTION: (Microbial infection) Plays an essential role in influenza A, B and C viral genome replication (PubMed:30666459, PubMed:32694517, PubMed:33045004, PubMed:33208942). Mechanistically, mediates the assembly of the viral replicase asymmetric dimers composed of PB1, PB2 and PA via its N-terminal region (PubMed:33208942). Also plays an essential role in foamy virus mRNA export from the nucleus (PubMed:21159877). {ECO:0000269|PubMed:21159877, ECO:0000269|PubMed:30666459, ECO:0000269|PubMed:32694517, ECO:0000269|PubMed:33045004, ECO:0000269|PubMed:33208942}. |
| O75116 | ROCK2 | T489 | Sugiyama | Rho-associated protein kinase 2 (EC 2.7.11.1) (Rho kinase 2) (Rho-associated, coiled-coil-containing protein kinase 2) (Rho-associated, coiled-coil-containing protein kinase II) (ROCK-II) (p164 ROCK-2) | Protein kinase which is a key regulator of actin cytoskeleton and cell polarity. Involved in regulation of smooth muscle contraction, actin cytoskeleton organization, stress fiber and focal adhesion formation, neurite retraction, cell adhesion and motility via phosphorylation of ADD1, BRCA2, CNN1, EZR, DPYSL2, EP300, MSN, MYL9/MLC2, NPM1, RDX, PPP1R12A and VIM. Phosphorylates SORL1 and IRF4. Acts as a negative regulator of VEGF-induced angiogenic endothelial cell activation. Positively regulates the activation of p42/MAPK1-p44/MAPK3 and of p90RSK/RPS6KA1 during myogenic differentiation. Plays an important role in the timely initiation of centrosome duplication. Inhibits keratinocyte terminal differentiation. May regulate closure of the eyelids and ventral body wall through organization of actomyosin bundles. Plays a critical role in the regulation of spine and synaptic properties in the hippocampus. Plays an important role in generating the circadian rhythm of the aortic myofilament Ca(2+) sensitivity and vascular contractility by modulating the myosin light chain phosphorylation. {ECO:0000269|PubMed:10579722, ECO:0000269|PubMed:15699075, ECO:0000269|PubMed:16574662, ECO:0000269|PubMed:17015463, ECO:0000269|PubMed:19131646, ECO:0000269|PubMed:19997641, ECO:0000269|PubMed:21084279, ECO:0000269|PubMed:21147781}. |
| O60841 | EIF5B | T78 | Sugiyama | Eukaryotic translation initiation factor 5B (eIF-5B) (EC 3.6.5.3) (Translation initiation factor IF-2) | Plays a role in translation initiation (PubMed:10659855, PubMed:35732735). Ribosome-dependent GTPase that promotes the joining of the 60S ribosomal subunit to the pre-initiation complex to form the 80S initiation complex with the initiator methionine-tRNA in the P-site base paired to the start codon (PubMed:10659855, PubMed:35732735). Together with eIF1A (EIF1AX), actively orients the initiator methionine-tRNA in a conformation that allows 60S ribosomal subunit joining to form the 80S initiation complex (PubMed:12569173, PubMed:35732735). Is released after formation of the 80S initiation complex (PubMed:35732735). Its GTPase activity is not essential for ribosomal subunits joining, but GTP hydrolysis is needed for eIF1A (EIF1AX) ejection quickly followed by EIF5B release to form elongation-competent ribosomes (PubMed:10659855, PubMed:35732735). In contrast to its procaryotic homolog, does not promote recruitment of Met-rRNA to the small ribosomal subunit (PubMed:10659855). {ECO:0000269|PubMed:10659855, ECO:0000269|PubMed:12569173, ECO:0000269|PubMed:35732735}. |
| P12277 | CKB | T327 | Sugiyama | Creatine kinase B-type (EC 2.7.3.2) (Brain creatine kinase) (B-CK) (Creatine kinase B chain) (Creatine phosphokinase B-type) (CPK-B) | Reversibly catalyzes the transfer of phosphate between ATP and various phosphogens (e.g. creatine phosphate) (PubMed:8186255). Creatine kinase isoenzymes play a central role in energy transduction in tissues with large, fluctuating energy demands, such as skeletal muscle, heart, brain and spermatozoa (Probable). Acts as a key regulator of adaptive thermogenesis as part of the futile creatine cycle: localizes to the mitochondria of thermogenic fat cells and acts by mediating phosphorylation of creatine to initiate a futile cycle of creatine phosphorylation and dephosphorylation (By similarity). During the futile creatine cycle, creatine and N-phosphocreatine are in a futile cycle, which dissipates the high energy charge of N-phosphocreatine as heat without performing any mechanical or chemical work (By similarity). {ECO:0000250|UniProtKB:Q04447, ECO:0000269|PubMed:8186255, ECO:0000305}. |
| Q96S59 | RANBP9 | T163 | Sugiyama | Ran-binding protein 9 (RanBP9) (BPM-L) (BPM90) (Ran-binding protein M) (RanBPM) (RanBP7) | May act as scaffolding protein, and as adapter protein to couple membrane receptors to intracellular signaling pathways (Probable). Acts as a mediator of cell spreading and actin cytoskeleton rearrangement (PubMed:18710924). Core component of the CTLH E3 ubiquitin-protein ligase complex that selectively accepts ubiquitin from UBE2H and mediates ubiquitination and subsequent proteasomal degradation of the transcription factor HBP1 (PubMed:29911972). May be involved in signaling of ITGB2/LFA-1 and other integrins (PubMed:14722085). Enhances HGF-MET signaling by recruiting Sos and activating the Ras pathway (PubMed:12147692). Enhances dihydrotestosterone-induced transactivation activity of AR, as well as dexamethasone-induced transactivation activity of NR3C1, but not affect estrogen-induced transactivation (PubMed:12361945, PubMed:18222118). Stabilizes TP73 isoform Alpha, probably by inhibiting its ubiquitination, and increases its proapoptotic activity (PubMed:15558019). Inhibits the kinase activity of DYRK1A and DYRK1B. Inhibits FMR1 binding to RNA. {ECO:0000269|PubMed:12147692, ECO:0000269|PubMed:12361945, ECO:0000269|PubMed:14500717, ECO:0000269|PubMed:14722085, ECO:0000269|PubMed:15381419, ECO:0000269|PubMed:15558019, ECO:0000269|PubMed:18222118, ECO:0000269|PubMed:18710924, ECO:0000269|PubMed:29911972, ECO:0000305}. |
| Q5JSH3 | WDR44 | T364 | Sugiyama | WD repeat-containing protein 44 (Rab11-binding protein) (Rab11BP) (Rabphilin-11) | Downstream effector for Rab11 which regulates Rab11 intracellular membrane trafficking functions such as endocytic recycling, intracellular ciliogenesis and protein export (PubMed:31204173, PubMed:32344433). ATK1-mediated phosphorylation of WDR44 induces binding to Rab11 which activates endocytic recycling of transferrin receptor back to the plasma membrane (PubMed:31204173). When bound to Rab11, prevents the formation of the ciliogenic Rab11-Rabin8/RAB3IP-RAB11FIP3 complex, therefore inhibiting preciliary trafficking and ciliogenesis (PubMed:31204173). Participates in neo-synthesized protein export by connecting the endoplasmic reticulum (ER) with the endosomal tubule via direct interactions with the integral ER proteins VAPA or VAPB and the endosomal protein GRAFs (GRAF1/ARHGAP26 or GRAF2/ARHGAP10), which facilitates the transfer of proteins such as E-cadherin, MPP14 and CFTR into a Rab8-Rab10-Rab11-dependent export route (PubMed:32344433). {ECO:0000269|PubMed:31204173, ECO:0000269|PubMed:32344433}. |
| P63104 | YWHAZ | T226 | Sugiyama | 14-3-3 protein zeta/delta (Protein kinase C inhibitor protein 1) (KCIP-1) | Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways (PubMed:14578935, PubMed:15071501, PubMed:15644438, PubMed:16376338, PubMed:16959763, PubMed:31024343, PubMed:9360956). Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif (PubMed:35662396). Binding generally results in the modulation of the activity of the binding partner (PubMed:35662396). Promotes cytosolic retention and inactivation of TFEB transcription factor by binding to phosphorylated TFEB (PubMed:35662396). Induces ARHGEF7 activity on RAC1 as well as lamellipodia and membrane ruffle formation (PubMed:16959763). In neurons, regulates spine maturation through the modulation of ARHGEF7 activity (By similarity). {ECO:0000250|UniProtKB:O55043, ECO:0000269|PubMed:14578935, ECO:0000269|PubMed:15071501, ECO:0000269|PubMed:15644438, ECO:0000269|PubMed:16376338, ECO:0000269|PubMed:16959763, ECO:0000269|PubMed:31024343, ECO:0000269|PubMed:35662396, ECO:0000269|PubMed:9360956}. |
| Q92688 | ANP32B | T105 | Sugiyama | Acidic leucine-rich nuclear phosphoprotein 32 family member B (Acidic protein rich in leucines) (Putative HLA-DR-associated protein I-2) (PHAPI2) (Silver-stainable protein SSP29) | Multifunctional protein that is involved in the regulation of many processes including cell proliferation, apoptosis, cell cycle progression or transcription (PubMed:18039846, PubMed:20015864). Regulates the proliferation of neuronal stem cells, differentiation of leukemic cells and progression from G1 to S phase of the cell cycle. As negative regulator of caspase-3-dependent apoptosis, may act as an antagonist of ANP32A in regulating tissue homeostasis (PubMed:20015864). Exhibits histone chaperone properties, able to recruit histones to certain promoters, thus regulating the transcription of specific genes (PubMed:18039846, PubMed:20538007). Also plays an essential role in the nucleocytoplasmic transport of specific mRNAs via the uncommon nuclear mRNA export receptor XPO1/CRM1 (PubMed:17178712). Participates in the regulation of adequate adaptive immune responses by acting on mRNA expression and cell proliferation (By similarity). {ECO:0000250|UniProtKB:Q9EST5, ECO:0000269|PubMed:17178712, ECO:0000269|PubMed:18039846, ECO:0000269|PubMed:20015864, ECO:0000269|PubMed:20538007}.; FUNCTION: (Microbial infection) Plays an essential role in influenza A and B viral genome replication (PubMed:31217244, PubMed:33045004). Also plays a role in foamy virus mRNA export from the nucleus to the cytoplasm (PubMed:21159877). {ECO:0000269|PubMed:21159877, ECO:0000269|PubMed:31217244, ECO:0000269|PubMed:33045004}. |
| Q99798 | ACO2 | T511 | Sugiyama | Aconitate hydratase, mitochondrial (Aconitase) (EC 4.2.1.3) (Citrate hydro-lyase) | Catalyzes the isomerization of citrate to isocitrate via cis-aconitate. {ECO:0000250|UniProtKB:P16276}. |
| Q5T9S5 | CCDC18 | T334 | Sugiyama | Coiled-coil domain-containing protein 18 (Sarcoma antigen NY-SAR-24) | None |
| Q14164 | IKBKE | T176 | Sugiyama | Inhibitor of nuclear factor kappa-B kinase subunit epsilon (I-kappa-B kinase epsilon) (IKK-E) (IKK-epsilon) (IkBKE) (EC 2.7.11.10) (Inducible I kappa-B kinase) (IKK-i) | Serine/threonine kinase that plays an essential role in regulating inflammatory responses to viral infection, through the activation of the type I IFN, NF-kappa-B and STAT signaling. Also involved in TNFA and inflammatory cytokines, like Interleukin-1, signaling. Following activation of viral RNA sensors, such as RIG-I-like receptors, associates with DDX3X and phosphorylates interferon regulatory factors (IRFs), IRF3 and IRF7, as well as DDX3X. This activity allows subsequent homodimerization and nuclear translocation of the IRF3 leading to transcriptional activation of pro-inflammatory and antiviral genes including IFNB. In order to establish such an antiviral state, IKBKE forms several different complexes whose composition depends on the type of cell and cellular stimuli. Thus, several scaffolding molecules including IPS1/MAVS, TANK, AZI2/NAP1 or TBKBP1/SINTBAD can be recruited to the IKBKE-containing-complexes. Activated by polyubiquitination in response to TNFA and interleukin-1, regulates the NF-kappa-B signaling pathway through, at least, the phosphorylation of CYLD. Phosphorylates inhibitors of NF-kappa-B thus leading to the dissociation of the inhibitor/NF-kappa-B complex and ultimately the degradation of the inhibitor. In addition, is also required for the induction of a subset of ISGs which displays antiviral activity, may be through the phosphorylation of STAT1 at 'Ser-708'. Phosphorylation of STAT1 at 'Ser-708' also seems to promote the assembly and DNA binding of ISGF3 (STAT1:STAT2:IRF9) complexes compared to GAF (STAT1:STAT1) complexes, in this way regulating the balance between type I and type II IFN responses. Protects cells against DNA damage-induced cell death. Also plays an important role in energy balance regulation by sustaining a state of chronic, low-grade inflammation in obesity, wich leads to a negative impact on insulin sensitivity. Phosphorylates AKT1. {ECO:0000269|PubMed:17568778, ECO:0000269|PubMed:18583960, ECO:0000269|PubMed:19153231, ECO:0000269|PubMed:20188669, ECO:0000269|PubMed:21138416, ECO:0000269|PubMed:21464307, ECO:0000269|PubMed:22532683, ECO:0000269|PubMed:23453969, ECO:0000269|PubMed:23478265}. |
| P51812 | RPS6KA3 | T157 | Sugiyama | Ribosomal protein S6 kinase alpha-3 (S6K-alpha-3) (EC 2.7.11.1) (90 kDa ribosomal protein S6 kinase 3) (p90-RSK 3) (p90RSK3) (Insulin-stimulated protein kinase 1) (ISPK-1) (MAP kinase-activated protein kinase 1b) (MAPK-activated protein kinase 1b) (MAPKAP kinase 1b) (MAPKAPK-1b) (Ribosomal S6 kinase 2) (RSK-2) (pp90RSK2) | Serine/threonine-protein kinase that acts downstream of ERK (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic and stress-induced activation of the transcription factors CREB1, ETV1/ER81 and NR4A1/NUR77, regulates translation through RPS6 and EIF4B phosphorylation, and mediates cellular proliferation, survival, and differentiation by modulating mTOR signaling and repressing pro-apoptotic function of BAD and DAPK1 (PubMed:16213824, PubMed:16223362, PubMed:17360704, PubMed:9770464). In fibroblast, is required for EGF-stimulated phosphorylation of CREB1 and histone H3 at 'Ser-10', which results in the subsequent transcriptional activation of several immediate-early genes (PubMed:10436156, PubMed:9770464). In response to mitogenic stimulation (EGF and PMA), phosphorylates and activates NR4A1/NUR77 and ETV1/ER81 transcription factors and the cofactor CREBBP (PubMed:16223362). Upon insulin-derived signal, acts indirectly on the transcription regulation of several genes by phosphorylating GSK3B at 'Ser-9' and inhibiting its activity (PubMed:8250835). Phosphorylates RPS6 in response to serum or EGF via an mTOR-independent mechanism and promotes translation initiation by facilitating assembly of the preinitiation complex (PubMed:17360704). In response to insulin, phosphorylates EIF4B, enhancing EIF4B affinity for the EIF3 complex and stimulating cap-dependent translation (PubMed:18508509, PubMed:18813292). Is involved in the mTOR nutrient-sensing pathway by directly phosphorylating TSC2 at 'Ser-1798', which potently inhibits TSC2 ability to suppress mTOR signaling, and mediates phosphorylation of RPTOR, which regulates mTORC1 activity and may promote rapamycin-sensitive signaling independently of the PI3K/AKT pathway (PubMed:18722121). Mediates cell survival by phosphorylating the pro-apoptotic proteins BAD and DAPK1 and suppressing their pro-apoptotic function (PubMed:16213824). Promotes the survival of hepatic stellate cells by phosphorylating CEBPB in response to the hepatotoxin carbon tetrachloride (CCl4) (PubMed:18508509, PubMed:18813292). Is involved in cell cycle regulation by phosphorylating the CDK inhibitor CDKN1B, which promotes CDKN1B association with 14-3-3 proteins and prevents its translocation to the nucleus and inhibition of G1 progression (By similarity). In LPS-stimulated dendritic cells, is involved in TLR4-induced macropinocytosis, and in myeloma cells, acts as effector of FGFR3-mediated transformation signaling, after direct phosphorylation at Tyr-529 by FGFR3 (By similarity). Negatively regulates EGF-induced MAPK1/3 phosphorylation via phosphorylation of SOS1 (By similarity). Phosphorylates SOS1 at 'Ser-1134' and 'Ser-1161' that create YWHAB and YWHAE binding sites and which contribute to the negative regulation of MAPK1/3 phosphorylation (By similarity). Phosphorylates EPHA2 at 'Ser-897', the RPS6KA-EPHA2 signaling pathway controls cell migration (PubMed:26158630). Acts as a regulator of osteoblast differentiation by mediating phosphorylation of ATF4, thereby promoting ATF4 transactivation activity (By similarity). {ECO:0000250|UniProtKB:P18654, ECO:0000269|PubMed:10436156, ECO:0000269|PubMed:16213824, ECO:0000269|PubMed:16223362, ECO:0000269|PubMed:17360704, ECO:0000269|PubMed:18722121, ECO:0000269|PubMed:26158630, ECO:0000269|PubMed:8250835, ECO:0000269|PubMed:9770464, ECO:0000303|PubMed:18508509, ECO:0000303|PubMed:18813292}. |
| Q15349 | RPS6KA2 | T148 | Sugiyama | Ribosomal protein S6 kinase alpha-2 (S6K-alpha-2) (EC 2.7.11.1) (90 kDa ribosomal protein S6 kinase 2) (p90-RSK 2) (p90RSK2) (MAP kinase-activated protein kinase 1c) (MAPK-activated protein kinase 1c) (MAPKAP kinase 1c) (MAPKAPK-1c) (Ribosomal S6 kinase 3) (RSK-3) (pp90RSK3) | Serine/threonine-protein kinase that acts downstream of ERK (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic and stress-induced activation of transcription factors, regulates translation, and mediates cellular proliferation, survival, and differentiation. May function as tumor suppressor in epithelial ovarian cancer cells. {ECO:0000269|PubMed:16878154, ECO:0000269|PubMed:7623830}. |
| Q15418 | RPS6KA1 | T151 | Sugiyama | Ribosomal protein S6 kinase alpha-1 (S6K-alpha-1) (EC 2.7.11.1) (90 kDa ribosomal protein S6 kinase 1) (p90-RSK 1) (p90RSK1) (p90S6K) (MAP kinase-activated protein kinase 1a) (MAPK-activated protein kinase 1a) (MAPKAP kinase 1a) (MAPKAPK-1a) (Ribosomal S6 kinase 1) (RSK-1) | Serine/threonine-protein kinase that acts downstream of ERK (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic and stress-induced activation of the transcription factors CREB1, ETV1/ER81 and NR4A1/NUR77, regulates translation through RPS6 and EIF4B phosphorylation, and mediates cellular proliferation, survival, and differentiation by modulating mTOR signaling and repressing pro-apoptotic function of BAD and DAPK1 (PubMed:10679322, PubMed:12213813, PubMed:15117958, PubMed:16223362, PubMed:17360704, PubMed:18722121, PubMed:26158630, PubMed:35772404, PubMed:9430688). In fibroblast, is required for EGF-stimulated phosphorylation of CREB1, which results in the subsequent transcriptional activation of several immediate-early genes (PubMed:18508509, PubMed:18813292). In response to mitogenic stimulation (EGF and PMA), phosphorylates and activates NR4A1/NUR77 and ETV1/ER81 transcription factors and the cofactor CREBBP (PubMed:12213813, PubMed:16223362). Upon insulin-derived signal, acts indirectly on the transcription regulation of several genes by phosphorylating GSK3B at 'Ser-9' and inhibiting its activity (PubMed:18508509, PubMed:18813292). Phosphorylates RPS6 in response to serum or EGF via an mTOR-independent mechanism and promotes translation initiation by facilitating assembly of the pre-initiation complex (PubMed:17360704). In response to insulin, phosphorylates EIF4B, enhancing EIF4B affinity for the EIF3 complex and stimulating cap-dependent translation (PubMed:16763566). Is involved in the mTOR nutrient-sensing pathway by directly phosphorylating TSC2 at 'Ser-1798', which potently inhibits TSC2 ability to suppress mTOR signaling, and mediates phosphorylation of RPTOR, which regulates mTORC1 activity and may promote rapamycin-sensitive signaling independently of the PI3K/AKT pathway (PubMed:15342917). Also involved in feedback regulation of mTORC1 and mTORC2 by phosphorylating DEPTOR (PubMed:22017876). Mediates cell survival by phosphorylating the pro-apoptotic proteins BAD and DAPK1 and suppressing their pro-apoptotic function (PubMed:10679322, PubMed:16213824). Promotes the survival of hepatic stellate cells by phosphorylating CEBPB in response to the hepatotoxin carbon tetrachloride (CCl4) (PubMed:11684016). Mediates induction of hepatocyte prolifration by TGFA through phosphorylation of CEBPB (PubMed:18508509, PubMed:18813292). Is involved in cell cycle regulation by phosphorylating the CDK inhibitor CDKN1B, which promotes CDKN1B association with 14-3-3 proteins and prevents its translocation to the nucleus and inhibition of G1 progression (PubMed:18508509, PubMed:18813292). Phosphorylates EPHA2 at 'Ser-897', the RPS6KA-EPHA2 signaling pathway controls cell migration (PubMed:26158630). In response to mTORC1 activation, phosphorylates EIF4B at 'Ser-406' and 'Ser-422' which stimulates bicarbonate cotransporter SLC4A7 mRNA translation, increasing SLC4A7 protein abundance and function (PubMed:35772404). {ECO:0000269|PubMed:10679322, ECO:0000269|PubMed:11684016, ECO:0000269|PubMed:12213813, ECO:0000269|PubMed:15117958, ECO:0000269|PubMed:15342917, ECO:0000269|PubMed:16213824, ECO:0000269|PubMed:16223362, ECO:0000269|PubMed:16763566, ECO:0000269|PubMed:17360704, ECO:0000269|PubMed:18722121, ECO:0000269|PubMed:22017876, ECO:0000269|PubMed:26158630, ECO:0000269|PubMed:35772404, ECO:0000269|PubMed:9430688, ECO:0000303|PubMed:18508509, ECO:0000303|PubMed:18813292}.; FUNCTION: (Microbial infection) Promotes the late transcription and translation of viral lytic genes during Kaposi's sarcoma-associated herpesvirus/HHV-8 infection, when constitutively activated. {ECO:0000269|PubMed:30842327}. |
| P80303 | NUCB2 | T248 | Sugiyama | Nucleobindin-2 (DNA-binding protein NEFA) (Epididymis secretory protein Li 109) (Gastric cancer antigen Zg4) (Prepronesfatin) [Cleaved into: Nesfatin-1] | Calcium-binding protein which may have a role in calcium homeostasis (By similarity). Acts as a non-receptor guanine nucleotide exchange factor which binds to and activates guanine nucleotide-binding protein (G-protein) alpha subunit GNAI3 (By similarity). {ECO:0000250|UniProtKB:P81117, ECO:0000250|UniProtKB:Q9JI85}.; FUNCTION: [Nesfatin-1]: Anorexigenic peptide, seems to play an important role in hypothalamic pathways regulating food intake and energy homeostasis, acting in a leptin-independent manner. May also exert hypertensive roles and modulate blood pressure through directly acting on peripheral arterial resistance. In intestinal epithelial cells, plays a role in the inhibition of hepatic glucose production via MC4R receptor leading to increased cyclic adenosine monophosphate (cAMP) levels and glucagon-like peptide 1 (GLP-1) secretion (PubMed:39562740). {ECO:0000250|UniProtKB:Q9JI85, ECO:0000269|PubMed:39562740}. |
| O75116 | ROCK2 | T878 | Sugiyama | Rho-associated protein kinase 2 (EC 2.7.11.1) (Rho kinase 2) (Rho-associated, coiled-coil-containing protein kinase 2) (Rho-associated, coiled-coil-containing protein kinase II) (ROCK-II) (p164 ROCK-2) | Protein kinase which is a key regulator of actin cytoskeleton and cell polarity. Involved in regulation of smooth muscle contraction, actin cytoskeleton organization, stress fiber and focal adhesion formation, neurite retraction, cell adhesion and motility via phosphorylation of ADD1, BRCA2, CNN1, EZR, DPYSL2, EP300, MSN, MYL9/MLC2, NPM1, RDX, PPP1R12A and VIM. Phosphorylates SORL1 and IRF4. Acts as a negative regulator of VEGF-induced angiogenic endothelial cell activation. Positively regulates the activation of p42/MAPK1-p44/MAPK3 and of p90RSK/RPS6KA1 during myogenic differentiation. Plays an important role in the timely initiation of centrosome duplication. Inhibits keratinocyte terminal differentiation. May regulate closure of the eyelids and ventral body wall through organization of actomyosin bundles. Plays a critical role in the regulation of spine and synaptic properties in the hippocampus. Plays an important role in generating the circadian rhythm of the aortic myofilament Ca(2+) sensitivity and vascular contractility by modulating the myosin light chain phosphorylation. {ECO:0000269|PubMed:10579722, ECO:0000269|PubMed:15699075, ECO:0000269|PubMed:16574662, ECO:0000269|PubMed:17015463, ECO:0000269|PubMed:19131646, ECO:0000269|PubMed:19997641, ECO:0000269|PubMed:21084279, ECO:0000269|PubMed:21147781}. |
| Q9Y5S2 | CDC42BPB | T858 | Sugiyama | Serine/threonine-protein kinase MRCK beta (EC 2.7.11.1) (CDC42-binding protein kinase beta) (CDC42BP-beta) (DMPK-like beta) (Myotonic dystrophy kinase-related CDC42-binding kinase beta) (MRCK beta) (Myotonic dystrophy protein kinase-like beta) | Serine/threonine-protein kinase which is an important downstream effector of CDC42 and plays a role in the regulation of cytoskeleton reorganization and cell migration. Regulates actin cytoskeletal reorganization via phosphorylation of PPP1R12C and MYL9/MLC2 (PubMed:21457715, PubMed:21949762). In concert with MYO18A and LURAP1, is involved in modulating lamellar actomyosin retrograde flow that is crucial to cell protrusion and migration (PubMed:18854160). Phosphorylates PPP1R12A (PubMed:21457715). In concert with FAM89B/LRAP25 mediates the targeting of LIMK1 to the lamellipodium resulting in its activation and subsequent phosphorylation of CFL1 which is important for lamellipodial F-actin regulation (By similarity). {ECO:0000250|UniProtKB:Q7TT50, ECO:0000269|PubMed:18854160, ECO:0000269|PubMed:21457715, ECO:0000269|PubMed:21949762}. |
| P43121 | MCAM | T104 | Sugiyama | Cell surface glycoprotein MUC18 (Cell surface glycoprotein P1H12) (Melanoma cell adhesion molecule) (Melanoma-associated antigen A32) (Melanoma-associated antigen MUC18) (S-endo 1 endothelial-associated antigen) (CD antigen CD146) | Plays a role in cell adhesion, and in cohesion of the endothelial monolayer at intercellular junctions in vascular tissue. Its expression may allow melanoma cells to interact with cellular elements of the vascular system, thereby enhancing hematogeneous tumor spread. Could be an adhesion molecule active in neural crest cells during embryonic development. Acts as a surface receptor that triggers tyrosine phosphorylation of FYN and PTK2/FAK1, and a transient increase in the intracellular calcium concentration. {ECO:0000269|PubMed:11036077, ECO:0000269|PubMed:8292890}. |
| Q8N568 | DCLK2 | T122 | Sugiyama | Serine/threonine-protein kinase DCLK2 (EC 2.7.11.1) (CaMK-like CREB regulatory kinase 2) (CL2) (CLICK-II) (CLICK2) (Doublecortin domain-containing protein 3B) (Doublecortin-like and CAM kinase-like 2) (Doublecortin-like kinase 2) | Protein kinase with a significantly reduced C(a2+)/CAM affinity and dependence compared to other members of the CaMK family. May play a role in the down-regulation of CRE-dependent gene activation probably by phosphorylation of the CREB coactivator CRTC2/TORC2 and the resulting retention of TORC2 in the cytoplasm (By similarity). {ECO:0000250}. |
| P31946 | YWHAB | T228 | Sugiyama | 14-3-3 protein beta/alpha (Protein 1054) (Protein kinase C inhibitor protein 1) (KCIP-1) [Cleaved into: 14-3-3 protein beta/alpha, N-terminally processed] | Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways. Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif. Binding generally results in the modulation of the activity of the binding partner. Negative regulator of osteogenesis. Blocks the nuclear translocation of the phosphorylated form (by AKT1) of SRPK2 and antagonizes its stimulatory effect on cyclin D1 expression resulting in blockage of neuronal apoptosis elicited by SRPK2. Negative regulator of signaling cascades that mediate activation of MAP kinases via AKAP13. {ECO:0000269|PubMed:17717073, ECO:0000269|PubMed:19592491, ECO:0000269|PubMed:21224381}. |
| Q8NG66 | NEK11 | T73 | Sugiyama | Serine/threonine-protein kinase Nek11 (EC 2.7.11.1) (Never in mitosis A-related kinase 11) (NimA-related protein kinase 11) | Protein kinase which plays an important role in the G2/M checkpoint response to DNA damage. Controls degradation of CDC25A by directly phosphorylating it on residues whose phosphorylation is required for BTRC-mediated polyubiquitination and degradation. {ECO:0000269|PubMed:12154088, ECO:0000269|PubMed:19734889, ECO:0000269|PubMed:20090422}. |
| Q9BWD1 | ACAT2 | T218 | Sugiyama | Acetyl-CoA acetyltransferase, cytosolic (EC 2.3.1.9) (Acetyl-CoA transferase-like protein) (Cytosolic acetoacetyl-CoA thiolase) | Involved in the biosynthetic pathway of cholesterol. {ECO:0000303|PubMed:15733928}. |
| Q9H4A3 | WNK1 | T209 | Sugiyama | Serine/threonine-protein kinase WNK1 (EC 2.7.11.1) (Erythrocyte 65 kDa protein) (p65) (Kinase deficient protein) (Protein kinase lysine-deficient 1) (Protein kinase with no lysine 1) (hWNK1) | Serine/threonine-protein kinase component of the WNK1-SPAK/OSR1 kinase cascade, which acts as a key regulator of blood pressure and regulatory volume increase by promoting ion influx (PubMed:15883153, PubMed:17190791, PubMed:31656913, PubMed:34289367, PubMed:36318922). WNK1 mediates regulatory volume increase in response to hyperosmotic stress by acting as a molecular crowding sensor, which senses cell shrinkage and mediates formation of a membraneless compartment by undergoing liquid-liquid phase separation (PubMed:36318922). The membraneless compartment concentrates WNK1 with its substrates, OXSR1/OSR1 and STK39/SPAK, promoting WNK1-dependent phosphorylation and activation of downstream kinases OXSR1/OSR1 and STK39/SPAK (PubMed:15883153, PubMed:16263722, PubMed:17190791, PubMed:19739668, PubMed:21321328, PubMed:22989884, PubMed:25477473, PubMed:34289367, PubMed:36318922). Following activation, OXSR1/OSR1 and STK39/SPAK catalyze phosphorylation of ion cotransporters SLC12A1/NKCC2, SLC12A2/NKCC1, SLC12A5/KCC2 and SLC12A6/KCC3, regulating their activity (PubMed:16263722, PubMed:21321328). Phosphorylation of Na-K-Cl cotransporters SLC12A2/NKCC1 and SLC12A2/NKCC1 promote their activation and ion influx; simultaneously, phosphorylation of K-Cl cotransporters SLC12A5/KCC2 and SLC12A6/KCC3 inhibit their activity, blocking ion efflux (PubMed:19665974, PubMed:21321328). Also acts as a regulator of angiogenesis in endothelial cells via activation of OXSR1/OSR1 and STK39/SPAK: activation of OXSR1/OSR1 regulates chemotaxis and invasion, while STK39/SPAK regulates endothelial cell proliferation (PubMed:25362046). Also acts independently of the WNK1-SPAK/OSR1 kinase cascade by catalyzing phosphorylation of other substrates, such as SYT2, PCF11 and NEDD4L (PubMed:29196535). Mediates phosphorylation of SYT2, regulating SYT2 association with phospholipids and membrane-binding (By similarity). Regulates mRNA export in the nucleus by mediating phosphorylation of PCF11, thereby decreasing the association between PCF11 and POLR2A/RNA polymerase II and promoting mRNA export to the cytoplasm (PubMed:29196535). Acts as a negative regulator of autophagy (PubMed:27911840). Required for the abscission step during mitosis, independently of the WNK1-SPAK/OSR1 kinase cascade (PubMed:21220314). May also play a role in actin cytoskeletal reorganization (PubMed:10660600). Also acts as a scaffold protein independently of its protein kinase activity: negatively regulates cell membrane localization of various transporters and channels, such as SLC4A4, SLC26A6, SLC26A9, TRPV4 and CFTR (By similarity). Involved in the regulation of epithelial Na(+) channel (ENaC) by promoting activation of SGK1 in a kinase-independent manner: probably acts as a scaffold protein that promotes the recruitment of SGK1 to the mTORC2 complex in response to chloride, leading to mTORC2-dependent phosphorylation and activation of SGK1 (PubMed:36373794). Acts as an assembly factor for the ER membrane protein complex independently of its protein kinase activity: associates with EMC2 in the cytoplasm via its amphipathic alpha-helix, and prevents EMC2 ubiquitination and subsequent degradation, thereby promoting EMC2 stabilization (PubMed:33964204). {ECO:0000250|UniProtKB:P83741, ECO:0000250|UniProtKB:Q9JIH7, ECO:0000269|PubMed:10660600, ECO:0000269|PubMed:15883153, ECO:0000269|PubMed:16263722, ECO:0000269|PubMed:17190791, ECO:0000269|PubMed:19665974, ECO:0000269|PubMed:19739668, ECO:0000269|PubMed:21220314, ECO:0000269|PubMed:21321328, ECO:0000269|PubMed:22989884, ECO:0000269|PubMed:25362046, ECO:0000269|PubMed:25477473, ECO:0000269|PubMed:27911840, ECO:0000269|PubMed:29196535, ECO:0000269|PubMed:31656913, ECO:0000269|PubMed:33964204, ECO:0000269|PubMed:34289367, ECO:0000269|PubMed:36318922, ECO:0000269|PubMed:36373794}.; FUNCTION: [Isoform 3]: Kinase-defective isoform specifically expressed in kidney, which acts as a dominant-negative regulator of the longer isoform 1 (PubMed:14645531). Does not directly inhibit WNK4 and has no direct effect on sodium and chloride ion transport (By similarity). Down-regulates sodium-chloride cotransporter activity indirectly by inhibiting isoform 1, it associates with isoform 1 and attenuates its kinase activity (By similarity). In kidney, may play an important role regulating sodium and potassium balance (By similarity). {ECO:0000250|UniProtKB:Q9JIH7, ECO:0000269|PubMed:14645531}. |
| Q9UHD2 | TBK1 | T176 | Sugiyama | Serine/threonine-protein kinase TBK1 (EC 2.7.11.1) (NF-kappa-B-activating kinase) (T2K) (TANK-binding kinase 1) | Serine/threonine kinase that plays an essential role in regulating inflammatory responses to foreign agents (PubMed:10581243, PubMed:11839743, PubMed:12692549, PubMed:12702806, PubMed:14703513, PubMed:15367631, PubMed:15485837, PubMed:18583960, PubMed:21138416, PubMed:23453971, PubMed:23453972, PubMed:23746807, PubMed:25636800, PubMed:26611359, PubMed:32404352, PubMed:34363755, PubMed:32298923). Following activation of toll-like receptors by viral or bacterial components, associates with TRAF3 and TANK and phosphorylates interferon regulatory factors (IRFs) IRF3 and IRF7 as well as DDX3X (PubMed:12692549, PubMed:12702806, PubMed:14703513, PubMed:15367631, PubMed:18583960, PubMed:25636800). This activity allows subsequent homodimerization and nuclear translocation of the IRFs leading to transcriptional activation of pro-inflammatory and antiviral genes including IFNA and IFNB (PubMed:12702806, PubMed:15367631, PubMed:25636800, PubMed:32972995). In order to establish such an antiviral state, TBK1 form several different complexes whose composition depends on the type of cell and cellular stimuli (PubMed:23453971, PubMed:23453972, PubMed:23746807). Plays a key role in IRF3 activation: acts by first phosphorylating innate adapter proteins MAVS, STING1 and TICAM1 on their pLxIS motif, leading to recruitment of IRF3, thereby licensing IRF3 for phosphorylation by TBK1 (PubMed:25636800, PubMed:30842653, PubMed:37926288). Phosphorylated IRF3 dissociates from the adapter proteins, dimerizes, and then enters the nucleus to induce expression of interferons (PubMed:25636800). Thus, several scaffolding molecules including FADD, TRADD, MAVS, AZI2, TANK or TBKBP1/SINTBAD can be recruited to the TBK1-containing-complexes (PubMed:21931631). Under particular conditions, functions as a NF-kappa-B effector by phosphorylating NF-kappa-B inhibitor alpha/NFKBIA, IKBKB or RELA to translocate NF-Kappa-B to the nucleus (PubMed:10783893, PubMed:15489227). Restricts bacterial proliferation by phosphorylating the autophagy receptor OPTN/Optineurin on 'Ser-177', thus enhancing LC3 binding affinity and antibacterial autophagy (PubMed:21617041). Phosphorylates SMCR8 component of the C9orf72-SMCR8 complex, promoting autophagosome maturation (PubMed:27103069). Phosphorylates ATG8 proteins MAP1LC3C and GABARAPL2, thereby preventing their delipidation and premature removal from nascent autophagosomes (PubMed:31709703). Seems to play a role in energy balance regulation by sustaining a state of chronic, low-grade inflammation in obesity, which leads to a negative impact on insulin sensitivity (By similarity). Attenuates retroviral budding by phosphorylating the endosomal sorting complex required for transport-I (ESCRT-I) subunit VPS37C (PubMed:21270402). Phosphorylates Borna disease virus (BDV) P protein (PubMed:16155125). Plays an essential role in the TLR3- and IFN-dependent control of herpes virus HSV-1 and HSV-2 infections in the central nervous system (PubMed:22851595). Acts both as a positive and negative regulator of the mTORC1 complex, depending on the context: activates mTORC1 in response to growth factors by catalyzing phosphorylation of MTOR, while it limits the mTORC1 complex by promoting phosphorylation of RPTOR (PubMed:29150432, PubMed:31530866). Acts as a positive regulator of the mTORC2 complex by mediating phosphorylation of MTOR, leading to increased phosphorylation and activation of AKT1 (By similarity). Phosphorylates and activates AKT1 (PubMed:21464307). Involved in the regulation of TNF-induced RIPK1-mediated cell death, probably acting via CYLD phosphorylation that in turn controls RIPK1 ubiquitination status (PubMed:34363755). Also participates in the differentiation of T follicular regulatory cells together with the receptor ICOS (PubMed:27135603). {ECO:0000250|UniProtKB:Q9WUN2, ECO:0000269|PubMed:10581243, ECO:0000269|PubMed:10783893, ECO:0000269|PubMed:11839743, ECO:0000269|PubMed:12692549, ECO:0000269|PubMed:12702806, ECO:0000269|PubMed:14703513, ECO:0000269|PubMed:15367631, ECO:0000269|PubMed:15485837, ECO:0000269|PubMed:15489227, ECO:0000269|PubMed:16155125, ECO:0000269|PubMed:18583960, ECO:0000269|PubMed:21138416, ECO:0000269|PubMed:21270402, ECO:0000269|PubMed:21464307, ECO:0000269|PubMed:21617041, ECO:0000269|PubMed:21931631, ECO:0000269|PubMed:22851595, ECO:0000269|PubMed:23453971, ECO:0000269|PubMed:23453972, ECO:0000269|PubMed:23746807, ECO:0000269|PubMed:25636800, ECO:0000269|PubMed:26611359, ECO:0000269|PubMed:27103069, ECO:0000269|PubMed:27135603, ECO:0000269|PubMed:29150432, ECO:0000269|PubMed:30842653, ECO:0000269|PubMed:31530866, ECO:0000269|PubMed:31709703, ECO:0000269|PubMed:32298923, ECO:0000269|PubMed:32972995, ECO:0000269|PubMed:34363755, ECO:0000269|PubMed:37926288}. |
| Q02952 | AKAP12 | T577 | Sugiyama | A-kinase anchor protein 12 (AKAP-12) (A-kinase anchor protein 250 kDa) (AKAP 250) (Gravin) (Myasthenia gravis autoantigen) | Anchoring protein that mediates the subcellular compartmentation of protein kinase A (PKA) and protein kinase C (PKC). |
| Q9P2E9 | RRBP1 | T1306 | Sugiyama | Ribosome-binding protein 1 (180 kDa ribosome receptor homolog) (RRp) (ES/130-related protein) (Ribosome receptor protein) | Acts as a ribosome receptor and mediates interaction between the ribosome and the endoplasmic reticulum membrane. {ECO:0000250}. |
Download
| reactome_id | name | p | -log10_p |
|---|---|---|---|
| R-HSA-111447 | Activation of BAD and translocation to mitochondria | 5.782839e-10 | 9.238 |
| R-HSA-75035 | Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | 2.694137e-10 | 9.570 |
| R-HSA-9755779 | SARS-CoV-2 targets host intracellular signalling and regulatory pathways | 5.782839e-10 | 9.238 |
| R-HSA-9735871 | SARS-CoV-1 targets host intracellular signalling and regulatory pathways | 5.782839e-10 | 9.238 |
| R-HSA-114452 | Activation of BH3-only proteins | 4.472192e-08 | 7.349 |
| R-HSA-9614399 | Regulation of localization of FOXO transcription factors | 2.087066e-07 | 6.680 |
| R-HSA-9705683 | SARS-CoV-2-host interactions | 4.074435e-07 | 6.390 |
| R-HSA-69473 | G2/M DNA damage checkpoint | 8.728193e-07 | 6.059 |
| R-HSA-1445148 | Translocation of SLC2A4 (GLUT4) to the plasma membrane | 7.971108e-07 | 6.098 |
| R-HSA-9692914 | SARS-CoV-1-host interactions | 1.343383e-06 | 5.872 |
| R-HSA-109606 | Intrinsic Pathway for Apoptosis | 2.042206e-06 | 5.690 |
| R-HSA-69481 | G2/M Checkpoints | 5.943772e-06 | 5.226 |
| R-HSA-5357801 | Programmed Cell Death | 6.310474e-06 | 5.200 |
| R-HSA-109581 | Apoptosis | 5.637180e-06 | 5.249 |
| R-HSA-9694516 | SARS-CoV-2 Infection | 2.871515e-05 | 4.542 |
| R-HSA-390522 | Striated Muscle Contraction | 3.302903e-05 | 4.481 |
| R-HSA-69620 | Cell Cycle Checkpoints | 4.342789e-05 | 4.362 |
| R-HSA-199920 | CREB phosphorylation | 7.857011e-05 | 4.105 |
| R-HSA-9678108 | SARS-CoV-1 Infection | 6.689010e-05 | 4.175 |
| R-HSA-9856649 | Transcriptional and post-translational regulation of MITF-M expression and activ... | 8.388602e-05 | 4.076 |
| R-HSA-166520 | Signaling by NTRKs | 1.321260e-04 | 3.879 |
| R-HSA-444257 | RSK activation | 1.416010e-04 | 3.849 |
| R-HSA-5628897 | TP53 Regulates Metabolic Genes | 1.634242e-04 | 3.787 |
| R-HSA-1640170 | Cell Cycle | 2.773667e-04 | 3.557 |
| R-HSA-9634285 | Constitutive Signaling by Overexpressed ERBB2 | 4.218553e-04 | 3.375 |
| R-HSA-2428933 | SHC-related events triggered by IGF1R | 4.218553e-04 | 3.375 |
| R-HSA-9842663 | Signaling by LTK | 4.218553e-04 | 3.375 |
| R-HSA-1227986 | Signaling by ERBB2 | 3.846365e-04 | 3.415 |
| R-HSA-373755 | Semaphorin interactions | 4.673030e-04 | 3.330 |
| R-HSA-9665230 | Drug resistance in ERBB2 KD mutants | 6.120319e-04 | 3.213 |
| R-HSA-9652282 | Drug-mediated inhibition of ERBB2 signaling | 6.120319e-04 | 3.213 |
| R-HSA-9665249 | Resistance of ERBB2 KD mutants to afatinib | 6.120319e-04 | 3.213 |
| R-HSA-9665244 | Resistance of ERBB2 KD mutants to sapitinib | 6.120319e-04 | 3.213 |
| R-HSA-9665251 | Resistance of ERBB2 KD mutants to lapatinib | 6.120319e-04 | 3.213 |
| R-HSA-9665233 | Resistance of ERBB2 KD mutants to trastuzumab | 6.120319e-04 | 3.213 |
| R-HSA-9665250 | Resistance of ERBB2 KD mutants to AEE788 | 6.120319e-04 | 3.213 |
| R-HSA-9665737 | Drug resistance in ERBB2 TMD/JMD mutants | 6.120319e-04 | 3.213 |
| R-HSA-9665247 | Resistance of ERBB2 KD mutants to osimertinib | 6.120319e-04 | 3.213 |
| R-HSA-9665246 | Resistance of ERBB2 KD mutants to neratinib | 6.120319e-04 | 3.213 |
| R-HSA-9665245 | Resistance of ERBB2 KD mutants to tesevatinib | 6.120319e-04 | 3.213 |
| R-HSA-9679506 | SARS-CoV Infections | 6.582268e-04 | 3.182 |
| R-HSA-168164 | Toll Like Receptor 3 (TLR3) Cascade | 6.729710e-04 | 3.172 |
| R-HSA-937061 | TRIF (TICAM1)-mediated TLR4 signaling | 8.344858e-04 | 3.079 |
| R-HSA-166166 | MyD88-independent TLR4 cascade | 8.344858e-04 | 3.079 |
| R-HSA-9665348 | Signaling by ERBB2 ECD mutants | 1.197611e-03 | 2.922 |
| R-HSA-9730414 | MITF-M-regulated melanocyte development | 1.214482e-03 | 2.916 |
| R-HSA-881907 | Gastrin-CREB signalling pathway via PKC and MAPK | 1.351950e-03 | 2.869 |
| R-HSA-416572 | Sema4D induced cell migration and growth-cone collapse | 1.518247e-03 | 2.819 |
| R-HSA-198753 | ERK/MAPK targets | 1.696833e-03 | 2.770 |
| R-HSA-9006934 | Signaling by Receptor Tyrosine Kinases | 1.629495e-03 | 2.788 |
| R-HSA-187037 | Signaling by NTRK1 (TRKA) | 1.861150e-03 | 2.730 |
| R-HSA-9665686 | Signaling by ERBB2 TMD/JMD mutants | 2.540275e-03 | 2.595 |
| R-HSA-8935964 | RUNX1 regulates expression of components of tight junctions | 2.391857e-03 | 2.621 |
| R-HSA-8863678 | Neurodegenerative Diseases | 2.540275e-03 | 2.595 |
| R-HSA-8862803 | Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's dis... | 2.540275e-03 | 2.595 |
| R-HSA-400685 | Sema4D in semaphorin signaling | 2.784867e-03 | 2.555 |
| R-HSA-9614085 | FOXO-mediated transcription | 3.170605e-03 | 2.499 |
| R-HSA-3928663 | EPHA-mediated growth cone collapse | 3.316420e-03 | 2.479 |
| R-HSA-9734009 | Defective Intrinsic Pathway for Apoptosis | 3.316420e-03 | 2.479 |
| R-HSA-9664565 | Signaling by ERBB2 KD Mutants | 3.906112e-03 | 2.408 |
| R-HSA-450282 | MAPK targets/ Nuclear events mediated by MAP kinases | 3.906112e-03 | 2.408 |
| R-HSA-166016 | Toll Like Receptor 4 (TLR4) Cascade | 3.862781e-03 | 2.413 |
| R-HSA-9828211 | Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | 4.444109e-03 | 2.352 |
| R-HSA-1250196 | SHC1 events in ERBB2 signaling | 4.223342e-03 | 2.374 |
| R-HSA-1227990 | Signaling by ERBB2 in Cancer | 4.223342e-03 | 2.374 |
| R-HSA-9725370 | Signaling by ALK fusions and activated point mutants | 4.411112e-03 | 2.355 |
| R-HSA-9700206 | Signaling by ALK in cancer | 4.411112e-03 | 2.355 |
| R-HSA-422475 | Axon guidance | 4.808187e-03 | 2.318 |
| R-HSA-111465 | Apoptotic cleavage of cellular proteins | 4.903650e-03 | 2.309 |
| R-HSA-442742 | CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | 5.267132e-03 | 2.278 |
| R-HSA-198725 | Nuclear Events (kinase and transcription factor activation) | 5.887958e-03 | 2.230 |
| R-HSA-199991 | Membrane Trafficking | 6.884022e-03 | 2.162 |
| R-HSA-9034864 | Activated NTRK3 signals through RAS | 7.074822e-03 | 2.150 |
| R-HSA-9675108 | Nervous system development | 7.794679e-03 | 2.108 |
| R-HSA-9026519 | Activated NTRK2 signals through RAS | 8.074807e-03 | 2.093 |
| R-HSA-9824878 | Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | 8.074807e-03 | 2.093 |
| R-HSA-9013973 | TICAM1-dependent activation of IRF3/IRF7 | 8.074807e-03 | 2.093 |
| R-HSA-8851805 | MET activates RAS signaling | 9.134433e-03 | 2.039 |
| R-HSA-168898 | Toll-like Receptor Cascades | 1.157282e-02 | 1.937 |
| R-HSA-381038 | XBP1(S) activates chaperone genes | 1.058111e-02 | 1.975 |
| R-HSA-75153 | Apoptotic execution phase | 1.270220e-02 | 1.896 |
| R-HSA-449147 | Signaling by Interleukins | 1.292097e-02 | 1.889 |
| R-HSA-381070 | IRE1alpha activates chaperones | 1.298341e-02 | 1.887 |
| R-HSA-437239 | Recycling pathway of L1 | 1.333572e-02 | 1.875 |
| R-HSA-2682334 | EPH-Ephrin signaling | 1.341481e-02 | 1.872 |
| R-HSA-9634597 | GPER1 signaling | 1.398699e-02 | 1.854 |
| R-HSA-9705671 | SARS-CoV-2 activates/modulates innate and adaptive immune responses | 1.456743e-02 | 1.837 |
| R-HSA-168928 | DDX58/IFIH1-mediated induction of interferon-alpha/beta | 1.476348e-02 | 1.831 |
| R-HSA-936964 | Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | 1.528857e-02 | 1.816 |
| R-HSA-6804114 | TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | 1.528857e-02 | 1.816 |
| R-HSA-918233 | TRAF3-dependent IRF activation pathway | 1.528857e-02 | 1.816 |
| R-HSA-5637812 | Signaling by EGFRvIII in Cancer | 1.668308e-02 | 1.778 |
| R-HSA-5637810 | Constitutive Signaling by EGFRvIII | 1.668308e-02 | 1.778 |
| R-HSA-1606322 | ZBP1(DAI) mediated induction of type I IFNs | 1.812972e-02 | 1.742 |
| R-HSA-392517 | Rap1 signalling | 1.962746e-02 | 1.707 |
| R-HSA-5653656 | Vesicle-mediated transport | 1.606686e-02 | 1.794 |
| R-HSA-397014 | Muscle contraction | 1.800298e-02 | 1.745 |
| R-HSA-9009391 | Extra-nuclear estrogen signaling | 1.823525e-02 | 1.739 |
| R-HSA-975871 | MyD88 cascade initiated on plasma membrane | 1.669090e-02 | 1.778 |
| R-HSA-168176 | Toll Like Receptor 5 (TLR5) Cascade | 1.669090e-02 | 1.778 |
| R-HSA-168142 | Toll Like Receptor 10 (TLR10) Cascade | 1.669090e-02 | 1.778 |
| R-HSA-2028269 | Signaling by Hippo | 1.668308e-02 | 1.778 |
| R-HSA-5673001 | RAF/MAP kinase cascade | 2.101375e-02 | 1.677 |
| R-HSA-71288 | Creatine metabolism | 2.117530e-02 | 1.674 |
| R-HSA-5663202 | Diseases of signal transduction by growth factor receptors and second messengers | 2.184630e-02 | 1.661 |
| R-HSA-5637815 | Signaling by Ligand-Responsive EGFR Variants in Cancer | 2.277226e-02 | 1.643 |
| R-HSA-1236382 | Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | 2.277226e-02 | 1.643 |
| R-HSA-5654704 | SHC-mediated cascade:FGFR3 | 2.277226e-02 | 1.643 |
| R-HSA-5654719 | SHC-mediated cascade:FGFR4 | 2.441735e-02 | 1.612 |
| R-HSA-380284 | Loss of proteins required for interphase microtubule organization from the centr... | 2.591552e-02 | 1.586 |
| R-HSA-380259 | Loss of Nlp from mitotic centrosomes | 2.591552e-02 | 1.586 |
| R-HSA-8854518 | AURKA Activation by TPX2 | 2.878977e-02 | 1.541 |
| R-HSA-352238 | Breakdown of the nuclear lamina | 2.629167e-02 | 1.580 |
| R-HSA-5357786 | TNFR1-induced proapoptotic signaling | 2.277226e-02 | 1.643 |
| R-HSA-5684996 | MAPK1/MAPK3 signaling | 2.337784e-02 | 1.631 |
| R-HSA-2428924 | IGF1R signaling cascade | 2.685554e-02 | 1.571 |
| R-HSA-2404192 | Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | 2.781363e-02 | 1.556 |
| R-HSA-9034015 | Signaling by NTRK3 (TRKC) | 2.441735e-02 | 1.612 |
| R-HSA-8939211 | ESR-mediated signaling | 2.788579e-02 | 1.555 |
| R-HSA-9825892 | Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | 2.441735e-02 | 1.612 |
| R-HSA-162582 | Signal Transduction | 2.530796e-02 | 1.597 |
| R-HSA-975138 | TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | 2.277785e-02 | 1.642 |
| R-HSA-975155 | MyD88 dependent cascade initiated on endosome | 2.338982e-02 | 1.631 |
| R-HSA-450294 | MAP kinase activation | 2.408979e-02 | 1.618 |
| R-HSA-168181 | Toll Like Receptor 7/8 (TLR7/8) Cascade | 2.593729e-02 | 1.586 |
| R-HSA-168138 | Toll Like Receptor 9 (TLR9) Cascade | 2.795332e-02 | 1.554 |
| R-HSA-373760 | L1CAM interactions | 2.934792e-02 | 1.532 |
| R-HSA-5654688 | SHC-mediated cascade:FGFR1 | 2.963188e-02 | 1.528 |
| R-HSA-166058 | MyD88:MAL(TIRAP) cascade initiated on plasma membrane | 3.151615e-02 | 1.501 |
| R-HSA-168188 | Toll Like Receptor TLR6:TLR2 Cascade | 3.151615e-02 | 1.501 |
| R-HSA-448424 | Interleukin-17 signaling | 3.287421e-02 | 1.483 |
| R-HSA-3371556 | Cellular response to heat stress | 3.301272e-02 | 1.481 |
| R-HSA-1643713 | Signaling by EGFR in Cancer | 3.333160e-02 | 1.477 |
| R-HSA-168179 | Toll Like Receptor TLR1:TLR2 Cascade | 3.377638e-02 | 1.471 |
| R-HSA-181438 | Toll Like Receptor 2 (TLR2) Cascade | 3.377638e-02 | 1.471 |
| R-HSA-450531 | Regulation of mRNA stability by proteins that bind AU-rich elements | 3.502379e-02 | 1.456 |
| R-HSA-5654699 | SHC-mediated cascade:FGFR2 | 3.524573e-02 | 1.453 |
| R-HSA-8866652 | Synthesis of active ubiquitin: roles of E1 and E2 enzymes | 3.524573e-02 | 1.453 |
| R-HSA-264876 | Insulin processing | 3.524573e-02 | 1.453 |
| R-HSA-9006115 | Signaling by NTRK2 (TRKB) | 3.524573e-02 | 1.453 |
| R-HSA-380270 | Recruitment of mitotic centrosome proteins and complexes | 3.612526e-02 | 1.442 |
| R-HSA-69278 | Cell Cycle, Mitotic | 3.725125e-02 | 1.429 |
| R-HSA-380287 | Centrosome maturation | 3.838128e-02 | 1.416 |
| R-HSA-5654708 | Downstream signaling of activated FGFR3 | 3.919810e-02 | 1.407 |
| R-HSA-5654716 | Downstream signaling of activated FGFR4 | 4.123461e-02 | 1.385 |
| R-HSA-8863795 | Downregulation of ERBB2 signaling | 4.123461e-02 | 1.385 |
| R-HSA-68877 | Mitotic Prometaphase | 4.156792e-02 | 1.381 |
| R-HSA-936440 | Negative regulators of DDX58/IFIH1 signaling | 4.331018e-02 | 1.363 |
| R-HSA-3249367 | STAT6-mediated induction of chemokines | 4.343693e-02 | 1.362 |
| R-HSA-5683057 | MAPK family signaling cascades | 4.629034e-02 | 1.335 |
| R-HSA-6811442 | Intra-Golgi and retrograde Golgi-to-ER traffic | 4.661068e-02 | 1.332 |
| R-HSA-2559582 | Senescence-Associated Secretory Phenotype (SASP) | 4.682793e-02 | 1.329 |
| R-HSA-5603029 | IkBA variant leads to EDA-ID | 6.859429e-02 | 1.164 |
| R-HSA-380320 | Recruitment of NuMA to mitotic centrosomes | 5.611095e-02 | 1.251 |
| R-HSA-5620912 | Anchoring of the basal body to the plasma membrane | 5.891261e-02 | 1.230 |
| R-HSA-354192 | Integrin signaling | 4.757521e-02 | 1.323 |
| R-HSA-1606341 | IRF3 mediated activation of type 1 IFN | 6.028237e-02 | 1.220 |
| R-HSA-6802948 | Signaling by high-kinase activity BRAF mutants | 5.886419e-02 | 1.230 |
| R-HSA-3371511 | HSF1 activation | 5.653796e-02 | 1.248 |
| R-HSA-6811434 | COPI-dependent Golgi-to-ER retrograde traffic | 7.075984e-02 | 1.150 |
| R-HSA-9725554 | Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | 6.361390e-02 | 1.196 |
| R-HSA-187687 | Signalling to ERKs | 5.424518e-02 | 1.266 |
| R-HSA-933541 | TRAF6 mediated IRF7 activation | 5.886419e-02 | 1.230 |
| R-HSA-205025 | NADE modulates death signalling | 5.189680e-02 | 1.285 |
| R-HSA-2565942 | Regulation of PLK1 Activity at G2/M Transition | 4.939615e-02 | 1.306 |
| R-HSA-68886 | M Phase | 6.903316e-02 | 1.161 |
| R-HSA-9680350 | Signaling by CSF1 (M-CSF) in myeloid cells | 5.198660e-02 | 1.284 |
| R-HSA-5250982 | Toxicity of tetanus toxin (tetX) | 5.189680e-02 | 1.285 |
| R-HSA-3134963 | DEx/H-box helicases activate type I IFN and inflammatory cytokines production | 6.028237e-02 | 1.220 |
| R-HSA-5250989 | Toxicity of botulinum toxin type G (botG) | 6.028237e-02 | 1.220 |
| R-HSA-9758919 | Epithelial-Mesenchymal Transition (EMT) during gastrulation | 6.859429e-02 | 1.164 |
| R-HSA-5654696 | Downstream signaling of activated FGFR2 | 5.424518e-02 | 1.266 |
| R-HSA-5654687 | Downstream signaling of activated FGFR1 | 5.424518e-02 | 1.266 |
| R-HSA-438064 | Post NMDA receptor activation events | 5.473473e-02 | 1.262 |
| R-HSA-9645723 | Diseases of programmed cell death | 5.611095e-02 | 1.251 |
| R-HSA-8964043 | Plasma lipoprotein clearance | 6.361390e-02 | 1.196 |
| R-HSA-1280215 | Cytokine Signaling in Immune system | 6.295837e-02 | 1.201 |
| R-HSA-201556 | Signaling by ALK | 6.361390e-02 | 1.196 |
| R-HSA-3700989 | Transcriptional Regulation by TP53 | 6.915900e-02 | 1.160 |
| R-HSA-381119 | Unfolded Protein Response (UPR) | 5.121261e-02 | 1.291 |
| R-HSA-9656223 | Signaling by RAF1 mutants | 7.097057e-02 | 1.149 |
| R-HSA-5674135 | MAP2K and MAPK activation | 7.097057e-02 | 1.149 |
| R-HSA-512988 | Interleukin-3, Interleukin-5 and GM-CSF signaling | 7.348179e-02 | 1.134 |
| R-HSA-5654743 | Signaling by FGFR4 | 7.602134e-02 | 1.119 |
| R-HSA-5250955 | Toxicity of botulinum toxin type D (botD) | 7.683319e-02 | 1.114 |
| R-HSA-5250981 | Toxicity of botulinum toxin type F (botF) | 7.683319e-02 | 1.114 |
| R-HSA-8964011 | HDL clearance | 7.683319e-02 | 1.114 |
| R-HSA-3928662 | EPHB-mediated forward signaling | 7.858853e-02 | 1.105 |
| R-HSA-8953854 | Metabolism of RNA | 7.964595e-02 | 1.099 |
| R-HSA-3371453 | Regulation of HSF1-mediated heat shock response | 8.029263e-02 | 1.095 |
| R-HSA-442755 | Activation of NMDA receptors and postsynaptic events | 8.029263e-02 | 1.095 |
| R-HSA-76009 | Platelet Aggregation (Plug Formation) | 8.118269e-02 | 1.091 |
| R-HSA-5654741 | Signaling by FGFR3 | 8.118269e-02 | 1.091 |
| R-HSA-9649948 | Signaling downstream of RAS mutants | 8.380313e-02 | 1.077 |
| R-HSA-6802946 | Signaling by moderate kinase activity BRAF mutants | 8.380313e-02 | 1.077 |
| R-HSA-6802955 | Paradoxical activation of RAF signaling by kinase inactive BRAF | 8.380313e-02 | 1.077 |
| R-HSA-6802949 | Signaling by RAS mutants | 8.380313e-02 | 1.077 |
| R-HSA-5357905 | Regulation of TNFR1 signaling | 8.380313e-02 | 1.077 |
| R-HSA-2470946 | Cohesin Loading onto Chromatin | 8.499973e-02 | 1.071 |
| R-HSA-9726840 | SHOC2 M1731 mutant abolishes MRAS complex function | 8.499973e-02 | 1.071 |
| R-HSA-5336415 | Uptake and function of diphtheria toxin | 8.499973e-02 | 1.071 |
| R-HSA-9824446 | Viral Infection Pathways | 8.610306e-02 | 1.065 |
| R-HSA-6811440 | Retrograde transport at the Trans-Golgi-Network | 8.644920e-02 | 1.063 |
| R-HSA-9660537 | Signaling by MRAS-complex mutants | 9.309452e-02 | 1.031 |
| R-HSA-9726842 | Gain-of-function MRAS complexes activate RAF signaling | 9.309452e-02 | 1.031 |
| R-HSA-5250958 | Toxicity of botulinum toxin type B (botB) | 9.309452e-02 | 1.031 |
| R-HSA-351906 | Apoptotic cleavage of cell adhesion proteins | 9.309452e-02 | 1.031 |
| R-HSA-2468052 | Establishment of Sister Chromatid Cohesion | 1.090714e-01 | 0.962 |
| R-HSA-3000484 | Scavenging by Class F Receptors | 1.325140e-01 | 0.878 |
| R-HSA-180336 | SHC1 events in EGFR signaling | 1.553441e-01 | 0.809 |
| R-HSA-354194 | GRB2:SOS provides linkage to MAPK signaling for Integrins | 1.628207e-01 | 0.788 |
| R-HSA-1250347 | SHC1 events in ERBB4 signaling | 1.702316e-01 | 0.769 |
| R-HSA-372708 | p130Cas linkage to MAPK signaling for integrins | 1.775774e-01 | 0.751 |
| R-HSA-1221632 | Meiotic synapsis | 1.028281e-01 | 0.988 |
| R-HSA-191859 | snRNP Assembly | 1.199737e-01 | 0.921 |
| R-HSA-194441 | Metabolism of non-coding RNA | 1.199737e-01 | 0.921 |
| R-HSA-159236 | Transport of Mature mRNA derived from an Intron-Containing Transcript | 1.622939e-01 | 0.790 |
| R-HSA-72202 | Transport of Mature Transcript to Cytoplasm | 1.907274e-01 | 0.720 |
| R-HSA-3371497 | HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of lig... | 1.468649e-01 | 0.833 |
| R-HSA-6802952 | Signaling by BRAF and RAF1 fusions | 1.377637e-01 | 0.861 |
| R-HSA-9027284 | Erythropoietin activates RAS | 1.553441e-01 | 0.809 |
| R-HSA-9613829 | Chaperone Mediated Autophagy | 1.848586e-01 | 0.733 |
| R-HSA-3270619 | IRF3-mediated induction of type I IFN | 1.553441e-01 | 0.809 |
| R-HSA-192905 | vRNP Assembly | 1.169547e-01 | 0.932 |
| R-HSA-110362 | POLB-Dependent Long Patch Base Excision Repair | 1.247687e-01 | 0.904 |
| R-HSA-68884 | Mitotic Telophase/Cytokinesis | 1.247687e-01 | 0.904 |
| R-HSA-5685939 | HDR through MMEJ (alt-NHEJ) | 1.401913e-01 | 0.853 |
| R-HSA-2559584 | Formation of Senescence-Associated Heterochromatin Foci (SAHF) | 1.401913e-01 | 0.853 |
| R-HSA-1810476 | RIP-mediated NFkB activation via ZBP1 | 1.553441e-01 | 0.809 |
| R-HSA-5651801 | PCNA-Dependent Long Patch Base Excision Repair | 1.848586e-01 | 0.733 |
| R-HSA-181429 | Serotonin Neurotransmitter Release Cycle | 1.848586e-01 | 0.733 |
| R-HSA-170968 | Frs2-mediated activation | 1.401913e-01 | 0.853 |
| R-HSA-430116 | GP1b-IX-V activation signalling | 1.011182e-01 | 0.995 |
| R-HSA-3134975 | Regulation of innate immune responses to cytosolic DNA | 1.702316e-01 | 0.769 |
| R-HSA-74749 | Signal attenuation | 1.090714e-01 | 0.962 |
| R-HSA-169893 | Prolonged ERK activation events | 1.628207e-01 | 0.788 |
| R-HSA-2980766 | Nuclear Envelope Breakdown | 1.141811e-01 | 0.942 |
| R-HSA-8983432 | Interleukin-15 signaling | 1.325140e-01 | 0.878 |
| R-HSA-170984 | ARMS-mediated activation | 1.011182e-01 | 0.995 |
| R-HSA-450385 | Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | 1.553441e-01 | 0.809 |
| R-HSA-399954 | Sema3A PAK dependent Axon repulsion | 1.553441e-01 | 0.809 |
| R-HSA-9754706 | Atorvastatin ADME | 1.628207e-01 | 0.788 |
| R-HSA-4419969 | Depolymerization of the Nuclear Lamina | 1.848586e-01 | 0.733 |
| R-HSA-8856688 | Golgi-to-ER retrograde transport | 1.454523e-01 | 0.837 |
| R-HSA-1834949 | Cytosolic sensors of pathogen-associated DNA | 1.529998e-01 | 0.815 |
| R-HSA-1834941 | STING mediated induction of host immune responses | 1.920757e-01 | 0.717 |
| R-HSA-450520 | HuR (ELAVL1) binds and stabilizes mRNA | 1.011182e-01 | 0.995 |
| R-HSA-983189 | Kinesins | 1.228971e-01 | 0.910 |
| R-HSA-9820962 | Assembly and release of respiratory syncytial virus (RSV) virions | 1.090714e-01 | 0.962 |
| R-HSA-69166 | Removal of the Flap Intermediate | 1.478012e-01 | 0.830 |
| R-HSA-450513 | Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | 1.553441e-01 | 0.809 |
| R-HSA-174437 | Removal of the Flap Intermediate from the C-strand | 1.775774e-01 | 0.751 |
| R-HSA-6790901 | rRNA modification in the nucleus and cytosol | 1.317692e-01 | 0.880 |
| R-HSA-4420097 | VEGFA-VEGFR2 Pathway | 1.082075e-01 | 0.966 |
| R-HSA-194138 | Signaling by VEGF | 1.292838e-01 | 0.888 |
| R-HSA-69275 | G2/M Transition | 1.107834e-01 | 0.956 |
| R-HSA-448706 | Interleukin-1 processing | 1.011182e-01 | 0.995 |
| R-HSA-9834752 | Respiratory syncytial virus genome replication | 1.011182e-01 | 0.995 |
| R-HSA-9013700 | NOTCH4 Activation and Transmission of Signal to the Nucleus | 1.011182e-01 | 0.995 |
| R-HSA-450604 | KSRP (KHSRP) binds and destabilizes mRNA | 1.628207e-01 | 0.788 |
| R-HSA-453274 | Mitotic G2-G2/M phases | 1.136847e-01 | 0.944 |
| R-HSA-71403 | Citric acid cycle (TCA cycle) | 1.685460e-01 | 0.773 |
| R-HSA-9909649 | Regulation of PD-L1(CD274) transcription | 1.407833e-01 | 0.851 |
| R-HSA-2187335 | The retinoid cycle in cones (daylight vision) | 1.628207e-01 | 0.788 |
| R-HSA-9856872 | Malate-aspartate shuttle | 1.478012e-01 | 0.830 |
| R-HSA-69183 | Processive synthesis on the lagging strand | 1.553441e-01 | 0.809 |
| R-HSA-9027307 | Biosynthesis of maresin-like SPMs | 1.702316e-01 | 0.769 |
| R-HSA-399955 | SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | 1.628207e-01 | 0.788 |
| R-HSA-6791312 | TP53 Regulates Transcription of Cell Cycle Genes | 1.141811e-01 | 0.942 |
| R-HSA-6806834 | Signaling by MET | 1.843471e-01 | 0.734 |
| R-HSA-69242 | S Phase | 1.840066e-01 | 0.735 |
| R-HSA-9020558 | Interleukin-2 signaling | 1.169547e-01 | 0.932 |
| R-HSA-446353 | Cell-extracellular matrix interactions | 1.553441e-01 | 0.809 |
| R-HSA-8852135 | Protein ubiquitination | 1.685460e-01 | 0.773 |
| R-HSA-5339562 | Uptake and actions of bacterial toxins | 1.000416e-01 | 1.000 |
| R-HSA-5654738 | Signaling by FGFR2 | 1.843471e-01 | 0.734 |
| R-HSA-5654736 | Signaling by FGFR1 | 1.113130e-01 | 0.953 |
| R-HSA-9679191 | Potential therapeutics for SARS | 1.884499e-01 | 0.725 |
| R-HSA-210993 | Tie2 Signaling | 1.848586e-01 | 0.733 |
| R-HSA-2262752 | Cellular responses to stress | 1.340391e-01 | 0.873 |
| R-HSA-8953897 | Cellular responses to stimuli | 1.546242e-01 | 0.811 |
| R-HSA-9006931 | Signaling by Nuclear Receptors | 1.271574e-01 | 0.896 |
| R-HSA-449836 | Other interleukin signaling | 1.920757e-01 | 0.717 |
| R-HSA-844456 | The NLRP3 inflammasome | 1.920757e-01 | 0.717 |
| R-HSA-1266738 | Developmental Biology | 1.027687e-01 | 0.988 |
| R-HSA-75893 | TNF signaling | 1.113130e-01 | 0.953 |
| R-HSA-9018519 | Estrogen-dependent gene expression | 1.558798e-01 | 0.807 |
| R-HSA-73887 | Death Receptor Signaling | 1.974188e-01 | 0.705 |
| R-HSA-9692916 | SARS-CoV-1 activates/modulates innate immune responses | 1.000416e-01 | 1.000 |
| R-HSA-2559583 | Cellular Senescence | 1.022852e-01 | 0.990 |
| R-HSA-8950505 | Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulati... | 1.377637e-01 | 0.861 |
| R-HSA-9020591 | Interleukin-12 signaling | 1.716875e-01 | 0.765 |
| R-HSA-9609523 | Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | 1.992295e-01 | 0.701 |
| R-HSA-6802957 | Oncogenic MAPK signaling | 2.003522e-01 | 0.698 |
| R-HSA-1500620 | Meiosis | 2.003522e-01 | 0.698 |
| R-HSA-167044 | Signalling to RAS | 2.063203e-01 | 0.685 |
| R-HSA-264642 | Acetylcholine Neurotransmitter Release Cycle | 2.063203e-01 | 0.685 |
| R-HSA-69186 | Lagging Strand Synthesis | 2.063203e-01 | 0.685 |
| R-HSA-162594 | Early Phase of HIV Life Cycle | 2.063203e-01 | 0.685 |
| R-HSA-70268 | Pyruvate metabolism | 2.100334e-01 | 0.678 |
| R-HSA-447115 | Interleukin-12 family signaling | 2.100334e-01 | 0.678 |
| R-HSA-9663891 | Selective autophagy | 2.132713e-01 | 0.671 |
| R-HSA-211979 | Eicosanoids | 2.133487e-01 | 0.671 |
| R-HSA-211958 | Miscellaneous substrates | 2.133487e-01 | 0.671 |
| R-HSA-2995383 | Initiation of Nuclear Envelope (NE) Reformation | 2.133487e-01 | 0.671 |
| R-HSA-977347 | Serine metabolism | 2.133487e-01 | 0.671 |
| R-HSA-1236974 | ER-Phagosome pathway | 2.165141e-01 | 0.665 |
| R-HSA-212676 | Dopamine Neurotransmitter Release Cycle | 2.203154e-01 | 0.657 |
| R-HSA-166208 | mTORC1-mediated signalling | 2.203154e-01 | 0.657 |
| R-HSA-168799 | Neurotoxicity of clostridium toxins | 2.203154e-01 | 0.657 |
| R-HSA-8964038 | LDL clearance | 2.203154e-01 | 0.657 |
| R-HSA-912526 | Interleukin receptor SHC signaling | 2.272207e-01 | 0.644 |
| R-HSA-211935 | Fatty acids | 2.272207e-01 | 0.644 |
| R-HSA-9018682 | Biosynthesis of maresins | 2.272207e-01 | 0.644 |
| R-HSA-174824 | Plasma lipoprotein assembly, remodeling, and clearance | 2.295273e-01 | 0.639 |
| R-HSA-933542 | TRAF6 mediated NF-kB activation | 2.340654e-01 | 0.631 |
| R-HSA-181430 | Norepinephrine Neurotransmitter Release Cycle | 2.340654e-01 | 0.631 |
| R-HSA-9836573 | Mitochondrial RNA degradation | 2.340654e-01 | 0.631 |
| R-HSA-9837999 | Mitochondrial protein degradation | 2.360545e-01 | 0.627 |
| R-HSA-6791226 | Major pathway of rRNA processing in the nucleolus and cytosol | 2.365772e-01 | 0.626 |
| R-HSA-418555 | G alpha (s) signalling events | 2.389245e-01 | 0.622 |
| R-HSA-5218921 | VEGFR2 mediated cell proliferation | 2.408498e-01 | 0.618 |
| R-HSA-5601884 | PIWI-interacting RNA (piRNA) biogenesis | 2.408498e-01 | 0.618 |
| R-HSA-9909648 | Regulation of PD-L1(CD274) expression | 2.412758e-01 | 0.617 |
| R-HSA-110373 | Resolution of AP sites via the multiple-nucleotide patch replacement pathway | 2.475746e-01 | 0.606 |
| R-HSA-210500 | Glutamate Neurotransmitter Release Cycle | 2.475746e-01 | 0.606 |
| R-HSA-190236 | Signaling by FGFR | 2.524134e-01 | 0.598 |
| R-HSA-174414 | Processive synthesis on the C-strand of the telomere | 2.542402e-01 | 0.595 |
| R-HSA-75109 | Triglyceride biosynthesis | 2.542402e-01 | 0.595 |
| R-HSA-5663205 | Infectious disease | 2.594936e-01 | 0.586 |
| R-HSA-5205685 | PINK1-PRKN Mediated Mitophagy | 2.608471e-01 | 0.584 |
| R-HSA-9757110 | Prednisone ADME | 2.608471e-01 | 0.584 |
| R-HSA-622312 | Inflammasomes | 2.608471e-01 | 0.584 |
| R-HSA-76002 | Platelet activation, signaling and aggregation | 2.655619e-01 | 0.576 |
| R-HSA-9006335 | Signaling by Erythropoietin | 2.673960e-01 | 0.573 |
| R-HSA-9674555 | Signaling by CSF3 (G-CSF) | 2.673960e-01 | 0.573 |
| R-HSA-8856825 | Cargo recognition for clathrin-mediated endocytosis | 2.720802e-01 | 0.565 |
| R-HSA-9860931 | Response of endothelial cells to shear stress | 2.720802e-01 | 0.565 |
| R-HSA-5619107 | Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC... | 2.738872e-01 | 0.562 |
| R-HSA-68962 | Activation of the pre-replicative complex | 2.738872e-01 | 0.562 |
| R-HSA-2424491 | DAP12 signaling | 2.738872e-01 | 0.562 |
| R-HSA-888590 | GABA synthesis, release, reuptake and degradation | 2.738872e-01 | 0.562 |
| R-HSA-1474151 | Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | 2.738872e-01 | 0.562 |
| R-HSA-9008059 | Interleukin-37 signaling | 2.738872e-01 | 0.562 |
| R-HSA-72203 | Processing of Capped Intron-Containing Pre-mRNA | 2.753420e-01 | 0.560 |
| R-HSA-8868773 | rRNA processing in the nucleus and cytosol | 2.793499e-01 | 0.554 |
| R-HSA-1855196 | IP3 and IP4 transport between cytosol and nucleus | 2.803213e-01 | 0.552 |
| R-HSA-1855229 | IP6 and IP7 transport between cytosol and nucleus | 2.803213e-01 | 0.552 |
| R-HSA-186763 | Downstream signal transduction | 2.803213e-01 | 0.552 |
| R-HSA-5617833 | Cilium Assembly | 2.841558e-01 | 0.546 |
| R-HSA-211000 | Gene Silencing by RNA | 2.851868e-01 | 0.545 |
| R-HSA-69190 | DNA strand elongation | 2.866988e-01 | 0.543 |
| R-HSA-72706 | GTP hydrolysis and joining of the 60S ribosomal subunit | 2.884606e-01 | 0.540 |
| R-HSA-9734779 | Developmental Cell Lineages of the Integumentary System | 2.884606e-01 | 0.540 |
| R-HSA-1236975 | Antigen processing-Cross presentation | 2.884606e-01 | 0.540 |
| R-HSA-1855170 | IPs transport between nucleus and cytosol | 2.930201e-01 | 0.533 |
| R-HSA-159227 | Transport of the SLBP independent Mature mRNA | 2.930201e-01 | 0.533 |
| R-HSA-176187 | Activation of ATR in response to replication stress | 2.930201e-01 | 0.533 |
| R-HSA-69273 | Cyclin A/B1/B2 associated events during G2/M transition | 2.930201e-01 | 0.533 |
| R-HSA-5675482 | Regulation of necroptotic cell death | 2.930201e-01 | 0.533 |
| R-HSA-159230 | Transport of the SLBP Dependant Mature mRNA | 2.992858e-01 | 0.524 |
| R-HSA-390471 | Association of TriC/CCT with target proteins during biosynthesis | 2.992858e-01 | 0.524 |
| R-HSA-170822 | Regulation of Glucokinase by Glucokinase Regulatory Protein | 2.992858e-01 | 0.524 |
| R-HSA-5673000 | RAF activation | 3.054964e-01 | 0.515 |
| R-HSA-9843970 | Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | 3.054964e-01 | 0.515 |
| R-HSA-9927426 | Developmental Lineage of Mammary Gland Alveolar Cells | 3.054964e-01 | 0.515 |
| R-HSA-203615 | eNOS activation | 3.054964e-01 | 0.515 |
| R-HSA-983170 | Antigen Presentation: Folding, assembly and peptide loading of class I MHC | 3.054964e-01 | 0.515 |
| R-HSA-180746 | Nuclear import of Rev protein | 3.054964e-01 | 0.515 |
| R-HSA-5205647 | Mitophagy | 3.054964e-01 | 0.515 |
| R-HSA-901042 | Calnexin/calreticulin cycle | 3.054964e-01 | 0.515 |
| R-HSA-9855142 | Cellular responses to mechanical stimuli | 3.080622e-01 | 0.511 |
| R-HSA-389948 | Co-inhibition by PD-1 | 3.082776e-01 | 0.511 |
| R-HSA-3301854 | Nuclear Pore Complex (NPC) Disassembly | 3.116523e-01 | 0.506 |
| R-HSA-9860927 | Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZ... | 3.116523e-01 | 0.506 |
| R-HSA-9772755 | Formation of WDR5-containing histone-modifying complexes | 3.116523e-01 | 0.506 |
| R-HSA-432720 | Lysosome Vesicle Biogenesis | 3.177541e-01 | 0.498 |
| R-HSA-8853659 | RET signaling | 3.177541e-01 | 0.498 |
| R-HSA-72737 | Cap-dependent Translation Initiation | 3.210749e-01 | 0.493 |
| R-HSA-72613 | Eukaryotic Translation Initiation | 3.210749e-01 | 0.493 |
| R-HSA-180910 | Vpr-mediated nuclear import of PICs | 3.238021e-01 | 0.490 |
| R-HSA-3769402 | Deactivation of the beta-catenin transactivating complex | 3.238021e-01 | 0.490 |
| R-HSA-2980736 | Peptide hormone metabolism | 3.243194e-01 | 0.489 |
| R-HSA-5693538 | Homology Directed Repair | 3.275599e-01 | 0.485 |
| R-HSA-202131 | Metabolism of nitric oxide: NOS3 activation and regulation | 3.297968e-01 | 0.482 |
| R-HSA-165054 | Rev-mediated nuclear export of HIV RNA | 3.297968e-01 | 0.482 |
| R-HSA-5213460 | RIPK1-mediated regulated necrosis | 3.297968e-01 | 0.482 |
| R-HSA-68875 | Mitotic Prophase | 3.340287e-01 | 0.476 |
| R-HSA-159231 | Transport of Mature mRNA Derived from an Intronless Transcript | 3.357388e-01 | 0.474 |
| R-HSA-168276 | NS1 Mediated Effects on Host Pathways | 3.357388e-01 | 0.474 |
| R-HSA-9820965 | Respiratory syncytial virus (RSV) genome replication, transcription and translat... | 3.357388e-01 | 0.474 |
| R-HSA-2500257 | Resolution of Sister Chromatid Cohesion | 3.372566e-01 | 0.472 |
| R-HSA-112314 | Neurotransmitter receptors and postsynaptic signal transmission | 3.397372e-01 | 0.469 |
| R-HSA-159234 | Transport of Mature mRNAs Derived from Intronless Transcripts | 3.416285e-01 | 0.466 |
| R-HSA-177243 | Interactions of Rev with host cellular proteins | 3.416285e-01 | 0.466 |
| R-HSA-176033 | Interactions of Vpr with host cellular proteins | 3.416285e-01 | 0.466 |
| R-HSA-451927 | Interleukin-2 family signaling | 3.416285e-01 | 0.466 |
| R-HSA-9854311 | Maturation of TCA enzymes and regulation of TCA cycle | 3.416285e-01 | 0.466 |
| R-HSA-3371568 | Attenuation phase | 3.416285e-01 | 0.466 |
| R-HSA-9604323 | Negative regulation of NOTCH4 signaling | 3.416285e-01 | 0.466 |
| R-HSA-5602358 | Diseases associated with the TLR signaling cascade | 3.416285e-01 | 0.466 |
| R-HSA-5260271 | Diseases of Immune System | 3.416285e-01 | 0.466 |
| R-HSA-9646399 | Aggrephagy | 3.416285e-01 | 0.466 |
| R-HSA-202433 | Generation of second messenger molecules | 3.416285e-01 | 0.466 |
| R-HSA-2132295 | MHC class II antigen presentation | 3.436984e-01 | 0.464 |
| R-HSA-168256 | Immune System | 3.463066e-01 | 0.461 |
| R-HSA-6809371 | Formation of the cornified envelope | 3.469120e-01 | 0.460 |
| R-HSA-5676590 | NIK-->noncanonical NF-kB signaling | 3.474663e-01 | 0.459 |
| R-HSA-5218920 | VEGFR2 mediated vascular permeability | 3.474663e-01 | 0.459 |
| R-HSA-9929491 | SPOP-mediated proteasomal degradation of PD-L1(CD274) | 3.474663e-01 | 0.459 |
| R-HSA-168271 | Transport of Ribonucleoproteins into the Host Nucleus | 3.474663e-01 | 0.459 |
| R-HSA-73933 | Resolution of Abasic Sites (AP sites) | 3.474663e-01 | 0.459 |
| R-HSA-5423646 | Aflatoxin activation and detoxification | 3.474663e-01 | 0.459 |
| R-HSA-3214841 | PKMTs methylate histone lysines | 3.474663e-01 | 0.459 |
| R-HSA-68882 | Mitotic Anaphase | 3.494102e-01 | 0.457 |
| R-HSA-2555396 | Mitotic Metaphase and Anaphase | 3.518266e-01 | 0.454 |
| R-HSA-5675221 | Negative regulation of MAPK pathway | 3.532527e-01 | 0.452 |
| R-HSA-174417 | Telomere C-strand (Lagging Strand) Synthesis | 3.532527e-01 | 0.452 |
| R-HSA-9927418 | Developmental Lineage of Mammary Gland Luminal Epithelial Cells | 3.589882e-01 | 0.445 |
| R-HSA-165159 | MTOR signalling | 3.589882e-01 | 0.445 |
| R-HSA-114608 | Platelet degranulation | 3.597139e-01 | 0.444 |
| R-HSA-112315 | Transmission across Chemical Synapses | 3.631654e-01 | 0.440 |
| R-HSA-2172127 | DAP12 interactions | 3.703080e-01 | 0.431 |
| R-HSA-2142691 | Synthesis of Leukotrienes (LT) and Eoxins (EX) | 3.703080e-01 | 0.431 |
| R-HSA-1474165 | Reproduction | 3.724244e-01 | 0.429 |
| R-HSA-5607761 | Dectin-1 mediated noncanonical NF-kB signaling | 3.758933e-01 | 0.425 |
| R-HSA-168333 | NEP/NS2 Interacts with the Cellular Export Machinery | 3.758933e-01 | 0.425 |
| R-HSA-6783310 | Fanconi Anemia Pathway | 3.758933e-01 | 0.425 |
| R-HSA-69613 | p53-Independent G1/S DNA Damage Checkpoint | 3.758933e-01 | 0.425 |
| R-HSA-69601 | Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | 3.758933e-01 | 0.425 |
| R-HSA-2453902 | The canonical retinoid cycle in rods (twilight vision) | 3.758933e-01 | 0.425 |
| R-HSA-168274 | Export of Viral Ribonucleoproteins from Nucleus | 3.814293e-01 | 0.419 |
| R-HSA-9861718 | Regulation of pyruvate metabolism | 3.814293e-01 | 0.419 |
| R-HSA-9664424 | Cell recruitment (pro-inflammatory response) | 3.814293e-01 | 0.419 |
| R-HSA-9660826 | Purinergic signaling in leishmaniasis infection | 3.814293e-01 | 0.419 |
| R-HSA-76005 | Response to elevated platelet cytosolic Ca2+ | 3.818917e-01 | 0.418 |
| R-HSA-445989 | TAK1-dependent IKK and NF-kappa-B activation | 3.869166e-01 | 0.412 |
| R-HSA-72312 | rRNA processing | 3.879134e-01 | 0.411 |
| R-HSA-1643685 | Disease | 3.916704e-01 | 0.407 |
| R-HSA-5693571 | Nonhomologous End-Joining (NHEJ) | 3.923556e-01 | 0.406 |
| R-HSA-9031628 | NGF-stimulated transcription | 3.923556e-01 | 0.406 |
| R-HSA-532668 | N-glycan trimming in the ER and Calnexin/Calreticulin cycle | 3.977466e-01 | 0.400 |
| R-HSA-1428517 | Aerobic respiration and respiratory electron transport | 3.992844e-01 | 0.399 |
| R-HSA-5658442 | Regulation of RAS by GAPs | 4.030901e-01 | 0.395 |
| R-HSA-3371571 | HSF1-dependent transactivation | 4.083866e-01 | 0.389 |
| R-HSA-2029482 | Regulation of actin dynamics for phagocytic cup formation | 4.099193e-01 | 0.387 |
| R-HSA-1632852 | Macroautophagy | 4.099193e-01 | 0.387 |
| R-HSA-72187 | mRNA 3'-end processing | 4.136363e-01 | 0.383 |
| R-HSA-112382 | Formation of RNA Pol II elongation complex | 4.136363e-01 | 0.383 |
| R-HSA-432722 | Golgi Associated Vesicle Biogenesis | 4.188398e-01 | 0.378 |
| R-HSA-75955 | RNA Polymerase II Transcription Elongation | 4.188398e-01 | 0.378 |
| R-HSA-445355 | Smooth Muscle Contraction | 4.188398e-01 | 0.378 |
| R-HSA-8856828 | Clathrin-mediated endocytosis | 4.191265e-01 | 0.378 |
| R-HSA-9754678 | SARS-CoV-2 modulates host translation machinery | 4.239975e-01 | 0.373 |
| R-HSA-72702 | Ribosomal scanning and start codon recognition | 4.341769e-01 | 0.362 |
| R-HSA-177929 | Signaling by EGFR | 4.341769e-01 | 0.362 |
| R-HSA-1483166 | Synthesis of PA | 4.391993e-01 | 0.357 |
| R-HSA-9856651 | MITF-M-dependent gene expression | 4.403238e-01 | 0.356 |
| R-HSA-388841 | Regulation of T cell activation by CD28 family | 4.445581e-01 | 0.352 |
| R-HSA-9820448 | Developmental Cell Lineages of the Exocrine Pancreas | 4.463033e-01 | 0.350 |
| R-HSA-446652 | Interleukin-1 family signaling | 4.463033e-01 | 0.350 |
| R-HSA-5693565 | Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at... | 4.491119e-01 | 0.348 |
| R-HSA-8979227 | Triglyceride metabolism | 4.491119e-01 | 0.348 |
| R-HSA-180786 | Extension of Telomeres | 4.491119e-01 | 0.348 |
| R-HSA-5693532 | DNA Double-Strand Break Repair | 4.492798e-01 | 0.347 |
| R-HSA-9609507 | Protein localization | 4.492798e-01 | 0.347 |
| R-HSA-69306 | DNA Replication | 4.492798e-01 | 0.347 |
| R-HSA-9764725 | Negative Regulation of CDH1 Gene Transcription | 4.540027e-01 | 0.343 |
| R-HSA-168273 | Influenza Viral RNA Transcription and Replication | 4.552061e-01 | 0.342 |
| R-HSA-9612973 | Autophagy | 4.581556e-01 | 0.339 |
| R-HSA-168325 | Viral Messenger RNA Synthesis | 4.588504e-01 | 0.338 |
| R-HSA-73856 | RNA Polymerase II Transcription Termination | 4.588504e-01 | 0.338 |
| R-HSA-9734767 | Developmental Cell Lineages | 4.607143e-01 | 0.337 |
| R-HSA-162587 | HIV Life Cycle | 4.610960e-01 | 0.336 |
| R-HSA-416476 | G alpha (q) signalling events | 4.630064e-01 | 0.334 |
| R-HSA-6784531 | tRNA processing in the nucleus | 4.636554e-01 | 0.334 |
| R-HSA-8852276 | The role of GTSE1 in G2/M progression after G2 checkpoint | 4.636554e-01 | 0.334 |
| R-HSA-1268020 | Mitochondrial protein import | 4.636554e-01 | 0.334 |
| R-HSA-2559586 | DNA Damage/Telomere Stress Induced Senescence | 4.636554e-01 | 0.334 |
| R-HSA-186797 | Signaling by PDGF | 4.636554e-01 | 0.334 |
| R-HSA-69615 | G1/S DNA Damage Checkpoints | 4.684179e-01 | 0.329 |
| R-HSA-8848021 | Signaling by PTK6 | 4.684179e-01 | 0.329 |
| R-HSA-9006927 | Signaling by Non-Receptor Tyrosine Kinases | 4.684179e-01 | 0.329 |
| R-HSA-74751 | Insulin receptor signalling cascade | 4.731385e-01 | 0.325 |
| R-HSA-211981 | Xenobiotics | 4.731385e-01 | 0.325 |
| R-HSA-168643 | Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signali... | 4.731385e-01 | 0.325 |
| R-HSA-1280218 | Adaptive Immune System | 4.770706e-01 | 0.321 |
| R-HSA-2467813 | Separation of Sister Chromatids | 4.814172e-01 | 0.317 |
| R-HSA-5693606 | DNA Double Strand Break Response | 4.870520e-01 | 0.312 |
| R-HSA-211897 | Cytochrome P450 - arranged by substrate type | 4.899827e-01 | 0.310 |
| R-HSA-9662360 | Sensory processing of sound by inner hair cells of the cochlea | 4.916083e-01 | 0.308 |
| R-HSA-5218859 | Regulated Necrosis | 4.916083e-01 | 0.308 |
| R-HSA-9925563 | Developmental Lineage of Pancreatic Ductal Cells | 4.961243e-01 | 0.304 |
| R-HSA-9764560 | Regulation of CDH1 Gene Transcription | 5.006005e-01 | 0.301 |
| R-HSA-8978934 | Metabolism of cofactors | 5.050373e-01 | 0.297 |
| R-HSA-199992 | trans-Golgi Network Vesicle Budding | 5.094349e-01 | 0.293 |
| R-HSA-9924644 | Developmental Lineages of the Mammary Gland | 5.094349e-01 | 0.293 |
| R-HSA-5578749 | Transcriptional regulation by small RNAs | 5.094349e-01 | 0.293 |
| R-HSA-69656 | Cyclin A:Cdk2-associated events at S phase entry | 5.094349e-01 | 0.293 |
| R-HSA-2029480 | Fcgamma receptor (FCGR) dependent phagocytosis | 5.123893e-01 | 0.290 |
| R-HSA-9749641 | Aspirin ADME | 5.137936e-01 | 0.289 |
| R-HSA-204998 | Cell death signalling via NRAGE, NRIF and NADE | 5.137936e-01 | 0.289 |
| R-HSA-983231 | Factors involved in megakaryocyte development and platelet production | 5.151448e-01 | 0.288 |
| R-HSA-674695 | RNA Polymerase II Pre-transcription Events | 5.181140e-01 | 0.286 |
| R-HSA-9013694 | Signaling by NOTCH4 | 5.181140e-01 | 0.286 |
| R-HSA-1236394 | Signaling by ERBB4 | 5.181140e-01 | 0.286 |
| R-HSA-1169408 | ISG15 antiviral mechanism | 5.223962e-01 | 0.282 |
| R-HSA-168255 | Influenza Infection | 5.260646e-01 | 0.279 |
| R-HSA-5689603 | UCH proteinases | 5.266406e-01 | 0.278 |
| R-HSA-416482 | G alpha (12/13) signalling events | 5.350174e-01 | 0.272 |
| R-HSA-191273 | Cholesterol biosynthesis | 5.350174e-01 | 0.272 |
| R-HSA-9925561 | Developmental Lineage of Pancreatic Acinar Cells | 5.391504e-01 | 0.268 |
| R-HSA-9659379 | Sensory processing of sound | 5.391504e-01 | 0.268 |
| R-HSA-2995410 | Nuclear Envelope (NE) Reassembly | 5.432469e-01 | 0.265 |
| R-HSA-9856530 | High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR... | 5.432469e-01 | 0.265 |
| R-HSA-5693607 | Processing of DNA double-strand break ends | 5.473073e-01 | 0.262 |
| R-HSA-9018677 | Biosynthesis of DHA-derived SPMs | 5.473073e-01 | 0.262 |
| R-HSA-5668541 | TNFR2 non-canonical NF-kB pathway | 5.553209e-01 | 0.255 |
| R-HSA-6785807 | Interleukin-4 and Interleukin-13 signaling | 5.604030e-01 | 0.251 |
| R-HSA-388396 | GPCR downstream signalling | 5.631463e-01 | 0.249 |
| R-HSA-72163 | mRNA Splicing - Major Pathway | 5.655274e-01 | 0.248 |
| R-HSA-141444 | Amplification of signal from unattached kinetochores via a MAD2 inhibitory si... | 5.670778e-01 | 0.246 |
| R-HSA-141424 | Amplification of signal from the kinetochores | 5.670778e-01 | 0.246 |
| R-HSA-8876198 | RAB GEFs exchange GTP for GDP on RABs | 5.670778e-01 | 0.246 |
| R-HSA-9909615 | Regulation of PD-L1(CD274) Post-translational modification | 5.670778e-01 | 0.246 |
| R-HSA-390466 | Chaperonin-mediated protein folding | 5.747437e-01 | 0.241 |
| R-HSA-1852241 | Organelle biogenesis and maintenance | 5.835453e-01 | 0.234 |
| R-HSA-112310 | Neurotransmitter release cycle | 5.859906e-01 | 0.232 |
| R-HSA-73884 | Base Excision Repair | 5.859906e-01 | 0.232 |
| R-HSA-72172 | mRNA Splicing | 5.929470e-01 | 0.227 |
| R-HSA-74752 | Signaling by Insulin receptor | 5.969420e-01 | 0.224 |
| R-HSA-391251 | Protein folding | 5.969420e-01 | 0.224 |
| R-HSA-6805567 | Keratinization | 5.977929e-01 | 0.223 |
| R-HSA-2730905 | Role of LAT2/NTAL/LAB on calcium mobilization | 6.145588e-01 | 0.211 |
| R-HSA-6807878 | COPI-mediated anterograde transport | 6.145588e-01 | 0.211 |
| R-HSA-5607764 | CLEC7A (Dectin-1) signaling | 6.145588e-01 | 0.211 |
| R-HSA-157579 | Telomere Maintenance | 6.179893e-01 | 0.209 |
| R-HSA-5368286 | Mitochondrial translation initiation | 6.213894e-01 | 0.207 |
| R-HSA-422356 | Regulation of insulin secretion | 6.213894e-01 | 0.207 |
| R-HSA-193704 | p75 NTR receptor-mediated signalling | 6.247596e-01 | 0.204 |
| R-HSA-69618 | Mitotic Spindle Checkpoint | 6.280999e-01 | 0.202 |
| R-HSA-70171 | Glycolysis | 6.280999e-01 | 0.202 |
| R-HSA-9020702 | Interleukin-1 signaling | 6.314107e-01 | 0.200 |
| R-HSA-112316 | Neuronal System | 6.341129e-01 | 0.198 |
| R-HSA-9842860 | Regulation of endogenous retroelements | 6.346922e-01 | 0.197 |
| R-HSA-8878171 | Transcriptional regulation by RUNX1 | 6.438914e-01 | 0.191 |
| R-HSA-162906 | HIV Infection | 6.460842e-01 | 0.190 |
| R-HSA-69239 | Synthesis of DNA | 6.537810e-01 | 0.185 |
| R-HSA-2672351 | Stimuli-sensing channels | 6.568647e-01 | 0.183 |
| R-HSA-73894 | DNA Repair | 6.585200e-01 | 0.181 |
| R-HSA-9648025 | EML4 and NUDC in mitotic spindle formation | 6.599211e-01 | 0.181 |
| R-HSA-69002 | DNA Replication Pre-Initiation | 6.599211e-01 | 0.181 |
| R-HSA-202403 | TCR signaling | 6.629505e-01 | 0.179 |
| R-HSA-372790 | Signaling by GPCR | 6.676802e-01 | 0.175 |
| R-HSA-2871796 | FCERI mediated MAPK activation | 6.689291e-01 | 0.175 |
| R-HSA-1483249 | Inositol phosphate metabolism | 6.689291e-01 | 0.175 |
| R-HSA-5693567 | HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | 6.748025e-01 | 0.171 |
| R-HSA-2871809 | FCERI mediated Ca+2 mobilization | 6.834190e-01 | 0.165 |
| R-HSA-9007101 | Rab regulation of trafficking | 6.890370e-01 | 0.162 |
| R-HSA-70326 | Glucose metabolism | 6.890370e-01 | 0.162 |
| R-HSA-73886 | Chromosome Maintenance | 6.999777e-01 | 0.155 |
| R-HSA-74160 | Gene expression (Transcription) | 7.016137e-01 | 0.154 |
| R-HSA-162909 | Host Interactions of HIV factors | 7.079316e-01 | 0.150 |
| R-HSA-69206 | G1/S Transition | 7.131175e-01 | 0.147 |
| R-HSA-109582 | Hemostasis | 7.246138e-01 | 0.140 |
| R-HSA-211945 | Phase I - Functionalization of compounds | 7.443171e-01 | 0.128 |
| R-HSA-446728 | Cell junction organization | 7.443171e-01 | 0.128 |
| R-HSA-163685 | Integration of energy metabolism | 7.446670e-01 | 0.128 |
| R-HSA-9820952 | Respiratory Syncytial Virus Infection Pathway | 7.469461e-01 | 0.127 |
| R-HSA-5368287 | Mitochondrial translation | 7.492049e-01 | 0.125 |
| R-HSA-9824443 | Parasitic Infection Pathways | 7.493023e-01 | 0.125 |
| R-HSA-9658195 | Leishmania infection | 7.493023e-01 | 0.125 |
| R-HSA-9664417 | Leishmania phagocytosis | 7.536627e-01 | 0.123 |
| R-HSA-9664407 | Parasite infection | 7.536627e-01 | 0.123 |
| R-HSA-9664422 | FCGR3A-mediated phagocytosis | 7.536627e-01 | 0.123 |
| R-HSA-162599 | Late Phase of HIV Life Cycle | 7.602022e-01 | 0.119 |
| R-HSA-9018678 | Biosynthesis of specialized proresolving mediators (SPMs) | 7.623435e-01 | 0.118 |
| R-HSA-72766 | Translation | 7.654751e-01 | 0.116 |
| R-HSA-168249 | Innate Immune System | 7.680578e-01 | 0.115 |
| R-HSA-453279 | Mitotic G1 phase and G1/S transition | 7.686542e-01 | 0.114 |
| R-HSA-199977 | ER to Golgi Anterograde Transport | 7.707205e-01 | 0.113 |
| R-HSA-2187338 | Visual phototransduction | 7.707205e-01 | 0.113 |
| R-HSA-9758941 | Gastrulation | 7.747984e-01 | 0.111 |
| R-HSA-2173782 | Binding and Uptake of Ligands by Scavenger Receptors | 7.768102e-01 | 0.110 |
| R-HSA-2142753 | Arachidonate metabolism | 7.807805e-01 | 0.107 |
| R-HSA-9917777 | Epigenetic regulation by WDR5-containing histone modifying complexes | 7.846807e-01 | 0.105 |
| R-HSA-1169410 | Antiviral mechanism by IFN-stimulated genes | 7.846807e-01 | 0.105 |
| R-HSA-9610379 | HCMV Late Events | 7.904021e-01 | 0.102 |
| R-HSA-877300 | Interferon gamma signaling | 7.941322e-01 | 0.100 |
| R-HSA-1500931 | Cell-Cell communication | 8.015647e-01 | 0.096 |
| R-HSA-5619102 | SLC transporter disorders | 8.084050e-01 | 0.092 |
| R-HSA-212165 | Epigenetic regulation of gene expression | 8.107891e-01 | 0.091 |
| R-HSA-72306 | tRNA processing | 8.151684e-01 | 0.089 |
| R-HSA-5621481 | C-type lectin receptors (CLRs) | 8.168219e-01 | 0.088 |
| R-HSA-9764265 | Regulation of CDH1 Expression and Function | 8.200849e-01 | 0.086 |
| R-HSA-9764274 | Regulation of Expression and Function of Type I Classical Cadherins | 8.200849e-01 | 0.086 |
| R-HSA-611105 | Respiratory electron transport | 8.279921e-01 | 0.082 |
| R-HSA-392499 | Metabolism of proteins | 8.292575e-01 | 0.081 |
| R-HSA-201681 | TCF dependent signaling in response to WNT | 8.355540e-01 | 0.078 |
| R-HSA-983712 | Ion channel transport | 8.441938e-01 | 0.074 |
| R-HSA-73857 | RNA Polymerase II Transcription | 8.446733e-01 | 0.073 |
| R-HSA-9609690 | HCMV Early Events | 8.537053e-01 | 0.069 |
| R-HSA-9759476 | Regulation of Homotypic Cell-Cell Adhesion | 8.537053e-01 | 0.069 |
| R-HSA-948021 | Transport to the Golgi and subsequent modification | 8.613975e-01 | 0.065 |
| R-HSA-2454202 | Fc epsilon receptor (FCERI) signaling | 8.626399e-01 | 0.064 |
| R-HSA-376176 | Signaling by ROBO receptors | 8.626399e-01 | 0.064 |
| R-HSA-1483206 | Glycerophospholipid biosynthesis | 8.626399e-01 | 0.064 |
| R-HSA-983169 | Class I MHC mediated antigen processing & presentation | 8.763292e-01 | 0.057 |
| R-HSA-913531 | Interferon Signaling | 8.763292e-01 | 0.057 |
| R-HSA-9748784 | Drug ADME | 8.810787e-01 | 0.055 |
| R-HSA-418990 | Adherens junctions interactions | 8.810787e-01 | 0.055 |
| R-HSA-9824439 | Bacterial Infection Pathways | 8.823480e-01 | 0.054 |
| R-HSA-8951664 | Neddylation | 8.842516e-01 | 0.053 |
| R-HSA-3247509 | Chromatin modifying enzymes | 8.970573e-01 | 0.047 |
| R-HSA-202733 | Cell surface interactions at the vascular wall | 8.998067e-01 | 0.046 |
| R-HSA-212436 | Generic Transcription Pathway | 9.010246e-01 | 0.045 |
| R-HSA-157118 | Signaling by NOTCH | 9.024831e-01 | 0.045 |
| R-HSA-446203 | Asparagine N-linked glycosylation | 9.065811e-01 | 0.043 |
| R-HSA-5619115 | Disorders of transmembrane transporters | 9.084551e-01 | 0.042 |
| R-HSA-4839726 | Chromatin organization | 9.100937e-01 | 0.041 |
| R-HSA-9609646 | HCMV Infection | 9.109020e-01 | 0.041 |
| R-HSA-421270 | Cell-cell junction organization | 9.117031e-01 | 0.040 |
| R-HSA-5688426 | Deubiquitination | 9.148367e-01 | 0.039 |
| R-HSA-71291 | Metabolism of amino acids and derivatives | 9.258729e-01 | 0.033 |
| R-HSA-6798695 | Neutrophil degranulation | 9.277325e-01 | 0.033 |
| R-HSA-597592 | Post-translational protein modification | 9.379203e-01 | 0.028 |
| R-HSA-1483257 | Phospholipid metabolism | 9.406929e-01 | 0.027 |
| R-HSA-195721 | Signaling by WNT | 9.422829e-01 | 0.026 |
| R-HSA-8957322 | Metabolism of steroids | 9.544040e-01 | 0.020 |
| R-HSA-211859 | Biological oxidations | 9.559601e-01 | 0.020 |
| R-HSA-196854 | Metabolism of vitamins and cofactors | 9.682977e-01 | 0.014 |
| R-HSA-8978868 | Fatty acid metabolism | 9.787672e-01 | 0.009 |
| R-HSA-71387 | Metabolism of carbohydrates and carbohydrate derivatives | 9.863057e-01 | 0.006 |
| R-HSA-382551 | Transport of small molecules | 9.943506e-01 | 0.002 |
| R-HSA-556833 | Metabolism of lipids | 9.980155e-01 | 0.001 |
| R-HSA-9709957 | Sensory Perception | 9.998835e-01 | 0.000 |
| R-HSA-1430728 | Metabolism | 9.999763e-01 | 0.000 |
Download
| kinase | JSD_mean | pearson_surrounding | kinase_max_IC_position | max_position_JSD |
|---|---|---|---|---|
GAK |
0.824 | -0.012 | 1 | 0.690 |
PKR |
0.823 | 0.058 | 1 | 0.725 |
EEF2K |
0.819 | 0.099 | 3 | 0.887 |
TAK1 |
0.819 | 0.003 | 1 | 0.730 |
TTK |
0.818 | 0.070 | -2 | 0.756 |
MINK |
0.817 | 0.053 | 1 | 0.711 |
TNIK |
0.816 | 0.072 | 3 | 0.915 |
GCK |
0.816 | 0.033 | 1 | 0.725 |
BRAF |
0.815 | 0.016 | -4 | 0.790 |
MST2 |
0.815 | 0.018 | 1 | 0.732 |
LRRK2 |
0.815 | -0.053 | 2 | 0.823 |
VRK2 |
0.814 | -0.186 | 1 | 0.759 |
ALPHAK3 |
0.814 | 0.086 | -1 | 0.699 |
MEKK2 |
0.813 | 0.002 | 2 | 0.783 |
MST1 |
0.813 | 0.011 | 1 | 0.711 |
NIK |
0.812 | 0.033 | -3 | 0.778 |
TAO2 |
0.812 | 0.000 | 2 | 0.827 |
KHS2 |
0.811 | 0.084 | 1 | 0.733 |
HGK |
0.811 | 0.036 | 3 | 0.918 |
ALK4 |
0.811 | 0.065 | -2 | 0.784 |
BMPR2 |
0.811 | -0.026 | -2 | 0.820 |
KHS1 |
0.810 | 0.044 | 1 | 0.722 |
MOS |
0.809 | 0.159 | 1 | 0.800 |
BMPR1B |
0.809 | 0.191 | 1 | 0.766 |
NEK1 |
0.809 | -0.036 | 1 | 0.679 |
NEK8 |
0.809 | 0.017 | 2 | 0.806 |
TAO3 |
0.808 | 0.012 | 1 | 0.701 |
VRK1 |
0.808 | -0.167 | 2 | 0.833 |
MEK5 |
0.808 | -0.123 | 2 | 0.794 |
MEK1 |
0.808 | -0.121 | 2 | 0.793 |
HPK1 |
0.808 | 0.022 | 1 | 0.728 |
ALK2 |
0.807 | 0.127 | -2 | 0.776 |
NLK |
0.807 | 0.145 | 1 | 0.766 |
MST3 |
0.807 | 0.042 | 2 | 0.801 |
CAMKK1 |
0.807 | 0.019 | -2 | 0.789 |
NEK5 |
0.806 | -0.057 | 1 | 0.701 |
MYO3A |
0.805 | 0.026 | 1 | 0.700 |
OSR1 |
0.805 | -0.013 | 2 | 0.756 |
CAMKK2 |
0.805 | -0.012 | -2 | 0.782 |
PDK1 |
0.805 | -0.091 | 1 | 0.699 |
JNK2 |
0.804 | 0.128 | 1 | 0.626 |
DAPK2 |
0.804 | -0.034 | -3 | 0.763 |
NEK4 |
0.804 | -0.008 | 1 | 0.696 |
DLK |
0.804 | -0.065 | 1 | 0.725 |
CDKL1 |
0.804 | 0.075 | -3 | 0.718 |
CAMLCK |
0.804 | -0.030 | -2 | 0.740 |
ASK1 |
0.803 | -0.118 | 1 | 0.656 |
MYO3B |
0.803 | 0.003 | 2 | 0.790 |
MEKK3 |
0.803 | -0.041 | 1 | 0.701 |
MAP3K15 |
0.802 | -0.094 | 1 | 0.664 |
ANKRD3 |
0.802 | -0.085 | 1 | 0.740 |
ACVR2A |
0.801 | 0.098 | -2 | 0.753 |
PRPK |
0.801 | -0.088 | -1 | 0.745 |
JNK3 |
0.801 | 0.106 | 1 | 0.649 |
CAMK1B |
0.800 | 0.009 | -3 | 0.771 |
YSK4 |
0.800 | -0.034 | 1 | 0.688 |
ACVR2B |
0.800 | 0.105 | -2 | 0.769 |
PRP4 |
0.799 | 0.053 | -3 | 0.641 |
LKB1 |
0.799 | -0.069 | -3 | 0.693 |
NEK11 |
0.799 | -0.086 | 1 | 0.705 |
BMPR1A |
0.799 | 0.181 | 1 | 0.765 |
P38A |
0.799 | 0.097 | 1 | 0.672 |
YSK1 |
0.798 | -0.044 | 2 | 0.783 |
ZAK |
0.798 | -0.047 | 1 | 0.678 |
PASK |
0.798 | -0.014 | -3 | 0.755 |
BIKE |
0.798 | -0.051 | 1 | 0.565 |
LATS1 |
0.798 | 0.007 | -3 | 0.774 |
DMPK1 |
0.798 | 0.040 | -3 | 0.712 |
MEKK6 |
0.798 | -0.098 | 1 | 0.679 |
ATR |
0.797 | -0.002 | 1 | 0.754 |
LOK |
0.797 | 0.000 | -2 | 0.709 |
MEKK1 |
0.797 | -0.133 | 1 | 0.699 |
TGFBR1 |
0.796 | 0.053 | -2 | 0.760 |
RAF1 |
0.796 | 0.046 | 1 | 0.770 |
P38B |
0.796 | 0.103 | 1 | 0.633 |
ICK |
0.796 | 0.035 | -3 | 0.742 |
CLK3 |
0.796 | 0.223 | 1 | 0.792 |
DAPK3 |
0.795 | 0.004 | -3 | 0.736 |
PERK |
0.795 | -0.029 | -2 | 0.804 |
GRK6 |
0.794 | 0.077 | 1 | 0.768 |
ERK5 |
0.793 | 0.098 | 1 | 0.730 |
SMMLCK |
0.793 | -0.039 | -3 | 0.724 |
ROCK2 |
0.792 | 0.018 | -3 | 0.714 |
MLK1 |
0.792 | 0.021 | 2 | 0.802 |
MEK2 |
0.792 | -0.194 | 2 | 0.771 |
ERK2 |
0.792 | 0.107 | 1 | 0.648 |
STLK3 |
0.792 | -0.159 | 1 | 0.658 |
COT |
0.791 | 0.128 | 2 | 0.861 |
PLK1 |
0.791 | -0.005 | -2 | 0.767 |
PBK |
0.790 | -0.077 | 1 | 0.609 |
HRI |
0.790 | -0.073 | -2 | 0.788 |
GRK7 |
0.789 | 0.049 | 1 | 0.700 |
TSSK2 |
0.789 | 0.091 | -5 | 0.805 |
SLK |
0.789 | -0.016 | -2 | 0.673 |
MLK2 |
0.788 | -0.106 | 2 | 0.789 |
DSTYK |
0.788 | 0.102 | 2 | 0.857 |
PKN3 |
0.787 | 0.043 | -3 | 0.728 |
CDK5 |
0.787 | 0.133 | 1 | 0.664 |
P38G |
0.787 | 0.098 | 1 | 0.559 |
CDK1 |
0.787 | 0.145 | 1 | 0.630 |
TLK1 |
0.787 | -0.037 | -2 | 0.767 |
TAO1 |
0.786 | -0.042 | 1 | 0.641 |
MLK4 |
0.786 | 0.034 | 2 | 0.731 |
WNK4 |
0.786 | -0.051 | -2 | 0.758 |
WNK1 |
0.786 | 0.031 | -2 | 0.753 |
MPSK1 |
0.785 | -0.105 | 1 | 0.621 |
AAK1 |
0.785 | -0.030 | 1 | 0.471 |
BUB1 |
0.785 | 0.116 | -5 | 0.766 |
CHAK2 |
0.785 | -0.001 | -1 | 0.757 |
NEK9 |
0.785 | -0.086 | 2 | 0.814 |
MLK3 |
0.785 | 0.072 | 2 | 0.734 |
GRK5 |
0.784 | -0.067 | -3 | 0.736 |
SKMLCK |
0.784 | -0.054 | -2 | 0.722 |
IRAK4 |
0.784 | -0.022 | 1 | 0.673 |
TLK2 |
0.784 | -0.073 | 1 | 0.705 |
PIM1 |
0.784 | 0.056 | -3 | 0.725 |
HIPK1 |
0.783 | 0.085 | 1 | 0.681 |
CAMK2G |
0.783 | -0.059 | 2 | 0.795 |
DAPK1 |
0.783 | -0.007 | -3 | 0.712 |
P38D |
0.783 | 0.119 | 1 | 0.577 |
NUAK2 |
0.783 | 0.060 | -3 | 0.763 |
CDK2 |
0.782 | 0.141 | 1 | 0.683 |
CDKL5 |
0.782 | 0.062 | -3 | 0.705 |
CDC7 |
0.782 | 0.128 | 1 | 0.819 |
ERK1 |
0.782 | 0.099 | 1 | 0.620 |
PKCD |
0.782 | 0.045 | 2 | 0.780 |
HASPIN |
0.782 | -0.002 | -1 | 0.611 |
ROCK1 |
0.782 | 0.019 | -3 | 0.689 |
CHK1 |
0.781 | 0.035 | -3 | 0.746 |
PKN2 |
0.780 | 0.048 | -3 | 0.743 |
PINK1 |
0.780 | -0.036 | 1 | 0.702 |
MRCKA |
0.780 | 0.037 | -3 | 0.696 |
PDHK4 |
0.780 | -0.213 | 1 | 0.762 |
RIPK3 |
0.779 | -0.028 | 3 | 0.781 |
JNK1 |
0.779 | 0.088 | 1 | 0.611 |
PIM2 |
0.779 | 0.042 | -3 | 0.684 |
CLK4 |
0.779 | 0.084 | -3 | 0.713 |
MST4 |
0.779 | 0.051 | 2 | 0.812 |
PIM3 |
0.779 | 0.025 | -3 | 0.759 |
GRK2 |
0.778 | -0.017 | -2 | 0.685 |
DYRK2 |
0.778 | 0.084 | 1 | 0.681 |
AMPKA1 |
0.778 | 0.007 | -3 | 0.758 |
MOK |
0.777 | 0.083 | 1 | 0.676 |
P70S6KB |
0.777 | 0.024 | -3 | 0.726 |
SRPK3 |
0.777 | 0.087 | -3 | 0.660 |
MAK |
0.777 | 0.076 | -2 | 0.641 |
DNAPK |
0.777 | 0.019 | 1 | 0.700 |
DCAMKL1 |
0.777 | -0.016 | -3 | 0.728 |
MRCKB |
0.776 | 0.021 | -3 | 0.675 |
NEK2 |
0.776 | -0.087 | 2 | 0.781 |
PDHK1 |
0.776 | -0.170 | 1 | 0.760 |
CDK6 |
0.776 | 0.106 | 1 | 0.609 |
TGFBR2 |
0.776 | 0.019 | -2 | 0.749 |
DCAMKL2 |
0.775 | -0.015 | -3 | 0.749 |
RIPK1 |
0.775 | -0.167 | 1 | 0.689 |
MASTL |
0.775 | -0.273 | -2 | 0.758 |
DRAK1 |
0.775 | -0.059 | 1 | 0.667 |
CDK3 |
0.775 | 0.163 | 1 | 0.577 |
IRE2 |
0.775 | 0.034 | 2 | 0.768 |
NEK7 |
0.775 | -0.029 | -3 | 0.727 |
ATM |
0.775 | 0.017 | 1 | 0.730 |
CRIK |
0.775 | 0.021 | -3 | 0.652 |
CDK14 |
0.774 | 0.093 | 1 | 0.630 |
DYRK1A |
0.774 | 0.067 | 1 | 0.702 |
ERK7 |
0.774 | 0.047 | 2 | 0.551 |
TBK1 |
0.774 | -0.007 | 1 | 0.673 |
CDK4 |
0.774 | 0.093 | 1 | 0.608 |
TSSK1 |
0.773 | 0.035 | -3 | 0.769 |
PLK3 |
0.773 | -0.052 | 2 | 0.760 |
IRE1 |
0.773 | 0.003 | 1 | 0.662 |
CHAK1 |
0.773 | -0.042 | 2 | 0.712 |
NEK3 |
0.773 | -0.135 | 1 | 0.647 |
CLK1 |
0.772 | 0.112 | -3 | 0.695 |
SRPK1 |
0.772 | 0.097 | -3 | 0.687 |
GRK1 |
0.771 | 0.077 | -2 | 0.752 |
CDK16 |
0.771 | 0.124 | 1 | 0.571 |
WNK3 |
0.771 | -0.099 | 1 | 0.703 |
ULK2 |
0.770 | -0.077 | 2 | 0.779 |
MTOR |
0.770 | -0.080 | 1 | 0.715 |
HIPK3 |
0.770 | 0.050 | 1 | 0.678 |
AKT2 |
0.770 | 0.043 | -3 | 0.645 |
CHK2 |
0.770 | 0.041 | -3 | 0.604 |
NEK6 |
0.770 | 0.022 | -2 | 0.801 |
IKKE |
0.768 | -0.006 | 1 | 0.679 |
SGK3 |
0.768 | -0.003 | -3 | 0.682 |
MYLK4 |
0.768 | -0.025 | -2 | 0.636 |
AMPKA2 |
0.767 | 0.012 | -3 | 0.739 |
IRAK1 |
0.767 | -0.141 | -1 | 0.672 |
MARK4 |
0.767 | -0.054 | 4 | 0.780 |
HUNK |
0.766 | -0.153 | 2 | 0.806 |
RSK2 |
0.766 | 0.041 | -3 | 0.710 |
MELK |
0.766 | 0.014 | -3 | 0.721 |
PKCH |
0.766 | 0.002 | 2 | 0.725 |
DYRK1B |
0.766 | 0.065 | 1 | 0.639 |
PRKD3 |
0.765 | 0.074 | -3 | 0.678 |
DYRK3 |
0.765 | 0.053 | 1 | 0.684 |
SMG1 |
0.765 | -0.043 | 1 | 0.711 |
GSK3B |
0.765 | -0.024 | 4 | 0.430 |
AKT1 |
0.765 | 0.049 | -3 | 0.658 |
PLK2 |
0.765 | 0.015 | -3 | 0.749 |
CDK17 |
0.765 | 0.079 | 1 | 0.562 |
P90RSK |
0.764 | 0.019 | -3 | 0.708 |
TTBK2 |
0.764 | -0.112 | 2 | 0.701 |
GSK3A |
0.763 | 0.002 | 4 | 0.443 |
PKCZ |
0.763 | -0.038 | 2 | 0.763 |
GRK4 |
0.762 | -0.074 | -2 | 0.766 |
CAMK2D |
0.762 | -0.079 | -3 | 0.728 |
CAMK4 |
0.762 | -0.055 | -3 | 0.734 |
IKKB |
0.762 | -0.020 | -2 | 0.752 |
CAMK1D |
0.762 | 0.009 | -3 | 0.642 |
PKCA |
0.762 | -0.002 | 2 | 0.723 |
SGK1 |
0.762 | 0.017 | -3 | 0.579 |
HIPK4 |
0.761 | 0.030 | 1 | 0.727 |
PKCB |
0.761 | 0.021 | 2 | 0.735 |
RIPK2 |
0.761 | -0.144 | 1 | 0.650 |
PAK2 |
0.761 | -0.083 | -2 | 0.643 |
CAMK1G |
0.761 | -0.003 | -3 | 0.693 |
CDK10 |
0.761 | 0.110 | 1 | 0.619 |
CAMK2B |
0.760 | 0.001 | 2 | 0.759 |
CDK13 |
0.760 | 0.051 | 1 | 0.637 |
PAK1 |
0.760 | -0.055 | -2 | 0.649 |
MAPKAPK3 |
0.760 | 0.001 | -3 | 0.698 |
QIK |
0.759 | -0.043 | -3 | 0.725 |
PKCE |
0.759 | 0.051 | 2 | 0.717 |
HIPK2 |
0.759 | 0.090 | 1 | 0.605 |
CDK18 |
0.759 | 0.075 | 1 | 0.594 |
CLK2 |
0.758 | 0.124 | -3 | 0.710 |
SRPK2 |
0.758 | 0.101 | -3 | 0.627 |
SSTK |
0.758 | -0.008 | 4 | 0.740 |
RSK4 |
0.758 | 0.044 | -3 | 0.690 |
NIM1 |
0.757 | -0.052 | 3 | 0.793 |
NDR1 |
0.757 | -0.037 | -3 | 0.754 |
ULK1 |
0.757 | -0.095 | -3 | 0.700 |
STK33 |
0.757 | -0.105 | 2 | 0.608 |
CDK8 |
0.757 | 0.046 | 1 | 0.643 |
PKCI |
0.756 | 0.002 | 2 | 0.734 |
PKCG |
0.756 | 0.005 | 2 | 0.732 |
AURB |
0.756 | -0.016 | -2 | 0.527 |
GCN2 |
0.756 | -0.073 | 2 | 0.782 |
DYRK4 |
0.756 | 0.067 | 1 | 0.625 |
NUAK1 |
0.755 | 0.036 | -3 | 0.729 |
CDK12 |
0.755 | 0.040 | 1 | 0.620 |
CDK7 |
0.754 | 0.035 | 1 | 0.656 |
MNK1 |
0.754 | 0.005 | -2 | 0.668 |
MARK2 |
0.754 | -0.044 | 4 | 0.681 |
PRKD2 |
0.754 | 0.078 | -3 | 0.706 |
PLK4 |
0.753 | -0.106 | 2 | 0.652 |
PAK3 |
0.753 | -0.088 | -2 | 0.654 |
SBK |
0.753 | 0.032 | -3 | 0.558 |
IKKA |
0.753 | -0.005 | -2 | 0.751 |
PKCT |
0.753 | -0.011 | 2 | 0.732 |
MNK2 |
0.752 | -0.006 | -2 | 0.656 |
RSK3 |
0.752 | 0.008 | -3 | 0.700 |
GRK3 |
0.752 | -0.024 | -2 | 0.646 |
CAMK2A |
0.752 | -0.019 | 2 | 0.763 |
CDK9 |
0.751 | 0.021 | 1 | 0.644 |
MARK1 |
0.751 | -0.050 | 4 | 0.743 |
CAMK1A |
0.751 | 0.019 | -3 | 0.623 |
PRKD1 |
0.750 | 0.025 | -3 | 0.712 |
PKACG |
0.750 | -0.040 | -2 | 0.617 |
CK1D |
0.750 | 0.003 | -3 | 0.455 |
AURA |
0.749 | -0.025 | -2 | 0.505 |
P70S6K |
0.749 | 0.006 | -3 | 0.641 |
MARK3 |
0.749 | -0.027 | 4 | 0.730 |
MSK1 |
0.749 | -0.027 | -3 | 0.674 |
PHKG1 |
0.749 | -0.006 | -3 | 0.742 |
QSK |
0.748 | -0.042 | 4 | 0.756 |
PKG2 |
0.748 | -0.027 | -2 | 0.545 |
MAPKAPK2 |
0.747 | 0.030 | -3 | 0.683 |
PKN1 |
0.747 | 0.030 | -3 | 0.656 |
MSK2 |
0.746 | -0.046 | -3 | 0.667 |
TTBK1 |
0.744 | -0.094 | 2 | 0.632 |
SIK |
0.744 | -0.015 | -3 | 0.696 |
CDK19 |
0.744 | 0.051 | 1 | 0.614 |
KIS |
0.744 | 0.128 | 1 | 0.676 |
CK1A2 |
0.743 | -0.005 | -3 | 0.458 |
LATS2 |
0.743 | -0.064 | -5 | 0.636 |
CK2A2 |
0.742 | 0.031 | 1 | 0.652 |
CK1E |
0.742 | 0.004 | -3 | 0.504 |
PDHK3_TYR |
0.741 | 0.072 | 4 | 0.828 |
AKT3 |
0.741 | 0.029 | -3 | 0.593 |
PHKG2 |
0.741 | 0.034 | -3 | 0.724 |
AURC |
0.741 | -0.010 | -2 | 0.523 |
BCKDK |
0.741 | -0.191 | -1 | 0.696 |
SNRK |
0.740 | -0.107 | 2 | 0.695 |
PKACB |
0.740 | -0.007 | -2 | 0.538 |
NDR2 |
0.740 | -0.068 | -3 | 0.752 |
YANK3 |
0.739 | -0.050 | 2 | 0.413 |
FAM20C |
0.738 | 0.068 | 2 | 0.624 |
PAK6 |
0.737 | 0.005 | -2 | 0.602 |
MAPKAPK5 |
0.736 | -0.070 | -3 | 0.634 |
BMPR2_TYR |
0.735 | 0.052 | -1 | 0.795 |
PDHK4_TYR |
0.734 | 0.020 | 2 | 0.837 |
TESK1_TYR |
0.734 | -0.026 | 3 | 0.906 |
EPHA6 |
0.733 | 0.107 | -1 | 0.792 |
PINK1_TYR |
0.733 | -0.006 | 1 | 0.719 |
CK2A1 |
0.733 | 0.008 | 1 | 0.628 |
MAP2K6_TYR |
0.733 | -0.029 | -1 | 0.787 |
YANK2 |
0.732 | -0.056 | 2 | 0.424 |
PKACA |
0.732 | -0.017 | -2 | 0.490 |
MAP2K4_TYR |
0.730 | -0.097 | -1 | 0.766 |
PDHK1_TYR |
0.730 | -0.021 | -1 | 0.813 |
BRSK2 |
0.730 | -0.092 | -3 | 0.724 |
MAP2K7_TYR |
0.729 | -0.182 | 2 | 0.832 |
BRSK1 |
0.728 | -0.076 | -3 | 0.716 |
EPHB4 |
0.727 | 0.032 | -1 | 0.750 |
LIMK2_TYR |
0.726 | -0.038 | -3 | 0.766 |
TXK |
0.726 | 0.082 | 1 | 0.732 |
PKMYT1_TYR |
0.726 | -0.148 | 3 | 0.880 |
TYRO3 |
0.725 | -0.015 | 3 | 0.848 |
RET |
0.725 | -0.067 | 1 | 0.701 |
ROS1 |
0.724 | 0.007 | 3 | 0.821 |
FER |
0.724 | 0.030 | 1 | 0.783 |
PRKX |
0.724 | 0.022 | -3 | 0.651 |
ABL2 |
0.723 | 0.032 | -1 | 0.736 |
ITK |
0.723 | 0.044 | -1 | 0.731 |
TYK2 |
0.723 | -0.054 | 1 | 0.703 |
MST1R |
0.723 | -0.071 | 3 | 0.842 |
CSF1R |
0.722 | -0.021 | 3 | 0.830 |
EPHA4 |
0.722 | 0.054 | 2 | 0.756 |
FLT3 |
0.722 | 0.016 | 3 | 0.841 |
LCK |
0.722 | 0.094 | -1 | 0.766 |
INSRR |
0.722 | 0.005 | 3 | 0.789 |
HCK |
0.722 | 0.057 | -1 | 0.755 |
JAK2 |
0.721 | -0.052 | 1 | 0.702 |
FRK |
0.721 | 0.106 | -1 | 0.793 |
EPHB1 |
0.720 | 0.021 | 1 | 0.778 |
ABL1 |
0.720 | 0.014 | -1 | 0.721 |
SRMS |
0.720 | 0.014 | 1 | 0.777 |
EPHB2 |
0.720 | 0.055 | -1 | 0.743 |
PAK5 |
0.720 | -0.060 | -2 | 0.533 |
LIMK1_TYR |
0.720 | -0.145 | 2 | 0.829 |
JAK3 |
0.719 | -0.034 | 1 | 0.674 |
YES1 |
0.719 | -0.019 | -1 | 0.730 |
FGR |
0.719 | -0.045 | 1 | 0.704 |
BLK |
0.719 | 0.085 | -1 | 0.776 |
KDR |
0.717 | -0.017 | 3 | 0.788 |
TEC |
0.717 | 0.026 | -1 | 0.656 |
BMX |
0.717 | 0.012 | -1 | 0.654 |
EPHB3 |
0.716 | 0.013 | -1 | 0.739 |
FYN |
0.716 | 0.085 | -1 | 0.741 |
KIT |
0.716 | -0.053 | 3 | 0.829 |
TEK |
0.715 | -0.012 | 3 | 0.782 |
BTK |
0.715 | -0.024 | -1 | 0.687 |
PDGFRB |
0.715 | -0.092 | 3 | 0.838 |
FGFR2 |
0.714 | -0.091 | 3 | 0.815 |
DDR1 |
0.713 | -0.188 | 4 | 0.744 |
MERTK |
0.712 | -0.032 | 3 | 0.797 |
SYK |
0.712 | 0.114 | -1 | 0.745 |
EPHA7 |
0.712 | 0.009 | 2 | 0.768 |
FLT1 |
0.711 | -0.031 | -1 | 0.788 |
WEE1_TYR |
0.710 | -0.036 | -1 | 0.652 |
MET |
0.710 | -0.059 | 3 | 0.810 |
LTK |
0.710 | -0.040 | 3 | 0.775 |
ALK |
0.709 | -0.048 | 3 | 0.758 |
LYN |
0.709 | 0.027 | 3 | 0.753 |
ERBB2 |
0.709 | -0.060 | 1 | 0.667 |
FGFR3 |
0.708 | -0.064 | 3 | 0.790 |
NEK10_TYR |
0.708 | -0.094 | 1 | 0.589 |
CK1G1 |
0.708 | -0.040 | -3 | 0.523 |
PAK4 |
0.708 | -0.065 | -2 | 0.533 |
EPHA5 |
0.708 | 0.028 | 2 | 0.754 |
FGFR1 |
0.708 | -0.117 | 3 | 0.788 |
TNK1 |
0.707 | -0.102 | 3 | 0.826 |
TNNI3K_TYR |
0.707 | -0.061 | 1 | 0.699 |
TNK2 |
0.707 | -0.124 | 3 | 0.761 |
PDGFRA |
0.707 | -0.120 | 3 | 0.839 |
AXL |
0.707 | -0.115 | 3 | 0.795 |
EPHA3 |
0.707 | -0.061 | 2 | 0.745 |
PTK2 |
0.706 | 0.057 | -1 | 0.745 |
EPHA8 |
0.706 | 0.015 | -1 | 0.752 |
EPHA1 |
0.706 | -0.043 | 3 | 0.792 |
FLT4 |
0.706 | -0.079 | 3 | 0.784 |
JAK1 |
0.705 | -0.074 | 1 | 0.660 |
MATK |
0.704 | -0.061 | -1 | 0.673 |
CK1G3 |
0.704 | -0.036 | -3 | 0.347 |
PTK6 |
0.702 | -0.121 | -1 | 0.631 |
PTK2B |
0.702 | -0.040 | -1 | 0.673 |
NTRK1 |
0.702 | -0.147 | -1 | 0.715 |
PKG1 |
0.702 | -0.070 | -2 | 0.467 |
CSK |
0.702 | -0.066 | 2 | 0.773 |
INSR |
0.701 | -0.099 | 3 | 0.771 |
EGFR |
0.701 | -0.046 | 1 | 0.580 |
NTRK2 |
0.700 | -0.143 | 3 | 0.781 |
SRC |
0.700 | -0.028 | -1 | 0.715 |
EPHA2 |
0.696 | -0.005 | -1 | 0.724 |
ERBB4 |
0.695 | -0.009 | 1 | 0.622 |
FGFR4 |
0.694 | -0.082 | -1 | 0.690 |
MUSK |
0.693 | -0.065 | 1 | 0.559 |
NTRK3 |
0.693 | -0.150 | -1 | 0.666 |
IGF1R |
0.692 | -0.067 | 3 | 0.713 |
CK1G2 |
0.691 | -0.023 | -3 | 0.438 |
DDR2 |
0.690 | -0.151 | 3 | 0.760 |
ZAP70 |
0.681 | -0.016 | -1 | 0.654 |
FES |
0.680 | -0.079 | -1 | 0.611 |
CK1A |
0.679 | -0.035 | -3 | 0.386 |